---
document_datetime: 2023-09-21 21:27:44
document_pages: 99
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/ultomiris-h-c-004954-ii-0026-epar-assessment-report-variation_en.pdf
document_name: ultomiris-h-c-004954-ii-0026-epar-assessment-report-variation_en.pdf
version: success
processing_time: 118.4006794
conversion_datetime: 2025-12-28 11:40:56.339298
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 July 2022 EMA/686052/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Ultomiris

International non-proprietary name: ravulizumab

Procedure No. EMEA/H/C/004954/II/0026

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................5                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................5  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................6                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................7                       |
| 2.1. Introduction.........................................................................................................7 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................7           |
| 2.1.2. About the product..............................................................................................9     |                                                                                                         |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                            | ........9                                                                                               |
| 2.1.4. General comments on compliance with GCP..........................................................9                   |                                                                                                         |
| 2.2. Non-clinical aspects                                                                                                   | ..............................................................................................9         |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................10                                             |
| 2.2.2. Discussion on non-clinical aspects......................................................................10           |                                                                                                         |
| 2.2.3. Conclusion on the non-clinical aspects................................................................10             |                                                                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11    |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                         |
| 2.3.2. Pharmacokinetics.............................................................................................11      |                                                                                                         |
| 2.3.3. Pharmacodynamics..........................................................................................23         |                                                                                                         |
| 2.3.4. PK/PD modelling..............................................................................................24      |                                                                                                         |
| 2.3.5. Discussion on clinical pharmacology...................................................................27             |                                                                                                         |
| 2.3.6. Conclusions on clinical pharmacology.................................................................28              |                                                                                                         |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................29    |
| 2.4.1. Dose response study........................................................................................29        |                                                                                                         |
| 2.4.2. Main study......................................................................................................30   |                                                                                                         |
| 2.4.3. Discussion on clinical efficacy............................................................................63        |                                                                                                         |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................68          |                                                                                                         |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................68  |
| 2.5.1. Discussion on clinical safety                                                                                        | ..............................................................................84                        |
| 2.5.2. Conclusions on clinical safety                                                                                       | ............................................................................86                          |
| 2.5.3. PSUR cycle                                                                                                           | .....................................................................................................86 |
| 2.6. Risk management plan........................................................................................86         |                                                                                                         |
| 2.7. Update of the Product information                                                                                      | ........................................................................91                              |
| 2.7.1. User consultation.............................................................................................91     |                                                                                                         |
| 3. Benefit-Risk Balance..............................................................................91                     |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ...........................................................................................91           |
| 3.1.1. Disease or condition.........................................................................................91      |                                                                                                         |
| 3.1.2. Available therapies and unmet medical                                                                                | need.......................................................92                                           |
| 3.1.3. Main clinical studies .........................................................................................92    |                                                                                                         |
| 3.2. Favourable effects                                                                                                     | ..............................................................................................92        |
| 3.3. Uncertainties and limitations about favourable effects.............................................94                  |                                                                                                         |
| 3.4. Unfavourable effects...........................................................................................94      |                                                                                                         |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | .........................................95                                                             |
| 3.6. Effects Table......................................................................................................95  |                                                                                                         |
| 3.7. Benefit-risk assessment and discussion.................................................................96              |                                                                                                         |

<div style=\"page-break-after: always\"></div>

| 3.7.1. Importance of favourable and unfavourable effects..............................................96                   |
|----------------------------------------------------------------------------------------------------------------------------|
| 3.7.2. Balance of benefits and risks.............................................................................97        |
| 3.7.3. Additional considerations on the benefit-risk balance ...........................................98                 |
| 3.8. Conclusions .......................................................................................................98 |
| 4. Recommendations.................................................................................98                      |
| 5. EPAR changes........................................................................................99                  |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

## Abbreviation or Term Definition

AChR

acetylcholine receptor

ADA

antidrug antibody

ADL

activities of daily life

aHUS

atypical hemolytic uremic syndrome

ARDS

acute respiratory distress syndrome

C5

complement component 5

CI

confidence interval

COVID-19

coronavirus disease 2019

CSF

cerebrospinal fluid

EMA

European Medicines Agency

FDA

(the US) Food and Drug Administration

gMG

generalized myasthenia gravis

ICH

International  Council  for  Harmonisation  of  Technical  Requirements  for

Pharmaceuticals for Human Use

IST

immunosuppressant therapy

IV

intravenous(ly)

IVIg

intravenous immunoglobulin

LS

least squares

mAb

monoclonal antibody

MAC

membrane attack complex

MedDRA

Medical Dictionary for Regulatory Activities

MG-ADL

Myasthenia Gravis Activities of Daily Living

MGFA

Myasthenia Gravis Foundation of America

MGFA-PIS

Myasthenia Gravis Foundation of America Post-Intervention Status

MG-QoL15r

Revised Myasthenia Gravis Quality of Life 15-item scale

MMRM

mixed-effects model for repeated measures

MMS

Minimal manifestation status

MuSK

muscle-specific kinase

Neuro-QoL

Neurological Quality of Life

NMJ

neuromuscular junction

NMOSD

Neuromyelitis Optica Spectrum Disorder

PD

pharmacodynamic(s)

PE

plasma exchange

PK

pharmacokinetic(s)

PMDA

Pharmaceuticals and Devices Agency (Japan)

PNH

paroxysmal nocturnal hemoglobinuria

PP

plasmapheresis

PY

patient years

q2w

every 2 weeks

q8w

every 8 weeks

QMG

Quantitative Myasthenia Gravis score for disease severity

REMS

Risk Evaluation and Mitigation Strategy

SAE

serious adverse event

SD

standard deviation

SMQ [N]/narrow SMQ

standardised MedDRA query (narrow)

SOC

System Organ Class

TEAE

treatment-emergent adverse event

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Alexion Europe SAS submitted to the European Medicines Agency on 19 November 2021 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with generalized myasthenia gravis (gMG).  As a consequence, Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPc and package leaflet. The Applicant also requested 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004).

## Information on paediatric requirements

Pursuant  to  Article  8  of  Regulation  (EC)  No  1901/2006,  the  application  included  (an)  EMA  Decision P/0230/2021 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ravulizumab (Ultomiris), (EMEA-001943-PIP03-20).

The waiver applies to:

- the paediatric population from birth to less than 6 years of age;
- concentrate for solution for infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## Derogation(s) of market exclusivity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application submitted a claim addressing the following derogation laid down in Article 8.3 of the same Regulation; the holder of the marketing authorisation for the original orphan medicinal product has given his consent to the MAH.

<div style=\"page-break-after: always\"></div>

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The MAH did not seek Scientific Advice at the CHMP.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

| Rapporteur:                                                                                                                                    | Blanca Garcia-Ochoa                                                                                                                            | Co-Rapporteur:                                                                                                                                 |                  |
|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|------------------|
| Timetable                                                                                                                                      |                                                                                                                                                |                                                                                                                                                | Actual dates     |
| Submission date                                                                                                                                |                                                                                                                                                |                                                                                                                                                | 19 November 2021 |
| Start of procedure:                                                                                                                            |                                                                                                                                                |                                                                                                                                                | 25 December 2021 |
| CHMP Rapporteur Assessment Report                                                                                                              |                                                                                                                                                |                                                                                                                                                | 1 March 2022     |
| PRAC Rapporteur Assessment Report                                                                                                              |                                                                                                                                                |                                                                                                                                                | 25 February 2022 |
| PRAC members                                                                                                                                   | comments                                                                                                                                       |                                                                                                                                                | 2 March 2022     |
| CHMP Co-Rapporteur Critique                                                                                                                    |                                                                                                                                                |                                                                                                                                                | 10 March 2022    |
| PRAC Outcome                                                                                                                                   |                                                                                                                                                |                                                                                                                                                | 10 March 2022    |
| CHMP members comments                                                                                                                          |                                                                                                                                                |                                                                                                                                                | 14 March 2022    |
| Updated CHMP Rapporteur(s) (Joint) Assessment                                                                                                  |                                                                                                                                                | Report                                                                                                                                         | 17 March 2022    |
| Request for supplementary information (RSI)                                                                                                    |                                                                                                                                                |                                                                                                                                                | 24 March 2022    |
| CHMP Rapporteur Assessment Report                                                                                                              |                                                                                                                                                |                                                                                                                                                | 31 May 2022      |
| PRAC Outcome                                                                                                                                   |                                                                                                                                                |                                                                                                                                                | 10 June 2022     |
| CHMP members                                                                                                                                   | comments                                                                                                                                       |                                                                                                                                                | 13 June 2022     |
| Updated CHMP Rapporteur Assessment Report                                                                                                      |                                                                                                                                                |                                                                                                                                                | 17 June 2022     |
| Request for supplementary information (RSI)                                                                                                    |                                                                                                                                                |                                                                                                                                                | 23 June 2022     |
| CHMP Rapporteur Assessment Report                                                                                                              |                                                                                                                                                |                                                                                                                                                | 6 July 2022      |
| CHMP members                                                                                                                                   | comments                                                                                                                                       |                                                                                                                                                | 14 July 2022     |
| Updated CHMP Rapporteur Assessment Report                                                                                                      |                                                                                                                                                |                                                                                                                                                | 15 July 2022     |
| Opinion                                                                                                                                        |                                                                                                                                                |                                                                                                                                                | 21 July 2022     |
| The CHMP adopted a report on similarity of Ultomiris with Soliris (Eculizumab) and Vyvgart (efgartigimod alfa) on                              | The CHMP adopted a report on similarity of Ultomiris with Soliris (Eculizumab) and Vyvgart (efgartigimod alfa) on                              | The CHMP adopted a report on similarity of Ultomiris with Soliris (Eculizumab) and Vyvgart (efgartigimod alfa) on                              | 21 July 2022     |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Ultomiris in comparison with existing therapies on | The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Ultomiris in comparison with existing therapies on | The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Ultomiris in comparison with existing therapies on | 21 July 2022     |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

The initially claimed therapeutic indication was:

'The treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) with remaining symptomatology despite at least one immunomodulatory therapy (see section 5.1).

Myasthenia gravis (gMG) is a rare, chronic, neuromuscular autoimmune disease mediated by pathogenic immunoglobulin G (IgG) autoantibodies, binding to acetylcholine receptors or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction (NMJ), which causes debilitating and potentially life-threatening muscle weakness.

## Epidemiology

In about two-thirds of patients, the first symptom is weakness of extrinsic ocular muscles. In 1 of 10 MG patients, symptoms remain limited to extrinsic ocular muscles (ocular myasthenia gravis). However, in more than 80% of patients, the symptoms progress within 2 years to affect other bulbar muscles as well as limb muscles (generalised MG). The generalized muscle weakness leads to difficulties in mobility, speech, swallowing, and vision, as well as impaired respiratory function and extreme fatigue. Up to 20% of patients experience potentially life-threatening myasthenic crisis, with respiratory failure requiring mechanical ventilation.

The disease presents with two peaks of incidence, below or above the age of 50, termed early-onset MG and late-onset MG, respectively. The prevalence of MG in the European Union is estimated at 3.7 in 10,000, equivalent to a total of around 191,000 people 1  .

## Aetiology and pathogenesis

MG  is caused  by  pathogenic  autoantibodies  that interfere with synaptic transmission at the neuromuscular junction and impair or prevent muscle contraction 2,3,4 . In approximately 85% of cases, circulating antibodies target the acetylcholine receptor (AChR)  itself.  In  the  remaining  15%, approximately half have antibodies against muscle-specific tyrosine kinase (MuSK), while the other half

1  EMA 2017 Recommendation for maintenance of orphan designation at the time of addition of a new indication to the marketing authorization Soliris (eculizumab) for the treatment of myasthenia gravis.

https://www.ema.europa.eu/documents/orphan-review/recommendation-maintenance-orphandesignation-timeaddition-new-indication-marketing-authorisation\\_en.pdf

2  Gilhus, N. E., &amp; Verschuuren, J. J. (2015). Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurology, 14(10), 1023-1036.

3  Gilhus, N. E. (2016a). Myasthenia Gravis. New England Journal of Medicine, 375(26), 2570-2581.

4  Gilhus, N. E., Skeie, G. O., Romi, F., Lazaridis, K., Zisimopoulou, P., &amp; Tzartos, S. (2016b). Myasthenia gravis autoantibody characteristics and their implications for therapy. Nature Reviews: Neurology, 12(5), 259-268.

<div style=\"page-break-after: always\"></div>

may be positive for autoantibodies against lipoprotein-related protein receptor 4 (LRP4) or other antigens associated with the neuromuscular junction 5,6 .

The  pathogenic  actions  of  IgG  autoantibodies  include  functional  blockade  of  AChR,  accelerated internalization and degradation of AChR, and activation of the complement system. These pathogenic actions result in reduced density of functional AChR and simplification of the NMJ, leading to failure of neuromuscular transmission. Anti-AChR autoantibodies are of the IgG1 and IgG3 subtypes. Anti-MuSK autoantibodies are IgG4 subtype and do not activate the complement pathway 7 .

## Clinical presentation, diagnosis and stage/prognosis

MG  is  an  autoimmune  disease  characterized  by  muscle  weakness  that  fluctuates,  worsening  with exertion, and improving with rest. In most cases, initial symptoms are ocular and include ptosis and diplopia,  but  within  2 to  3 years  of  onset,  the  disease  usually  worsens,  and  other  muscles  become affected; this is referred to as generalized MG (gMG) 8 . Additional symptoms typically include difficulty chewing, dysphagia, dysarthria, hypophonia, dyspnea, difficulty holding the head upright, and fatigue, marked reductions in the ability to perform activities of daily living (ADLs), extreme fatigue, and episodes of pulmonary failure requiring mechanical ventilation 9   10 .

Hospitalizations for gMG exacerbations are common, with the need for respiratory support, including mechanical  ventilation  secondary  to  respiratory  failure  (eg, myasthenic  crisis)  with  no  substantial improvement in mortality or length of hospitalization over time.

The  Myasthenia  Gravis  Foundation  of  America  (MGFA)  Clinical  Classification  categorizes  patients according to clinical evaluation, which in increasing severity can be: ocular MG; mild, moderate, severe generalized symptoms of MG; MG that requires intubation 11 .

The diagnosis of myasthenia gravis is confirmed by the combination of relevant symptoms and signs, a positive  test  for  specific  autoantibodies  and  a  positive  neurophysiological  examination,  including repetitive nerve stimulation or single-fiber electromyography, and symptomatic improvement following treatment with acetylcholinesterase (AChE) inhibitors.

## Management

Current treatment options include acetylcholinesterase inhibitors and long-term immune therapies with immunosuppressive agents such as corticosteroids, azathioprine, cyclosporine, and mycophenolate, but tacrolimus, methotrexate, and cyclophosphamide are also used. Thymectomy is also a treatment option. Monoclonal antibodies such as rituximab are used. Eculizumab, an anti-C5 treatment, was approved in the  EU  for  the  treatment  of  patients  with  refractory  gMG  and  who  are  AChR-Ab  seropositive. Plasmapheresis/plasma exchange (PLEX) and intravenous immunoglobulins (IVIg) are mostly used as rescue therapies in situations of clinical deterioration 12 .

5  Meriggioli, M. N., &amp; Sanders, D. B. (2012). Expert Review of Clinical Immunology, 8(5), 427-438.

6  Zhang, B. et al. (2012). Archives of Neurology, 69(4), 445-451.

7  Howard JF et al. Lancet Neurol 2017;16:976-86.

8  Trouth AJ,  Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Autoimmune Dis. 2012; 2012: 874680.

9  Juel C et al. Orphanet J Rare Dis. 2007

10  Meriggoli MN and Sanders DB. Lancet Neurol. 2009 May; 8(5): 475-490.

11  Jaretzki A et al. Neurology 2000;55:16-23.

12  Mantegazza R et al. Immunotargets Ther. 2020; 9: 317-331.

<div style=\"page-break-after: always\"></div>

At the time of this application, with the exception of AChE inhibitors, corticosteroids, the complement inhibitor eculizumab (Soliris), and azathioprine (Jayempi), which have received regulatory approval for the treatment of gMG, all other existing therapies are used off-label.

Patients with AChR-Ab seronegative gMG have greater limitations on treatment options, as AChE inhibitors are known to have reduced efficacy in this population and eculizumab is approved only for AChR-Ab seropositive patients and is limited to treatment of refractory MG.

## 2.1.2. About the product

Ravulizumab  (Ultomiris,  ALXN1210)  is  a  humanized  monoclonal  antibody  (mAb)  that  binds  to complement component 5 (C5) and blocks its activation by complement pathway convertases.

Pharmacotherapeutic group: Selective immunosuppressants, ATC code: L04AA43

Currently, Ultomiris is approved for Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Haemolytic Uremic Syndrome (aHUS):

Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with paroxysmal nocturnal haemoglobinuria (PNH)

- -in patients with haemolysis with clinical symptom(s) indicative of high disease activity.
- -in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).

Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).

Ravulizumab,  derived  through  targeted  engineering  from  eculizumab  (h5G1.1-mAb;  Soliris),  is  a terminal complement inhibitor that specifically binds to C5 with high affinity, inhibiting the enzymatic cleavage of C5 into C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the membrane attack complex [MAC or C5b-9]). By binding specifically to C5, ravulizumab antagonizes terminal complement-mediated inflammation, cell activation, and cell lysis. This mechanism of action provides a therapeutic rationale for the use of ravulizumab in diseases in which activation of terminal complement plays an etiologic role.

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

Not applicable.

## 2.1.4. General comments on compliance with GCP

The clinical trial was performed in accordance with GCP as claimed by the MA.

## 2.2. Non-clinical aspects

No additional nonclinical data with ravulizumab have been generated for this application.

<div style=\"page-break-after: always\"></div>

Direct  testing  of  ravulizumab  in  non-clinical  models  of  Myasthenia  Gravis  (MG)  is  precluded  by ravulizumab being a highly specific monoclonal antibody that binds only to human C5.

A summary of results from relevant published studies has been submitted.

In MG, complement activation initiates an inflammatory cascade that induces blockade of neuromuscular transmission and resulting in skeletal muscle weakness 13 . Published nonclinical experiments of MG have demonstrated  that  uncontrolled  complement  activation  leads  to  membrane  attack  complex  (MAC) deposition at the neuromuscular junction (NMJ) and impairment of the neuromuscular transmission in anti-AChR  antibody-positive  MG 14 15 16 17 .  The  pro-inflammatory  properties  of  the  activated  terminal complement components, C5a and C5b 9, have been implicated in a wide range of inflammatory disease states 18 . Data presented supports terminal C5 inhibition with anti-C5 mAb, such as ravulizumab, as a viable therapeutic approach for patients with MG.

## 2.2.1. Ecotoxicity/environmental risk assessment

According to the CHMP guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447/00) vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates and lipids are exempted of environmental risk assessment because, due to their nature they are unlikely to result in significant risk to the environment. Due to the fact that ravulizumab is a monoclonal antibody and thus a protein, no Environmental Risk Assessment is provided for this application which was considered acceptable by CHMP.

## 2.2.2. Discussion on non-clinical aspects

No additional nonclinical data with ravulizumab have been generated for this application since the dose and administration route proposed for this new indication of gMG is the same that was previously approved for atypical haemolytic uremic syndrome (aHUS) and paroxysmal nocturnal haemoglobinuria (PNH) indications. This was considered acceptable by CHMP.

## 2.2.3. Conclusion on the non-clinical aspects

A full nonclinical package was provided as part of the initial marketing authorisation application (MAA) for Ultomiris in 2018. With the exception of the published studies discussed above, no additional nonclinical data have been generated. This is considered acceptable by CHMP.

Considering the above data, ravulizumab is not expected to pose a risk to the environment.

The non-clinical data available supports the use of Ultomiris in the approved indication.

13  Jacob S. Myasthenia Gravis - A Review of Current Therapeutic Options. European neurological review. DOI:10.17925/ENR.2018.13.2.86.

14  Engel AG, Lambert EH, Howard FM. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clinic Proceedings. 1977 May;52(5):267-280. PMID: 870771

15  Sahashi K, Engel AG, Lambert EH, Howard FM Jr. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol. 1980 Mar;39(2):160-72. doi: 10.1097/00005072-198003000-00005. PMID: 7373347.

16  Nakano S, Engel AG. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology. 1993 Jun;43(6):1167-72. doi: 10.1212/wnl.43.6.1167. PMID: 8170563.

17  Tüzün E, Scott BG, Goluszko E, Higgs S, Christadoss P. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol. 2003 Oct 1;171(7):3847-54. doi: 10.4049/jimmunol.171.7.3847. PMID: 14500686.

18  Matis, L., Rollins, S. Complement-specific antibodies: Designing novel anti-inflammatories. Nat Med 1, 839-842 (1995). https://doi.org/10.1038/nm0895-839

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 1 - Tabular overview of clinical studies

| Type of Study       | Study Identifier   | Location of Study Report   | Objective(s) of the Study                                                                               | Study Design and Iype of Control                                                                                                                                                                                                   | Test Product(s) Dosage Regimen Route of Administration                                                                                                                                                                                                                                                                            | Number of Subjects (Planned/ Treated)   | Healthy Subjects or Diagnosis of Patients   | Duration of Treatment                                                                          | Study Status Type of Report                                                                        |
|---------------------|--------------------|----------------------------|---------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|---------------------------------------------|------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Efficacy and Safety | ALXN1210- MG-306   | M5.3.5.1                   | To assess the efficacy, safety, immunogenicity, PK, PD, safety, and efficacy in adult patients with gMG | Phase 3, randomized, double-blind, parallel-group, placebo- controlled, multicenter study with an ongoing Open-Label Extension Period of up to 2 years in adult patients with gMG who were naive to complement inhibitor treatment | PrimaryEvaluation Period (Day 1): Ravulizumab IV weight-basedloadingd doseonDay 1 and weight-based maintenance dose starting on Day 15 and q8w thereafter Placebo Matched dosing to ravulizumab IV Blindedloadingdose (900mg)for allpatients at Week 26 ExtensionPeriod (Week 28): Ravulizumab IV weight-based maintenancedoseqSw | 160/175 Ravulizumab 80/86 Placebo 80/89 | Adult patients with gMG                     | 26-week Randomized- Controlled Period followed by Open-Label Extension Period of up to 2 years | Ongoing Open-Label Extension Period (Randomized- Controlled Period Completed) Primary Analysis CSR |

## 2.3.2. Pharmacokinetics

Data from a Phase 3 study of patients with gMG (Study ALXN1210-MG-306) are incorporated in the current clinical pharmacology analyses. Only data collected during the Randomized-Controlled Period are included. Durations of PK, PD, and immunogenicity data coverage and data cut-off dates for Study ALXN1210-MG-306 are summarized in Table 2.

<div style=\"page-break-after: always\"></div>

Table 2  -  Summary  of  PK,  PD,  and  Immunogenicity  Data  for  the  Ravulizumab  gMG  Development Program

| Study Identifier: (Population Studied)                                         | Study Description                                                                                                                                                       | Number of Patients   | Duration of PK, PD, and ADA Data Coverage   | PK, PD, and Immunogenicity Data Cutoff Date for Pooled Analysis                                                                                                 |
|--------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ALXN1210-MG-306 (Adult complement inhibitor treatment-naïve patients with gMG) | Phase 3, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy, PK, PD, immunogenicity, and safety of ravulizumab IV | 175 a                | RCP: Up to Day 183                          | All PK, PD, and immunogenicity data through the RCP included for the PK Analysis Set, Full Analysis Set, and Safety Set, respectively; data cutoff: 11 May 2021 |

Table 3 summarizes the dosing and sampling schedules for Study ALXN1210-MG-306.

Table 3 -Dosing and Sampling Schedules for the Randomized-Controlled Period (Study ALXN1210-MG-306)

| Parameter                 | Dosing and Sampling Schedules                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Dosing regimen            | Ravulizumab IV 10 mg/mL body weight-based dosing: Patients weighing ≥ 40 to < 60 kg: loading dose 2400 mg on Day 1, maintenance dose 3000 mg on Days 15, 71, and 127 Patients weighing ≥ 60 to < 100 kg: loading dose 2700 mg on Day 1, maintenance dose 3300 mg on Days 15, 71, and 127 Patients weighing ≥ 100 kg: loading dose 3000 mg on Day 1, maintenance dose 3600 mg on Days 15, 71, and 127 Patients in the placebo group received equivalent dosing with placebo. |
| PK and PD (serum free C5) | Within 30 minutes before start of infusion (predose) on Days 1, 15, 71, 127, and 183; and within 30 minutes after completion of infusion (post dose) on Days 1, 15, 71, and 127. In the event of clinical deterioration, blood samples were to be obtained for PK and PD.                                                                                                                                                                                                   |
| Immunogenicity (ADA)      | Within 30 minutes before start of infusion (predose) on Days 1, 15, 71, 127, and 183. In the event of clinical deterioration, blood samples were to be obtained for ADAs.                                                                                                                                                                                                                                                                                                   |

Note: Day 1 refers to start of dosing.

Abbreviations:  ADA  =  antidrug  antibody;  C5  =  complement  component 5;  IV  =  intravenous; PD = pharmacodynamics; PK = pharmacokinetics

## Absorption

Ravulizumab is intended to be administered intravenously which results in 100% bioavailability. The tmax is expected at the end of infusion or soon after end of infusion. Over the studied dose and regimen range, ravulizumab exhibited dose proportional and time linear PK.

<div style=\"page-break-after: always\"></div>

## Distribution

The mean (SD) Vss in adult patients with gMG is 5.74 (1.16) L.

## Elimination

As an IgG monoclonal antibody, ravulizumab is expected to be metabolized in the same manner as any endogenous IgG (degraded into small peptides and amino acids via catabolic pathways) and is subject to similar elimination. Ravulizumab contains only natural occurring amino acids and has no known active metabolites. The mean (SD) t½ and CL of ravulizumab in adult patients with gMG is 56.6 (8.36) days and 0.00313 (0.000996) L/h, respectively.

## Pharmacokinetics in the target population

## Exploratory PK data

The mean (SD) ravulizumab serum concentration versus time profile (semi-log scale) is presented in Figure 1.

Figure 1 - Mean (SD) Ravulizumab Serum Concentration, Semi-Log Scale (Study ALXN1210-MG-306 PK Analysis Set)

<!-- image -->

Note: For ravulizumab concentrations that were BLQ of &lt; 1.00 or &lt; 4.00 μg/mL (depending on degree of sample dilution), LLOQ/2 = 0.50 or 2.00 μg/mL wer e utilized, respectively. Abbreviations: BLQ = below the limit of quantitation; LLOQ = lower limit of quantitation; PK = pharmacokinetic; SD = standard deviation

Pharmacokinetic parameters for ravulizumab during the Randomized-Controlled Period are summarized by dosing interval in Table 4 and Table 5 for the loading and last maintenance doses, respectively.

| Table 4: (Study ALXN1210-MG-306   | Ravulizumab PK Parameters PK Analysis Set)   | Ravulizumab PK Parameters PK Analysis Set)   | Following          | the First         | (Loading) Dose    |
|-----------------------------------|----------------------------------------------|----------------------------------------------|--------------------|-------------------|-------------------|
| Parameter                         | Statistics                                   | All Patients                                 | ≥ 40 to < 60 kg    | ≥ 60 to < 100 kg  | ≥ 100 kg          |
| C max (μg/mL)                     | n                                            | 86                                           | 7                  | 47                | 32                |
| C max (μg/mL)                     | Mean (SD)                                    | 874.1 (184.24)                               | 1054.3 (163.57)    | 912.1 (170.39)    | 778.8 (160.96)    |
| C max (μg/mL)                     | CV%                                          | 21.1                                         | 15.5               | 18.7              | 20.7              |
| C max (μg/mL)                     | Median (min, max)                            | 836.0 (399, 1420)                            | 1060.0 (778, 1310) | 868.0 (692, 1420) | 779.5 (399, 1350) |
|                                   | n                                            | 85                                           | 7                  | 46                | 32                |

<div style=\"page-break-after: always\"></div>

Table 4: Ravulizumab PK Parameters Following the First (Loading) Dose (Study ALXN1210-MG-306 PK Analysis Set)

| Parameter        | Statistics   | All Patients   | ≥ 40 to < 60 kg   | ≥ 60 to < 100 kg   | ≥ 100 kg      |
|------------------|--------------|----------------|-------------------|--------------------|---------------|
| C trough (μg/mL) | Mean (SD)    | 417.8 (115.51) | 555.7 (116.45)    | 438.5 (118.11)     | 357.8 (68.12) |
| C trough (μg/mL) | CV%          | 27.6           | 21.0              | 26.9               | 19.0          |
| C trough (μg/mL) | Median       | 397.0          | 520.0             | 422.0              | 339.0         |
| C trough (μg/mL) | (min, max)   | (234, 1000)    | (451, 751)        | (305, 1000)        | (234, 570)    |

Abbreviations:  Cmax = maximum  observed  serum  concentration;  Ctrough = concentration  at  the  end  of  the dosage  interval;  CV = coefficient  of  variation;  max = maximum;  min = minimum;  PK = pharmacokinetics; SD = standard deviation

Table 5: Ravulizumab PK Parameters Following the Final Maintenance Dose (Study ALXN1210-MG-306 PK Analysis Set)

| Parameter        | Statistics        | All Patients       | ≥ 40 to < 60 kg     | ≥ 60 to < 100 kg    | ≥ 100 kg           |
|------------------|-------------------|--------------------|---------------------|---------------------|--------------------|
| C max (μg/mL)    | n                 | 76                 | 4                   | 43                  | 29                 |
| C max (μg/mL)    | Mean (SD)         | 1548.3 (359.43)    | 2015.0 (345.40)     | 1645.3 (337.63)     | 1340.1 (267.95)    |
| C max (μg/mL)    | CV%               | 23.2               | 17.1                | 20.5                | 20.0               |
| C max (μg/mL)    | Median (min, max) | 1500.0 (810, 2510) | 1900.0 (1750, 2510) | 1660.0 (1060, 2410) | 1340.0 (810, 1990) |
| C trough (μg/mL) | n                 | 70                 | 4                   | 39                  | 27                 |
| C trough (μg/mL) | Mean (SD)         | 586.6 (173.91)     | 887.3 (82.72)       | 635.7 (157.28)      | 471.3 (109.47)     |
| C trough (μg/mL) | CV%               | 29.6               | 9.3                 | 24.7                | 23.2               |
| C trough (μg/mL) | Median (min, max) | 570.0 (211, 1030)  | 866.5 (817, 999)    | 649.0 (241, 1030)   | 456.0 (211, 635)   |

Note: Data were excluded for patients after they received a supplemental dose following PE, PP, or IVIg. Abbreviations:  Cmax = maximum  observed  serum  concentration;  Ctrough = concentration  at  the  end  of  the dosage interval; CV = coefficient of variation; IVIg = intravenous immunoglobulin; max = maximum; min = minimum; PE = plasma exchange; PK = pharmacokinetics; PP = plasmapheresis; SD = standard deviation

## Population PK model

A  Pop-PK  analysis  was  previously  performed  to  assess  concentration-time  profiles  of  ravulizumab following IV administration in healthy subjects and patients with PNH. A 2-compartment model with linear clearance adequately characterized the concentration-time profiles of ravulizumab. The Pop-PK analysis included 38 (12.7%) healthy subjects and 261 (87.3%) patients with PNH. The Pop-PK model in patients with PNH included the effect of body weight on all clearance and volume parameters (CL, Q, Vc,  and  Vp).  In  addition,  the  Pop-PK  model  included  the  effect  of  BMI  on  volume  of  distribution parameters (Vc and Vp). Finally, the PNH model included the effect of hemoglobin on central parameters (CL and Vc).

Rescue therapy (e.g, high-dose corticosteroid, PE/PP, or IVIg) was allowed if a patient experienced clinical deterioration as defined in the protocol for Study ALXN1210-MG-306. PE/PP interventions are expected  to  result  in  the  bulk  removal  and  replacement  of  plasma,  thereby  removing  pathologic substances such as pathologic antibodies, immune complexes, and cytokines, as well as ravulizumab. Also, IVIg treatment is expected to competitively bind the endosomal neonatal Fc receptor recycling mechanism of monoclonal antibodies and, thus, inhibit neonatal recycling of ravulizumab, resulting in reduced serum ravulizumab concentration 19 . Thus, supplemental dosing of study drug was implemented in Study ALXN1210-gMG-306 if PE/PP or IVIg rescue therapy was administered. As a result, the Pop-PK

19  Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ. An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 2011; 16(2): 84-91

<div style=\"page-break-after: always\"></div>

base model was developed to account for additional pathways of elimination of ravulizumab as a potential effect of PE/PP or IVIg and supplemental doses administered secondary to these interventions.

Figure 2: Final Population-PK Model of Ravulizumab: Goodness-of-Fit

<!-- image -->

Note: Thick line on all plots is the LOESS line. Dashed line is the line of identity. Observed and individual/population predicted values are ravulizumab concentrations (µg/mL).

Abbreviations: LOESS = locally weighted scatter-plot smoothing; PK = pharmacokinetic

A pcVPC was used to assess the model performance for describing PK in adult patients with gMG in Study ALXN1210-MG-306 (Figure 3). The observed median, 5th, and 95th percentiles of ravulizumab concentrations were consistent with model predicted values.

<div style=\"page-break-after: always\"></div>

Figure 3: Final  Population  PK  Model  of  Ravulizumab  in  Adult  Patients  with  gMG:  PredictionCorrected Visual Predictive Check Semi-log Scale

<!-- image -->

Notes: The pcVPC (500 replications) retains the visual interpretation of the traditional VPC while removing the variability that arises from binning across independent variables by normalizing the observed and simulated dependent variable based on the typical population prediction for the median independent variable in the bin.

Abbreviation:  CI  =  confidence  interval;  gMG  =  generalized  myasthenia  gravis;  pcVPC = prediction-corrected  VPC;  PK  = pharmacokinetic; VPC = visual predictive check

Final Pop-PK pharmacostatistical parameter estimates for ravulizumab are presented in Table 6.

A sensitivity analysis was performed by using the Pop-PK model developed in patients with PNH as a reference model for assessing which (if any) covariates should be included in the gMG Pop-PK base model.  For  patients  with  PNH,  the  final  model  included  body  weight,  BMI,  sex,  and  hemoglobin  as significant covariates on PK. The PNH model was used to model the current data from Study ALXN1210-MG-306.

Table 6: Final Population PK Model: Ravulizumab Parameter and Covariate in Adult Patients with gMG

| Parameter   | Estimates a                                                                                                                  | RSE                 | BSV b          | Shrinkage     |
|-------------|------------------------------------------------------------------------------------------------------------------------------|---------------------|----------------|---------------|
| CL (L/h)    | 0.00237 (without PE/PP or IVIg Intervention) 0.0108 during IVIg Intervention 0.793 during PE/PP Intervention × (WT/70) 0.975 | 2.89 3.92 45.5 8.47 | 18.5% NA NA NA | 7.2% NA NA NA |
| Q (L/h)     | 0.0158, Fixed × (WT/70) 0.975                                                                                                | NA 8.47             | NA NA          | NA NA         |
| Vc (L)      | 2.95 × (WT/70) 0.702 × 0.920 if Female                                                                                       | 2.64 6.47 2.89      | 9.33% NA NA    | 21.0% NA NA   |
| Vp (L)      | 1.94, Fixed                                                                                                                  | NA                  | NA             | NA            |

<div style=\"page-break-after: always\"></div>

|                                    |   × (WT/70) 0.702 |   6.47 | NA   | NA   |
|------------------------------------|-------------------|--------|------|------|
| Error model Proportional Error (%) |              13.5 |    5.9 | NA   | NA   |

Note: The reference subject was a 70-kg male patient with gMG.

a  Parameter estimates are back-transformed from the log-transformed domain. Additional parameter estimates and parameter correlations are presented in gMG Pop-PK-PD Report Section 12.1.

b  BSV is presented as the standard deviation of the random effect ( η i),  with  the  %  coefficient of  variation (100 × (exp(ω 2 )-1) 0.5 ) in parentheses.

Abbreviations:  BSV  =  between-subject  variability;  CI  =  confidence  interval;  CL  =  clearance;  NA  =  not applicable; Q = intercompartmental clearance; RSE = relative standard error; Vc = volume of distribution in the central compartment; Vp = volume of distribution in the peripheral compartment

The covariate effects on CL and Q of ravulizumab are presented below.

- The CL of ravulizumab was dependent on body weight. The exponent for the effect of weight on CL was 0.975 [(Body Weight/70)0.975], suggesting higher CL values in patients with higher body  weight.  For  example,  typical  subjects  with  body  weight  values  of  40.0  and  166  kg (corresponding to minimum and maximum values in the PK population; refer to Table 2) are expected to have CL values 42% lower and 2.3-fold (0.00137 and 0.00550 L/h, respectively) relative to a typical subject with a body weight of 70 kg, respectively.
- The CL of ravulizumab during an IVIg intervention was 0.0108 L/h. The effect of IVIg intervention on the CL of ravulizumab was robustly estimated (RSE &lt;5%). The faster CL of ravulizumab during an IVIg intervention corresponded to a t1/2β of 14.7 d ays.
- The CL of ravulizumab during a PP/PE intervention was 0.793 L/h. The RSE for the effect of PP/PE on CL was high (RSE = 45.5%) since only two patients in the PK population required PP/PE. The faster CL of ravulizumab during a PP/PE intervention corres ponded to a t1/2β of 3.6 days.
- The Q of ravulizumab was dependent on body weight. Similar to CL, the exponent for the effect of weight on Q was 0.975 [(Body Weight/70)0.975]. The effect of weight on Q had therefore the same magnitude of effect as that presented for CL.

Covariate effects on Vc and Vp of ravulizumab are presented below.

- The Vc of ravulizumab was dependent on body weight. The exponent for the effect of weight on Vc was 0.702 [(Body Weight/70)0.702], suggesting higher Vc values in patients with higher body weight. For example, typical subjects with body weight values of 40.0 and 166 kg (corresponding to minimum and maximum values in the PK population) are expected to have Vc values 32% lower and 1.8-fold higher (1.99 and 5.41 L, respectively) relative to a typical subject with a body weight of 70 kg, respectively.
- Female patients presented a Vc approximately 8% lower than that derived in male patients.
- The Vp of ravulizumab was dependent on body weight and BMI. The effect of weight on Vp had the same magnitude as that presented for Vc.

## Summary of Ravulizumab PK parameters in subpopulations of interest

The effect of specific covariates on the CL and Vc of ravulizumab relative to the reference population is presented in Figure 4.

<div style=\"page-break-after: always\"></div>

Figure 4: Forest Plot: Impact of Covariates on the CL and Vc of Ravulizumab CovariateEffects on CL Median[95%CI]

Body Weight (kg)

<!-- image -->

<!-- image -->

Note The reference patient was a typical 70-kg male patient with gMG.

Abbreviations: CI = confidence interval; CL = central clearance; gMG = generalized myasthenia gravis; Vc = central volume of distribution

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note The reference patient was a typical 70-kg male patient with gMG.

Abbreviations: CI = confidence interval; Cmax,ss = maximum observed serum concentration under steady-state conditions; Ctrough, ss = concentration at the end of the dosage interval under steady-state conditions; gMG = generalized myasthenia gravis

## Comparison of PK and PD in Patients with PNH, aHUS, or gMG

The PK parameters following body weight-based dosing of ravulizumab IV to patients with PNH, aHUS, or gMG is presented in the table below (Table 7). The ravulizumab exposure parameters in adult patients with gMG are similar to those observed in adult patients with PNH or aHUS.

Table 7: PK Parameters of Ravulizumab IV Following the Loading Dose and the Last Maintenance Dose During the Primary Evaluation Period for Adult Patients with PNH, aHUS, or gMG

<div style=\"page-break-after: always\"></div>

| PK Paramet er (unit)   | Dosin g Perio d   | Statist ic         | Adult Patients with PNH                | Adult Patients with PNH    | Adult Patients with aHUS               | Adult Patients with gMG                |
|------------------------|-------------------|--------------------|----------------------------------------|----------------------------|----------------------------------------|----------------------------------------|
| PK Paramet er (unit)   | Dosin g Perio d   | Statist ic         | Compleme nt Inhibitor Treatment -Naïve | Eculizuma b- Experienc ed  | Compleme nt Inhibitor Treatment -Naïve | Compleme nt Inhibitor Treatment -Naïve |
| C max (μg/mL)          | LD                | Mean ± SD (CV%); n | 771.4 ± 165.89 (21.5); 125             | 842.9 ± 203.47 (24.1); 96  | 754.3 ± 265.31 (35.2); 52              | 874.1 ± 184.24 (21.1); 86              |
| C max (μg/mL)          | Last MD           | Mean ± SD (CV%); n | 1378.5 ± 275.94 (20.0); 124            | 1386.3 ± 268.42 (19.4); 95 | 1458.4 ± 256.19 (17.6); 46             | 1548.3 ± 359.43 (23.2); 76             |
| C trough (μg/mL)       | LD                | Mean ± SD (CV%); n | 391.2 ± 136.77 (35.0); 125             | 405.4 ± 121.24 (29.9); 96  | 313.2 ± 106.16 (33.9); 55              | 417.8 ± 115.51 (27.6); 85              |
| C trough (μg/mL)       | Last MD           | Mean ± SD (CV%); n | 472.7 ± 157.94 (33.4); 124             | 500.8 ± 143.17 (28.6); 95  | 506.9 ± 215.51 (42.5); 46              | 586.6 ± 173.91 (29.6); 70              |

Abbreviations:  aHUS = atypical  hemolytic  uremic  syndrome;  Cmax = maximum  observed  serum  concentration; Ctrough = concentration at the end of the dosing interval; CV = coefficient of variation; gMG = generalized myasthenia gravis; IV = intravenous; LD = loading dose; MD = maintenance dose; PNH = paroxysmal nocturnal hemoglobinuria; SD = standard deviation

The PD following body weight-based dosing of ravulizumab IV to patients with PNH, aHUS, or gMG is similar in that serum free C5 concentration was less than 0.5 μg/mL in 100% of samples obtained during treatment in adult patients with gMG or PNH and in greater than 99.5% of samples in adult patients with aHUS.

## Immunogenicity

There were no treatment-emergent ADA-positive findings (ie, positive findings in patients that were not present at baseline or were present at baseline but the titer was higher after study drug administration) after ravulizumab administration during the Randomized-Controlled Period of Study ALXN1210-MG-306. In the ravulizumab group, 8 (9.3%) patients had an ADA-positive sample at baseline (pretreatment) but otherwise had ADA-negative samples at all times post treatment.

A total of 78 (90.7%) patients presented with negative ADA at baseline and 8 (9.3%) presented with confirmed positive ADA at baseline. Baseline ADA did not affect the CL of ravulizumab according to covariate analysis. All post-dose samples were associated with negative ADA in patients who received ravulizumab in the Randomized-Controlled Period.

## Special populations

## Body weight

A summary of the final Pop-PK model post hoc parameters in adult patients with gMG are shown in Table 8.. The mean (SD) CL and Vc of ravulizumab increased as a function of body weight.

<div style=\"page-break-after: always\"></div>

Table 8 - Summary of Post Hoc PK Parameters for Ravulizumab in Adult Patients with gMG by Body Weight Group

| Parameters Statistics                        | ≥ 40 to < 60 kg (N = 7)                        | ≥ 60 to < 100 kg (N = 47)                      | ≥ 100 kg (N = 32)                              | All Patients (N = 86)                          |
|----------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
| CL (L/h)                                     |                                                |                                                |                                                |                                                |
| Mean (SD) Median [2.5th - 97.5th percentile] | 0.00182 (0.000429) 0.00191 [0.00119 - 0.00234] | 0.00278 (0.000653) 0.00264 [0.00203 - 0.00462] | 0.00392 (0.000911) 0.00370 [0.00288 - 0.00633] | 0.00313 (0.000996) 0.00303 [0.00169 - 0.00507] |
| Q(L/h)                                       |                                                |                                                |                                                |                                                |
| Mean (SD) Median [2.5th - 97.5th percentile] | 0.0114 (0.00170) 0.0114 [0.00923 - 0.0134]     | 0.0183 (0.00245) 0.0181 [0.0142 - 0.0221]      | 0.0257 (0.00289) 0.0249 [0.0225 - 0.0316]      | 0.0205 (0.00510) 0.0205 [0.0105 - 0.0299]      |
| Vc (L)                                       |                                                |                                                |                                                |                                                |
| Mean (SD)                                    | 2.23 (0.287) 2.31 [1.82 - 2.55]                | (0.462)                                        | 4.09 (0.577) 4.06 [3.21 - 5.45]                | 3.42 (0.756) 3.44                              |
| [2.5th                                       |                                                |                                                |                                                |                                                |
|                                              |                                                | 3.14 3.04                                      |                                                |                                                |
| Median - 97.5th percentile]                  |                                                | [2.34 - 3.93]                                  |                                                | [2.20 - 4.84]                                  |
| Vp (L)                                       |                                                |                                                |                                                |                                                |
| Mean (SD)                                    | 1.53 (0.166)                                   | 2.16 (0.209)                                   | 2.75 (0.218)                                   | 2.33 (0.423)                                   |
| Median                                       |                                                | 2.15                                           | 2.70                                           | 2.35                                           |
| [2.5th                                       | 1.54                                           | [1.80 - 2.47]                                  | [2.51 - 3.20]                                  | [1.45 - 3.08]                                  |
| - 97.5th percentile]                         | [1.32 - 1.73]                                  |                                                |                                                |                                                |
| Vss (L)                                      |                                                |                                                |                                                |                                                |
| Mean (SD)                                    | 3.76 (0.436)                                   | 5.29 (0.644)                                   | 6.84 (0.764)                                   | 5.74 (1.16)                                    |
| Median                                       | 3.85                                           | 5.23                                           | 6.69                                           | 5.85                                           |
| [2.5th - 97.5th percentile]                  | [3.14 - 4.21]                                  | [4.30 - 6.28]                                  | [5.79 - 8.66]                                  | [3.73 - 7.83]                                  |
| t ½ (days)                                   |                                                |                                                |                                                |                                                |
| Mean (SD)                                    | 63.3 (9.88)                                    | 57.9 (7.85)                                    | 53.1 (7.43)                                    | 56.6 (8.36)                                    |
| Median                                       | 61.6                                           | 58.3                                           | 53.5                                           | 57.2                                           |
| [2.5th - 97.5th percentile]                  | [52.2 - 79.9]                                  | [38.5 - 70.8]                                  | [39.8 - 64.8]                                  | [37.8 - 70.9]                                  |

Abbreviations: CL =central clearance; gMG = generalized myasthenia gravis; PK = pharmacokinetic; Q = intercompartmental  clearance;  t½ =  terminal  elimination  half-life;  Vc = central  volume  of  distribution; Vp = peripheral volume of distribution; Vss = volume of distribution at steady state

Table  9:  Descriptive  Statistics  of  Steady  State  Exposure  Parameters  of  Ravulizumab  in  Study ALXN1210-MG-306

| Parameters                                 | ≥40 to ≤ 60 kg (N=7)                                             | ≥60 to ≤ 100 kg (N=47)                    | 2100 kg (N=32)                          | All Patients (N=86)                       |
|--------------------------------------------|------------------------------------------------------------------|-------------------------------------------|-----------------------------------------|-------------------------------------------|
| Cinugha (μg/mL)                            |                                                                  |                                           |                                         |                                           |
| Mean (SD) Median [2.5h - 97.5* percentile] | 922 (305) 823 [625 - 1430]                                       | 635 (160) 625 [305 - 865]                 | 473 (118) 482 [254 - 667]               | 598 (202) 569 [268 -1060]                 |
| Cmu (μg/mL)                                |                                                                  |                                           |                                         |                                           |
| Mean (SD) Median [2.5h-97.5percentile]     | 2280 (485) 2080 [1860-3040]                                      | 1700 (297) 1750 [1220-2230]               | 1360 (215) 1390 [881-1770]              | 1620 (382) 1580 [1130-2540]               |
| Cga (μg/mL)                                |                                                                  |                                           |                                         |                                           |
| Mean (SD) Median [2.5h -97.5 percentile]   | 1300 (357) 1170 [954-1880]                                       | 925 (193) 931 [537-1210]                  | 713 (140) 724 [424-931]                 | 877 (250) 834 [494- 1440]                 |
| AUC(μg.h/mL)                               |                                                                  |                                           |                                         |                                           |
| Mean (SD) Median                           | 1750000(480000) 1570000 [2.5h -97.5percentile][1280000 -2530000] | 1240000 (260000) 1250000 [722000-1620000] | 958000 (188000) 972000 [569000-1250000] | 1180000 (336000) 1120000 [664000-1940000] |

Abbreviations: AUCss = area under the curve over the dosing interval under steady state conditions (ie, 8 weeks); Cavg,ss = average concentrations under steady state conditions; Cmax,ss = maximum concentrations under steady state conditions; Ctrough,ss =minimum concentrations under steady state conditions.

Note: Ravulizumab dosing in patients with body weight ≥ 40 to &lt; 60 kg (2400 mg LD / 3000 mg MD q8w), ≥ 60 to &lt; 100 kg (2700 mg LD / 3300 mg MD q8w), and ≥ 100 kg (3000 mg LD / 3600 mg MD q8w).

Patients with body weight ≥ 40 to &lt; 60 kg treated with a 3000 -mg MD q8w presented median Ctrough,ss, Cmax,ss, and Cavg,ss values of approximately 32%, 19%, and 26% higher than patients with body weight ≥ 60 to &lt; 100 kg treated with a 3300 -mg MD q8w, respectively.

<div style=\"page-break-after: always\"></div>

Patients with body weight ≥ 100 kg treated with a 3600 -mg MD q8w presented median Ctrough,ss, Cmax,ss, and Cavg,ss values of 23%, 21%, and 22% lower than patients with body weight ≥ 60 to &lt; 100 kg treated with a 3300-mg MD q8w, respectively.

Japanese vs. non-Japanese patients

Table 10: Descriptive Statistics of PK and Steady State Exposure Parameters of Ravulizumab in Study ALXN1210-MG-306 - Japanese and Non-Japanese Patients

| Parameters                | Japanese (N=6)     | Non-Japanese (N=80)   | All Patients (N=86)   |
|---------------------------|--------------------|-----------------------|-----------------------|
| CL (L/b)                  |                    |                       |                       |
| Mean (SD)                 | 0.00231 (0.000471) | 0.00319 (0.000999)    | 0.00313 (0.000996)    |
| Median                    | 0.00216            | 0.00306               | 0.00303               |
| [2.5h- 97.5 percentile]   | [0.00192-0.00308]  | [0.00165-0.00511]     | [0.00169-0.00507]     |
| Q (L/h)                   |                    |                       |                       |
| Mean (SD)                 | 0.0155 (0.00393)   | 0.0208 (0.00500)      | 0.0205 (0.00510)      |
| Median                    | 0.0155             | 0.0208                | 0.0205                |
| [2.5h- 97.5'percentile]   | [0.0107-0.0214]    | [0.0114 -0.0302]      | [0.0105-0.0299]       |
| Vc (L)                    |                    |                       |                       |
| Mean (SD)                 | 2.77 (0.595)       | 3.46 (0.748)          | 3.42 (0.756)          |
| Median                    | 2.59               | 3.54                  | 3.44                  |
| [2.5h- 97.5\" percentile]  | [2.28-3.71]        | [2.18-4.90]           | [2.20-4.84]           |
| Vp (L)                    |                    |                       |                       |
| Mean (SD)                 | 1.91 (0.347)       | 2.36 (0.413)          | 2.33 (0.423)          |
| Median                    | 1.92               | 2.37                  | 2.35                  |
| [2.5h-- 97.5 percentile]  | [1.47-2.41]        | [1.54-3.10]           | [1.45-3.08]           |
| Vss (L)                   |                    |                       |                       |
| Mean (SD)                 | 4.68 (0.902)       | 5.82 (1.14)           | 5.74 (1.16)           |
| Median                    | 4.55               | 5.90                  | 5.85                  |
| [2.5h - 97.5h percentile] | [3.76 - 6.11]      | [3.84 - 7.87]         | [3.73 - 7.83]         |
| tunp (days)               |                    |                       |                       |
| Mean (SD)                 | 60.2 (2.73)        | 56.3 (8.58)           | 56.6 (8.36)           |
| Median                    | 60.2               | 56.7                  | 57.2                  |
| [2.5*- 97.5* percentile]  | [56.8 - 63.1]      | [37.4 - 71.2]         | [37.8- 70.9]          |
| Cinngh (μg/mL)            |                    |                       |                       |
| Mean (SD)                 | 735 (112)          | 588 (204)             | 598 (202)             |
| Median                    | 771                | 557                   | 569                   |
| [2.5h- 97.5 percentile]   | [553 -829]         | [266-1090]            | [268-1060]            |
| Cmaa (μg/mL)              |                    |                       |                       |
| Mean (SD)                 | 1920 (303)         | 1600 (380)            | 1620 (382)            |
| Median                    | 2010               | 1530                  | 1580                  |
| [2.5h- 97.5 percentile]   | [1440-2230]        | [1120-2590]           | [1130-2540]           |
| C.. (μg/mL)               |                    |                       |                       |
| Mean (SD)                 | 1060 (156)         | 863 (251)             | 877 (250)             |
| Median                    | 1120               | 820                   | 834                   |
| [2.5- 97.5\"percentile]    | [802 - 1180]       | [491 -1480]           | [494 -1440]           |
| AUC (ug.h/mL)             |                    |                       |                       |
| Mean (SD)                 | 1420000 (210000)   | 1160000 (337000)      | 1180000 (336000)      |
| Median                    | 1500000            | 1100000               | 1120000               |
| [2.5h- 97.5\"percentile]   | [1080000-1590000]  | [659000-1990000]      | [664000-1940000]      |

Abbreviations: CL = clearance; Q = intercompartmental clearance; t1/2 β = terminal elimination half -life; Vc = volume of distribution in the central compartment; Vp = volume of distribution in the peripheral compartment. Vss = apparent volume of distribution at equilibrium, SD = standard deviation; t1/2  = terminal elimination half-life; AUCss = area under the curve over the dosing interval under steady state conditions (ie, 8 weeks); Cavg,ss = average concentrations under steady state conditions; Cmax,ss = maximum concentrations under steady state conditions; Ctrough,ss = minimum concentrations under steady state conditions

<div style=\"page-break-after: always\"></div>

Table  11:  Descriptive  Statistics  of  Steady  State  Exposure  Parameters  of  Ravulizumab  in  Study ALXN1210-MG-306 - Japanese and Non-Japanese Patients by Body Weight Groups

<!-- image -->

|                                            | 240 to ≤ 60 kg               | 240 to ≤ 60 kg                | ≥60 to < 100 lg                                                                                         | ≥60 to < 100 lg                           | 2100 kg                                 |
|--------------------------------------------|------------------------------|-------------------------------|---------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------------|
| Parameters                                 | Japanese (N=2)               | Non-Japanese (N=5)            | Japanese (f=ND                                                                                          | Non-Japanese (N=43)                       | Nou-Japanese (N=32)                     |
| Cireaa (μg/mL)                             |                              |                               |                                                                                                         |                                           |                                         |
| Mean (SD) Median [2.5 - g7.5 percentile]   | 799 (NA) 799 [775 -822]      | 971 (359) 840 [619 -1440]     | 703 (128) 723 [546- 825]                                                                                | 629 (162) 599 [289 -866]                  | 473 (118) 482 [254 - 667]               |
| Cma (μg/mL)                                |                              |                               |                                                                                                         |                                           |                                         |
| Mean (SD) Median [2.5* - 97.5° percentile] | 2080 (NA) 2080 [2080 - 2080] | 2360 (570) 2130 [1860 - 3050] | 1830 (355) 1850 [1420-2220]                                                                             | 1690 (293) 1730 [1220 -2160]              | 1360 (215) 1390 [881-1770]              |
| C. (μg/mL)                                 |                              |                               |                                                                                                         |                                           |                                         |
| Mean (SD) Median [2.5a - g7.5* percenile]  | 1160 (NA) 1160 [1150 -1170]  | 1360 (421) 1200 [949-1890]    | 1010 (176) 1040 [792 -1180]                                                                             | 917 (195) 898 [520-1210]                  | 713 (140) 724 [424 - 931]               |
| AUC, (μg.h/mL)                             |                              |                               |                                                                                                         |                                           |                                         |
| Mean (SD) Median                           | 1550000 (NA) 1550000         | 1820000 (566000) 1620000      | 1360000 (236000) 1400000 [2.5°- 97.5°percentile][1540000 -1570000][1280000- 2540000][1060000 - 1590000] | 1230000 (262000) 1210000 [698000-1630000] | 958000 (188000) 972000 [569000-1250000] |

Abbreviations: AUCss = area under the curve over the dosing interval under steady state conditions (ie, 8 weeks); Cavg,ss = average concentrations under steady state conditions; Cmax,ss = maximum concentrations under steady  state  conditions;  Ctrough,ss  =  minimum  concentrations  under  steady  state  conditions;  NA  =  not applicable.

Note: a standard deviation was not derived for a sample size less than three.

In Japanese patients ≥40 to &lt; 60 kg, the median Ctrough,ss, Cmax,ss, and Cavg,ss of ravulizumab were 4.9%, 2.3%, and 3.3% lower than those observed in non-Japanese patients, respectively.

In Japanese patients ≥60 to &lt; 100 kg, the median Ctrough,ss, Cmax,ss, and Cavg,ss of ravulizumab were 17.2%, 6.5%, and 13.7% higher than those observed in non-Japanese patients, respectively.

## 2.3.3. Pharmacodynamics

## Mechanism of action

Ravulizumab  is  a  humanized  monoclonal  antibody  that  binds  to  C5  and  blocks  its  activation  by complement pathway convertases, thereby preventing the release of the proinflammatory anaphylatoxin C5a and the formation of the terminal complement complex via C5b.

Autoantibodies recognize targeted neural or muscle tissues, including the acetylcholine receptor (AChR), leading to uncontrolled terminal complement activation at the neural or muscle surface 20 . Autoantibodydriven uncontrolled terminal complement activation with membrane attack complex (MAC)-dependent lysis and activation, and C5a-dependent inflammation at the neuromuscular junction (NMJ) causes AChR loss and failure of neuromuscular transmission.

20  Ha, J. C., &amp; Richman, D. P. (2015). Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1852(4), 651-657.

<div style=\"page-break-after: always\"></div>

Consistent with this model, both complement component (C) 3 (C3a and C3b) fragments and the MAC C5b-9 have been found in NMJs of MG patients 21  . Taken together, the data support that uncontrolled terminal complement activation at the NMJ plays a role in the destruction of post-synaptic structure. Rapid, complete, and sustained inhibition of terminal complement activation is a biologically rational approach to prevent the damage caused in patients with gMG.

## 2.3.4. PK/PD modelling

## Exposure-efficacy relationship

All serum free C5 concentrations post dose for the ravulizumab-treated patients during the RandomizedControlled  Period  were  &lt; 0.5 μg/mL  ( Figure ),  including  patients  experiencing  clinical  deterioration. Thus,  ravulizumab  treatment  resulted  in  immediate,  complete,  and  sustained  terminal  complement inhibition in all patients with gMG throughout the entire treatment period with body weight-based dosing.

Figure 6: Serum Free C5 Concentration-Time Profiles (Study ALXN1210-MG-306 Full Analysis Set)

<!-- image -->

Note: For serum free C5 concentrations that were BLQ, LLOQ/2 = 0.00915 µg/mL was utilized. Y-axis is presented on a log scale. The horizontal line in the middle of each box indicates the median, a diamond indicates the mean, and the top and the bottom borders of the box mark the 75th and 25th percentiles, respectively. The whiskers represent the 1.5 IQR of the lower quartile and upper  quartile.  Outliers  are  represented  by  asterisk  beyond  the  whiskers.  Dashed  horizontal  line  indicates  serum  free  C5 concentration of 0.5 µg/mL. Only data from scheduled visits were included in this figure.

Abbreviations: BLQ = below the limit of quantification; C5 = complement component 5; IQR = interquartile range; LLOQ = lower limit of quantification

21  Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J Neuropathol Exp Neurol. 1978;37(2):212-223.

<div style=\"page-break-after: always\"></div>

## Exposure-safety analysis

Table 12: Summary of Adverse Events Occurring in Greater Than or Equal to 5% of Ravulizumabtreated Patients During the Randomized-Controlled Period of Study ALXN1210-MG306

| Adverse Event           |   Frequency |   Percent (%) a |
|-------------------------|-------------|-----------------|
| Any adverse event       |          78 |            90.7 |
| Headache                |          16 |            18.6 |
| Diarrhoea               |          13 |            15.1 |
| Nausea                  |           9 |            10.5 |
| Dizziness               |           8 |             9.3 |
| Back pain               |           7 |             8.1 |
| Arthralgia              |           6 |             7   |
| Fatigue                 |           6 |             7   |
| Abdominal pain          |           5 |             5.8 |
| COVID-19                |           5 |             5.8 |
| Urinary tract infection |           5 |             5.8 |

The probability of an AE observed as a function of model-predicted Cmax,ss of ravulizumab is presented by Cmax,ss quartiles in Table 13 and as a function of model-predicted AUCss by AUCss quartiles in Table 14.

Similar results were observed for the Ctrough,ss and Cavg,ss of ravulizumab).

Table 13: Probability of Adverse Events as a Function of Model-Predicted Ravulizumab Maximum Concentration at Steady State by Quartile in Study ALXN1210-MG-306

| Adverse Event Statistic   | Q1 of C max,ss (874 - 1372 µg/mL) (N = 22)   | Q2 of C max,ss (1383 - 1572 µg/mL) (N = 21)   | Q3 of C max,ss (1586 - 1838 µg/mL) (N = 21)   | Q4 of C max,ss (1860 - 3072 µg/mL) (N = 22)   | Overall (N = 86)        |
|---------------------------|----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------|
| Any adverse event         | Any adverse event                            | Any adverse event                             | Any adverse event                             | Any adverse event                             | Any adverse event       |
| n (%) [95% CI]            | 21 (95.5) [77.2 - 99.9]                      | 19 (90.5) [69.6 - 98.8]                       | 19 (90.5) [69.6 - 98.8]                       | 19 (86.4) [65.1 - 97.1]                       | 78 (90.7) [82.5 - 95.9] |
| Headache                  | Headache                                     | Headache                                      | Headache                                      | Headache                                      | Headache                |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                         | 5 (23.8) [8.2 - 47.2]                         | 4 (19.9) [5.4 - 41.9]                         | 5 (22.7) [7.8 - 45.4]                         | 16 (18.6) [11.0 - 28.4] |
| Diarrhoea                 | Diarrhoea                                    | Diarrhoea                                     | Diarrhoea                                     | Diarrhoea                                     | Diarrhoea               |
| n (%) [95% CI]            | 6 (27.3) [10.7 - 50.2]                       | 0 [0.0 - 16.1]                                | 3 (14.3) [3.0 - 36.3]                         | 4 (18.2) [5.2 - 40.3]                         | 13 (15.1) [8.3 - 24.5]  |
| Nausea                    | Nausea                                       | Nausea                                        | Nausea                                        | Nausea                                        | Nausea                  |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                         | 4 (19.0) [5.4 - 41.9]                         | 2 (9.5) [1.2 - 30.4]                          | 2 (9.1) [1.1 - 29.2]                          | 9 (10.5) [4.9 - 18.9]   |
| Dizziness                 | Dizziness                                    | Dizziness                                     | Dizziness                                     | Dizziness                                     | Dizziness               |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                         | 3 (14.3) [3.0 - 36.3]                         | 1 (4.8) [0.1 - 23.8]                          | 2 (9.1) [1.1 - 29.2]                          | 8 (9.3) [4.1 - 17.5]    |
| Back pain                 | Back pain                                    | Back pain                                     | Back pain                                     | Back pain                                     | Back pain               |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                         | 2 (9.5) [1.2 - 30.4]                          | 2 (9.5) [1.2 - 30.4]                          | 2 (9.1) [1.1 - 29.2]                          | 7 (8.1) [3.3 - 16.1]    |
| Arthralgia                |                                              |                                               |                                               |                                               |                         |

<div style=\"page-break-after: always\"></div>

Table 13: Probability of Adverse Events as a Function of Model-Predicted Ravulizumab Maximum Concentration at Steady State by Quartile in Study ALXN1210-MG-306

| Adverse Event Statistic   | Q1 of C max,ss (874 - 1372 µg/mL) (N = 22)   | Q2 of C max,ss (1383 - 1572 µg/mL) (N = 21)   | Q3 of C max,ss (1586 - 1838 µg/mL) (N = 21)   | Q4 of C max,ss (1860 - 3072 µg/mL) (N = 22)   | Overall (N = 86)        |
|---------------------------|----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------|
| n (%) [95% CI]            | 0 [0.0 - 15.4]                               | 1 (4.8) [0.1 - 23.8]                          | 2 (9.5) [1.2 - 30.4]                          | 3 (13.6) [2.9 - 34.9]                         | 6 (7.0) [2.6 - 14.6]    |
| Fatigue                   |                                              |                                               |                                               |                                               |                         |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                         | 3 (14.3) [3.0 - 36.3]                         | 1 (4.8) [0.1 - 23.8]                          | 0 [0.0 - 15.4]                                | 6 (7.0) [2.6 - 14.6]    |
| Abdominal pain            |                                              |                                               |                                               |                                               |                         |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                         | 0 [0.0 - 16.1]                                | 3 (14.3) [3.0 - 36.3]                         | 0 [0.0 - 15.4]                                | 5 (5.8) [1.9 - 13.0]    |
| COVID-19                  |                                              |                                               |                                               |                                               |                         |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                         | 3 (14.3) [3.0 - 36.3]                         | 0 [0.0 - 16.1]                                | 1 (4.5) [0.1 - 22.8]                          | 5 (5.8) [1.9 - 13.0]    |
| Urinary tract infection   | Urinary tract infection                      | Urinary tract infection                       | Urinary tract infection                       | Urinary tract infection                       | Urinary tract infection |
| n (%) [95% CI]            | 0 [0.0 - 15.4]                               | 2 (9.5) [1.2 - 30.4]                          | 1 (4.8) [0.1 - 23.8]                          | 2 (9.1) [1.1 - 29.2]                          | 5 (5.8) [1.9 - 13.0]    |

Note: 95% CI are calculated using the Clopper and Pearson method. Adverse events that occurred in ≥ 5% of ravulizumab-treated patients during the Randomized-Controlled Period of Study ALXN-MG306 are included.

Abbreviations:  CI = confidence  interval;  Cmax,ss = maximum  observed  serum  concentration  under steady-state conditions; Q1 = 1st quartile; Q2 = 2nd quartile; Q3 = 3rd quartile; Q4 = 4th quartile

Table 14: Probability of Adverse Events as a Function of Model-Predicted Ravulizumab Area Under the Concentration-Time Curve at Steady State by Quartile in Study ALXN1210-MG-306

| Adverse Event Statistic   | Q1 of AUC ss (525660 - 971458 µg × h/mL) (N = 22)   | Q2 of AUC ss (9 73510 - 1116088 µg × h/mL) (N = 21)   | Q3 of AUC ss (1125641 - 1359394 µg × h/mL) (N = 21)   | Q4 of AUC ss (1379040 - 2573600 µg × h/mL) (N = 22)   | Overall (N = 86)        |
|---------------------------|-----------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------|
| Any adverse event         | Any adverse event                                   | Any adverse event                                     | Any adverse event                                     | Any adverse event                                     | Any adverse event       |
| n (%) [95% CI]            | 21 (95.5) [77.2 - 99.9]                             | 19 (90.5) [69.6 - 98.8]                               | 19 (90.5) [69.6 - 98.8]                               | 19 (86.4) [65.1 - 97.1]                               | 78 (90.7) [82.5 - 95.9] |
| Headache                  | Headache                                            | Headache                                              | Headache                                              | Headache                                              | Headache                |
| n (%) [95% CI]            | 3 (13.6) [2.9 - 34.9]                               | 3 (14.3) [3.0 - 36.3]                                 | 5 (23.8) [8.2 - 47.2]                                 | 5 (22.7) [7.8 - 45.4]                                 | 16 (18.6) [11.0 - 28.4] |
| Diarrhoea                 | Diarrhoea                                           | Diarrhoea                                             | Diarrhoea                                             | Diarrhoea                                             | Diarrhoea               |
| n (%) [95% CI]            | 5 (22.7) [7.8 - 45.4]                               | 1 (4.8) [0.1 - 23.8]                                  | 4 (19.0) [5.4 - 41.9]                                 | 3 (13.6) [2.9 - 34.9]                                 | 13 (15.1) [8.3 - 24.5]  |
| Nausea                    | Nausea                                              | Nausea                                                | Nausea                                                | Nausea                                                | Nausea                  |
| n (%) [95% CI]            | 5 (22.7) [7.8 - 45.4]                               | 1 (4.8) [0.1 - 23.8]                                  | 1 (4.8) [0.1 - 23.8]                                  | 2 (9.1) [1.1 - 29.2]                                  | 9 (10.5) [4.9 - 18.9]   |
| Dizziness                 | Dizziness                                           | Dizziness                                             | Dizziness                                             | Dizziness                                             | Dizziness               |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                                | 4 (19.0) [5.4 - 41.9]                                 | 0 [0.0 - 16.1]                                        | 2 (9.1) [1.1 - 29.2]                                  | 8 (9.3) [4.1 - 17.5]    |
| Back pain                 | Back pain                                           | Back pain                                             | Back pain                                             | Back pain                                             | Back pain               |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                                | 1 (4.8) [0.1 - 23.8]                                  | 4 (19.0) [5.4 - 41.9]                                 | 1 (4.5) [0.1 - 22.8]                                  | 7 (8.1) [3.3 - 16.1]    |
| Arthralgia                | Arthralgia                                          | Arthralgia                                            | Arthralgia                                            | Arthralgia                                            | Arthralgia              |

<div style=\"page-break-after: always\"></div>

Table 14: Probability of Adverse Events as a Function of Model-Predicted Ravulizumab Area Under the Concentration-Time Curve at Steady State by Quartile in Study ALXN1210-MG-306

| Adverse Event Statistic   | Q1 of AUC ss (525660 - 971458 µg × h/mL) (N = 22)   | Q2 of AUC ss (9 73510 - 1116088 µg × h/mL) (N = 21)   | Q3 of AUC ss (1125641 - 1359394 µg × h/mL) (N = 21)   | Q4 of AUC ss (1379040 - 2573600 µg × h/mL) (N = 22)   | Overall (N = 86)        |
|---------------------------|-----------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------|
| n (%) [95% CI]            | 0 [0.0 - 15.4]                                      | 1 (4.8) [0.1 - 23.8]                                  | 2 (9.5) [1.2 - 30.4]                                  | 3 (13.6) [2.9 - 34.9]                                 | 6 (7.0) [2.6 - 14.6]    |
| Fatigue                   |                                                     |                                                       |                                                       |                                                       |                         |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                                | 4 (19.0) [5.4 - 41.9]                                 | 0 [0.0 - 16.1]                                        | 0 [0.0 - 15.4]                                        | 6 (7.0) [2.6 - 14.6]    |
| Abdominal                 | pain                                                |                                                       |                                                       |                                                       |                         |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                                | 1 (4.8) [0.1 - 23.8]                                  | 2 (9.5) [1.2 - 30.4]                                  | 1 (4.5) [0.1 - 22.8]                                  | 5 (5.8) [1.9 - 13.0]    |
| COVID- 19                 | COVID- 19                                           |                                                       |                                                       |                                                       |                         |
| n (%) [95% CI]            | 2 (9.1) [1.1 - 29.2]                                | 2 (9.5) [1.2 - 30.4]                                  | 0 [0.0 - 16.1]                                        | 1 (4.5) [0.1 - 22.8]                                  | 5 (5.8) [1.9 - 13.0]    |
| Urinary tract infection   | Urinary tract infection                             | Urinary tract infection                               | Urinary tract infection                               | Urinary tract infection                               | Urinary tract infection |
| n (%) [95% CI]            | 1 (4.5) [0.1 - 22.8]                                | 1 (4.8) [0.1 - 23.8]                                  | 1 (4.8) [0.1 - 23.8]                                  | 2 (9.1) [1.1 - 29.2]                                  | 5 (5.8) [1.9 - 13.0]    |

Note:  95%  CI  are  calculated  using  the  Clopper  and  Pearson  method.  Adverse  events  that  occurred  in ≥ 5%  of ravulizumab-treated patients during the Randomized-Controlled Period of Study ALXN-MG-306 are included. Abbreviations: AUCss = area under the serum concentration-time curve at steady state; CI = confidence interval; Q1 = 1st quartile; Q2 = 2nd quartile; Q3 = 3rd quartile; Q4 = 4th quartile

## 2.3.5. Discussion on clinical pharmacology

The clinical pharmacology properties of ravulizumab in patients with gMG has been characterized using experimental information from Study ALXN1210-MG-306, which included pharmacokinetic and pharmacodynamic observations in 86 patients receiving ravulizumab and 89 patients in the placebo group. The model development programs were considered adequate by CHMP.

Ravulizumab Cmax and Ctrough concentrations were remarkably lower in the highest (above 100 kg) weight group compared to the lowest one (40-60 kg) even after the first (loading) dose. This difference became much more pronounced through the last maintenance dose, reaching a difference of 47% in Ctrough between the highest and the lowest bodyweight groups.

The population PK model used incorporates a two-compartment model with linear clearance that was previously developed in healthy subjects and patients with PNH. In general, the structural and stochastic elements of the population PK model are adequate to properly describe the observed data in patients with gMG. PK parameters of the peripheral compartment (Q and Vp) were fixed to the value obtained in patients with PNH and healthy subjects, but CL, Vc and covariates effects were reestimated in patients with gMG. This modelling strategy might be explained by the lack of sufficient data in the alpha- and beta-distribution phases. However, the assumption that similar Vp and Q across the different indications is unclear and it may cause a model-misspecification on other PK parameters of the model. Despite of this, the relative standard errors of PK parameters were below 10%, except for IVIg intervention (due to the unbalanced and scarce (n=2) distribution of subjects), showing the adequacy of the final parameter estimates.

A sensitivity analysis was performed by using the Pop-PK model developed in patients with PNH as a reference model for assessing which (if any) covariates should be included in the gMG Pop-PK base model.  For  patients  with  PNH,  the  final  model  included  body  weight,  BMI,  sex,  and  hemoglobin  as

<div style=\"page-break-after: always\"></div>

significant  covariates  on  PK.  It  was  noted  that,  the  effect  of  hemoglobin  on  CL  and  Vc  were  not statistically  significant  because  the  95%  CI  included  0.  The  effect  of  BMI  on  Vc  and  Vp  remained statistically significant. The effect of sex on Vc was also statistically significant. Overall, the effect of hemoglobin originally identified in patients with PNH was no longer significant in patients with gMG.

Comparison of exposure in patients with PNH, aHUS and gMG showed similar exposure PK metrics and half-life of ravulizumab, suggesting no significant differences due to disease condition.

Regarding assessment of immunogenicity, there were no treatment-emergent ADA-positive findings and as such no impact of immunogenicity on ravulizumab PK or PD is expected in patients with gMG.

Of note, the covariate analysis revealed a clinically relevant effect of body weight on Ctrough,ss and Cmax,ss, suggesting that differences &gt;20% are expected in patients with body weight &lt;52 and &gt;93 kg compared to the reference patient (70 kg). Despite the fact that experimental ravulizumab PK exposure metrics following the maintenance dose  are different to model-predicted ravulizumab PK exposure metrics following the maintenance dose, both suggest clear differences in exposure despite the different dosing regimen by body weight group. From the PK/PD relationship no clinically relevant differences in biomarker response and safety events among the three body-weight sub-groups of adult patients have been identified and the dosing regimen recommended in patients with gMG is identical to the one proposed in patients with PNH or aHUS. This is considered adequate by the CHMP.

Regarding the clinical evaluation of the effect of ravulizumab in Japanese and non-Japanese patients no relevant differences in exposure were observed. However, since only six Japanese patients were enrolled no definitive conclusions can be made at this time.

The PK/PD relationship has been empirically established through the graphical representation of experimental PK and PD observations, but no model-based approach has been conducted that would enable to understand whether alternative dosing strategies might be of interest. Based on the experimental evidence, the selection of 175 µg/mL might be justified based on C5 free concentration in treated patients vs. placebo arm. This result is in line with the threshold identified for patients with PNH and aHUS. Free C5 concentrations in the ravulizumab group were definitely below this threshold not only post-dose, but also pre-dose, even the outliers. It was further clarified that these low free C5 values were bioanalytical outliers most likely, since no assignable cause of these low free C5 values were revealed by the bioanalytical run data and subsequent sample analysis report and ravulizumab concentrations of these patients were always below the level of quantification, justifying that they were not exposed inadvertently to ravulizumab during the study.

The exposure-safety evaluation revealed no clinically relevant relationship of ravulizumab quartiles and the incidence/probability of adverse events. A minor trend was observed for arthralgia, headache and nausea, but in general the probability were below 25%. Therefore, no significant exposure-safety relationship in patients with gMG is observed in Study ALXN1210-MG-306.

## 2.3.6. Conclusions on clinical pharmacology

The clinical pharmacology properties of ravulizumab in patients with gMG have been characterized in 86 patients receiving ravulizumab and 89 subjects receiving placebo (Study ALXN1210-MG-306). The modelling strategy and study design conditions seem appropriate to achieve the planned objectives. A previously developed population PK model in patients with PNH has been applied, showing its ability to characterize the observed data.

The available clinical pharmacology data submitted supports the use of ravulizumab in the approved indication.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Dose response study

The ravulizumab dosing regimen was designed based on modelling and simulation analyses using data from healthy subjects and patients with PNH and aHUS to maintain efficacious concentrations across the longer dosing interval.

The body weight-based ravulizumab treatment regimen proposed for adult patients with gMG is identical to the one approved for PNH and aHUS which includes a loading dose on Day 1, followed by maintenance doses on Day 15 and every 8 weeks (q8w) thereafter, administered by IV infusion (Table 15 ).

Table 15 : Ravulizumab Weight-Based Dosing Regimen

| Body Weight      |   Loading Dose (mg) |   Maintenance Dose (mg) |
|------------------|---------------------|-------------------------|
| ≥ 40 to < 60 kg  |                2400 |                    3000 |
| ≥ 60 to < 100 kg |                2700 |                    3300 |
| ≥ 100 kg         |                3000 |                    3600 |

Plasma exchange (PE), plasmapheresis (PP), and intravenous immunoglobulin (IVIg) have been shown to reduce ravulizumab serum levels Information on Supplemental Doses after PE, PP or IVIg are shown in Table 16.

Table 16: Supplemental Doses after PE, PP or IVIg

|                 |   Most Recent Dose (mg) |   Supplemental Dose (mg) following each PP or session | Body Weight   |
|-----------------|-------------------------|-------------------------------------------------------|---------------|
| ≥ 40 to < 60 kg |                    2400 |                                                  1200 | of IVIg 600   |
| ≥ 40 to < 60 kg |                    3000 |                                                  1500 | of IVIg 600   |
| ≥ 40 to < 60 kg |                    2700 |                                                  1500 | 600           |
| ≥ 40 to < 60 kg |                    3300 |                                                  1800 | 600           |
| ≥ 100 kg        |                    3000 |                                                  1500 | 600           |
| ≥ 100 kg        |                    3600 |                                                  1800 | 600           |

Abbreviations: IVIg = intravenous immunoglobulin; PE = plasma exchange; PP = plasmapheresis.

The dose recommendations by body weight are justified based on differences in exposure that ensure serum free complement component complete inhibition (see tables 17 and 18).

Table 1 7 : Ravulizumab PK Parameters Following the First (Loading) Dose (Study ALXN1210-MG-306 PK Analysis Set)

| Parameter        | Statistics        | All Patients      | ≥ 40 to < 60 kg    | ≥ 60 to < 100 kg   | ≥ 100 kg          |
|------------------|-------------------|-------------------|--------------------|--------------------|-------------------|
| C max (μg/mL)    | n                 | 86                | 7                  | 47                 | 32                |
| C max (μg/mL)    | Mean (SD)         | 874.1 (184.24)    | 1054.3 (163.57)    | 912.1 (170.39)     | 778.8 (160.96)    |
| C max (μg/mL)    | CV%               | 21.1              | 15.5               | 18.7               | 20.7              |
| C max (μg/mL)    | Median (min, max) | 836.0 (399, 1420) | 1060.0 (778, 1310) | 868.0 (692, 1420)  | 779.5 (399, 1350) |
| C trough (μg/mL) | n                 | 85                | 7                  | 46                 | 32                |
| C trough (μg/mL) | Mean (SD)         | 417.8 (115.51)    | 555.7 (116.45)     | 438.5 (118.11)     | 357.8 (68.12)     |
| C trough (μg/mL) | CV%               | 27.6              | 21.0               | 26.9               | 19.0              |
| C trough (μg/mL) | Median (min, max) | 397.0 (234, 1000) | 520.0 (451, 751)   | 422.0 (305, 1000)  | 339.0 (234, 570)  |

<div style=\"page-break-after: always\"></div>

| Parameter   | Statistics   | All Patients   | ≥ 40 to < 60 kg   | ≥ 60 to < 100 kg ≥   | 100 kg   |
|-------------|--------------|----------------|-------------------|----------------------|----------|

Abbreviations:  Cmax = maximum  observed  serum  concentration;  Ctrough = concentration  at  the  end  of  the dosage  interval;  CV = coefficient  of  variation;  max = maximum;  min = minimum;  PK = pharmacokinetics; SD = standard deviation

Table 18: Ravulizumab PK Parameters Following the Final Maintenance Dose (Study ALXN1210-MG-306 PK Analysis Set

| Parameter        | Statistics        | All Patients       | ≥ 40 to < 60 kg     | ≥ 60 to < 100 kg    | ≥ 100 kg           |
|------------------|-------------------|--------------------|---------------------|---------------------|--------------------|
| C max (μg/mL)    | n                 | 76                 | 4                   | 43                  | 29                 |
| C max (μg/mL)    | Mean (SD)         | 1548.3 (359.43)    | 2015.0 (345.40)     | 1645.3 (337.63)     | 1340.1 (267.95)    |
| C max (μg/mL)    | CV%               | 23.2               | 17.1                | 20.5                | 20.0               |
| C max (μg/mL)    | Median (min, max) | 1500.0 (810, 2510) | 1900.0 (1750, 2510) | 1660.0 (1060, 2410) | 1340.0 (810, 1990) |
| C trough (μg/mL) | n                 | 70                 | 4                   | 39                  | 27                 |
| C trough (μg/mL) | Mean (SD)         | 586.6 (173.91)     | 887.3 (82.72)       | 635.7 (157.28)      | 471.3 (109.47)     |
| C trough (μg/mL) | CV%               | 29.6               | 9.3                 | 24.7                | 23.2               |
| C trough (μg/mL) | Median (min, max) | 570.0 (211, 1030)  | 866.5 (817, 999)    | 649.0 (241, 1030)   | 456.0 (211, 635)   |

Note: Data were excluded for patients after they received a supplemental dose following PE, PP, or IVIg. Abbreviations:  Cmax = maximum  observed  serum  concentration;  Ctrough = concentration  at  the  end  of  the dosage interval; CV = coefficient of variation; IVIg = intravenous immunoglobulin; max = maximum; min = minimum; PE = plasma exchange; PK = pharmacokinetics; PP = plasmapheresis; SD = standard deviation

## 2.4.2. Main study

## A  Phase  3,  Randomized,  Double-Blind,  Placebo-Controlled,  Multicenter  Study  to Evaluate  the  Safety  and  Efficacy  of  Ravulizumab  in  Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis

Study ALXN1210 MG 306 is a Phase 3, randomized, double-blind, parallel-group, placebo controlled, multicenter  study  with  an  ongoing  open-label  extension  to  evaluate  the  safety  and  efficacy  of ravulizumab administered by IV infusion for the treatment of adult patients with gMG.

The study consists of an up to 4 week Screening Period, a 26 week double-blind, Randomized Controlled Period, and an Open-Label Extension Period of up to 2 years (Figure 8).

<!-- image -->

<div style=\"page-break-after: always\"></div>

Abbreviations: DB = double-blind; IV = intravenous; LD = loading dose; MD = maintenance dose.

## Methods

## Study participants

Enrolled in this study were male and female patients ≥ 18 years of age (at the time of informed consent) diagnosed with gMG (at least 6 months prior to the Screening Visit) confirmed by positive serologic test for anti-AChR antibodies.

With respect to the type of Patient and Disease Characteristics the main following criteria were required

1. Diagnosed with MG at least 6 months (180 days) prior to the date of the Screening Visit
2. Confirmation of eligibility by:
- a. Positive serologic test for anti-AChR Abs as confirmed at screening, and
- b. One of the following (either historical or during screening):
- abnormal neuromuscular transmission test demonstrated by single-fiber electromyography or repetitive nerve stimulation
- positive anticholinesterase test (eg, edrophonium chloride test)
- demonstrated improvement in MG signs on oral cholinesterase inhibitors, as assessed by the treating physician
3. Myasthenia Gravis Foundation of America Clinical Classification Class II to IV at screening
4. MGADL profile must be ≥ 6 at screening and randomization (Day 1)

5. Patients receiving treatment with any of the following must have been receiving treatment and on a stable dose for the time periods specified below prior to the date of the Screening Visit:

- Azathioprine (AZA): Must h ave been on AZA for ≥ 6 months (180 days) and have been on a stable dose for ≥ 2 months (60 days)
- Immunosuppressive therapies (ie, mycophenolate mofetil [MMF], methotrexate [MTX], cyclosporine [CYC], tacrolimus [TAC], or cyclophosphamide [CY]), must have been on the IST for ≥ 3 months (90 days) and have been on a stable dose for ≥ 1 month (30 days)
- Oral corticosteroids, must have been on a stable dose for ≥4 weeks (28 days)
- A cholinesterase inhibitor, at the time of the Screening Visit, must have been on a stable dose for ≥ 2 weeks (14 days)

6. All patients must be vaccinated against meningococcal infections within the 3 years prior to, or at the time of, initiating study drug.

## 7. Body weight ≥ 40 kg at the time of screening

Patients were excluded from the study if they had any active or untreated thymoma or history of thymic carcinoma or thymic malignancy; history of thymectomy, thymomectomy, or any thymic surgery within the  12  months  prior  to  screening;  clinical  features  that  are  consistent  with  myasthenia  gravis

<div style=\"page-break-after: always\"></div>

crisis/exacerbation or Clinical Deterioration at the time of the Screening Visit, or at any time prior to randomization; or previous treatment with complement inhibitors.

## Treatments

During the Randomized-Controlled Period, patients received a weight-based loading dose of ravulizumab (Table 19) or placebo on Day 1 followed by blinded maintenance doses of ravulizumab or placebo on Day 15 and then once every 8 weeks (q8w) thereafter. Both ravulizumab and placebo were administered by IV infusion.

Table 19: Ravulizumab Dosing Regimen for the Randomized-Controlled Period

| Body Weight      | Loading Dose (Day 1)   | Maintenance Dose (Day 15; administered q8w)   |
|------------------|------------------------|-----------------------------------------------|
| ≥ 40 to < 60 kg  | 2400 mg                | 3000 mg                                       |
| ≥ 60 to < 100 kg | 2700 mg                | 3300 mg                                       |
| ≥ 100 kg         | 3000 mg                | 3600 mg                                       |

Abbreviation: q8w = every 8 weeks

Following completion of the Day 183 (Week 26) assessments, in order to maintain the blind of the Randomized-Controlled Period, patients in the placebo group received a blinded loading dose of ravulizumab (2400 mg for thos e weighing ≥ 40 to &lt; 60 kg, 2700 mg for those weighing ≥ 60 to &lt; 100 kg, or 3000 mg for those weighing ≥ 100 kg). Patients in the ravulizumab group received a blinded ravulizumab dose of 900 mg starting at Week 28, all patients began open-label ravulizumab maintenance dosing q8w.

Throughout the study, rescue therapy (eg, high-dose corticosteroid, PE/PP, or IVIg) was allowed if a patient experienced protocol-defined Clinical Deterioration.  For this protocol, Clinical Deterioration is defined as any of the following:

1. Patients who experience an MG Crisis, which is defined as weakness from MG that is severe enough to  necessitate  intubation  or  to  delay  extubation  following  surgery.  The  respiratory  failure  is  due  to weakness of respiratory muscles. Severe bulbar (oropharyngeal) muscle weakness often accompanies the respiratory muscle weakness, or may be the predominant feature in some patients; or,
2. Significant symptomatic worsening to a score of 3 or a 2-point worsening from Baseline on any one of the individual MG-Activities of Daily Living (MG-ADL) items other than double vision or eyelid droop; or,
3. Administration of rescue therapy to a patient whose, in the opinion of the Investigator or Investigatordesignated physician, health would be in jeopardy, if rescue therapy were not given (eg, emergent situations).

During the OLE period, all patients from investigative sites in the concerned countries will switch from the 10 mg/mL to the 100 mg/mL formulation of ravulizumab with no change to the weight-based dose regimen until end of the study (Section 4.5). Following the formulation change, all subsequent ravulizumab doses will use the 100 mg/mL formulation

## Objectives

Primary

<div style=\"page-break-after: always\"></div>

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the MG-ADL profile

## Secondary

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in the QMG total score.

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on the improvement in quality of life measures.

To assess the efficacy of ravulizumab compared with placebo in the treatment of gMG based on other efficacy endpoints.

## Exploratory

To  assess  the  efficacy  of  ravulizumab  in  the  treatment  of  gMG  based  on  other  efficacy  endpoints throughout the study.

## PK/PD/Immunogenicity

To evaluate the PK/PD and immunogenicity of ravulizumab in the treatment of gMG throughout the study.

## Safety

To characterize the overall safety of ravulizumab in the treatment of gMG.

## Outcomes/endpoints

## Primary

Change from Baseline in MG-ADL total score at Week 26 of the Randomized-Controlled Period.

## Secondary

- Change from Baseline in QMG total score at Week 26.
- Improvement of at least 5 points in the QMG total score from Baseline at Week 26.
- Change from Baseline in the MG-QoL15r score at Week 26.
- Change from Baseline in Neuro-QoL Fatigue score at Week 26.
- Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26.

## Exploratory

- Change from Baseline in the MGC score at Week 26.
- MGFA PIS at Week 26
- Change from Baseline in EQ 5D 5L at Week 26.
- Change from Baseline in MG-ADL subcomponent scores (bulbar, limbs, respiratory, and ocular) at Week 26.
- Change from Baseline in QMG subcomponent scores (bulbar, limbs, respiratory, and ocular) at Week 26.
- Incidence of hospitalizations/MG-related hospitalizations.

<div style=\"page-break-after: always\"></div>

- Incidence of Clinical Deterioration/MG crisis.

PK/PD/Immunogenicity

- Change in serum ravulizumab concentration over time.
- Change in serum free C5 concentration over time.
- Incidence of treatment-emergent antidrug antibodies over time

Safety

- Incidence of adverse events and serious adverse events over time.
- Changes from Baseline in vital signs and laboratory assessments

## Sample size

The power calculations were based on the longitudinal change from baseline in MG-ADL total score observed in REGAIN (Study ECU-MG-301 - the Phase 3 study conducted with eculizumab in refractory gMG patients). The treatment effect (difference between the eculizumab and the placebo arms in mean change (95% CI) from baseline to Week 6 for MG-ADL) was estimated to be -1.9 (-3.27, -0.55) and the estimated common SD was 3.7. Based on these parameter estimates and the assumption that Study ALXN1210-MG-306 would provide similar results, a total of N = 160 patients was required to ensure at least 90% power to reject the null hypothesis of no treatment effect for MG-ADL at the Type I error rate = 5% (2-sided) based on a t-statistic for 2 independent samples.

## Randomisation

Patients  were  stratified  by  region  (North  America,  Europe,  Asia-Pacific,  and  Japan)  and  were  then randomly assigned in a 1:1 ratio to either the ravulizumab or placebo group.

## Blinding (masking)

All  investigative  site  personnel,  Sponsor  staff,  Sponsor  designees,  staff  directly  associated  with  the conduct of the study, and all patients were blinded to patient treatment assignments. The double-blind was maintained by using identical study drug kits and labels for ravulizumab and placebo. The placebo had an identical appearance to that of ravulizumab.

After the 26-Week Randomized- Controlled Period and assessments on Day 183 (Week 26), patients in the placebo group received a blinded loading dose of ravulizumab and patients in the ravulizumab group received a blinded ravulizumab dose of 900 mg.

Starting at Week 28, all patients will begin open-label ravulizumab maintenance doses q8w. For patients in the ravulizumab group, a blinded ravulizumab dose of 900 mg was chosen to ensure maintenance of complete C5 inhibition until the next scheduled maintenance dose at Week 28 (Day 197).

## Statistical methods

The primary hypothesis for this study is that ravulizumab is superior to placebo in improving MG-ADL total  score  at  Week  26.  The  treatment  effect  based  on  the  primary  endpoint  was  estimated  by  the difference in means between the ravulizumab group and the placebo group in the change from Baseline

<div style=\"page-break-after: always\"></div>

in MG-ADL total score at Week 26 irrespective of rescue therapy. A lower value of the corresponding estimate indicates a beneficial treatment effect.

The following secondary hypotheses were included in step-wise multiplicity adjustment (provided the null hypothesis for primary endpoint was rejected)

1. Ravulizumab is superior to placebo in improvement of QMG total score at Week 26.
2. Ravulizumab is superior to placebo in QMG 5point response (≥ 5 -point improvement from baseline in QMG total score) at Week 26.
3. Ravulizumab is superior to placebo in improvement of the MG-QOL15r total score at Week 26.
4. Ravulizumab is superior to placebo in improvement of Neuro-QOL Fatigue total score at Week 26.

5. Ravulizumab is superior to placebo in MG-ADL 3point response (≥ 3 -point improvement from baseline in MG-ADL total score) at Week 26.

The  study  was  designed  to  control  the  overall  2sided  Type  I  error  of  α  =  0.05.  The  primary  null hypothesis was to be tested first at α=0.05. If statistically significant, 5 secondary hypotheses were tested for superiority using a closed-testing procedure with the following order:

1. Change from Baseline in QMG total score at Week 26
2. Proportion of patients with improvement of at least 5 points in the QMG total score from baseline at Week 26
3. Change from Baseline in MG-QOL15r at Week 26
4. Change from Baseline in Neuro-QOL Fatigue at Week 26

5. Proportion of patients with improvement of at least 3 points in the MG-ADL total score from baseline at Week 26

The testing proceeded from (#1) to (#5), and if statistical significance was not achieved (p-value &gt;0.05), then  subsequent  endpoints  were  not  considered  statistically  significant.  Estimates  and  CIs  were computed for all these secondary endpoints regardless of the outcome of the closed testing procedure.

Under this prespecified closed testing procedure, no adjustment of the Type I error was required.

## Analysis Populations

The following analysis sets are defined in the SAP:

- Randomized Set: All patients who were randomized. Patients were analyzed according to the treatment they were randomized to receive, regardless of the treatment received.
- Full Analysis Set: All randomized patients who received at least 1 dose of study drug
- Per Protocol Set: All patients in the Full Analysis Set without any major protocol deviations during the  Randomized-Controlled  Period  and  who  met  all  of  the  prespecified  criteria  outlined  in Appendix 16.1.9 SAP Section 6.2
- Modified Full Analysis Set: A subset of patients in the Full Analysis Set which excludes patients who were impacted by COVID-19 during the Randomized-Controlled Period (details provided in Appendix 16.1.9 SAP Addendum 1.0)
- Safety Set: All patients who received at least 1 dose of study drug (ravulizumab or placebo). Patients were analyzed according to the treatment they actually received (must have received that treatment for the entire duration of the Randomized-Controlled Period).

<div style=\"page-break-after: always\"></div>

- PK Analysis Set: All patients who received at least 1 dose of ravulizumab and who had at least 1 post-baseline PK concentration available
- Ravulizumab Treated Set: All patients who received at least 1 dose of ravulizumab either in the Randomized-Controlled Period or the Open-Label Extension Period
- Open-Label Extension Set: All patients who received at least 1 dose of ravulizumab starting from Week 26 and who have completed Week 52 study visit or who would have completed Week 52 by the data cutoff date but withdrew from the study
- Open-Label Efficacy Extension Set: All patients in the Open-Label Efficacy Extension Set who have completed Week 52 study visit or withdrew from the study prior to Week 52

The FAS will be the primary population used for the analyses of all efficacy endpoints for the RandomizedControlled  Period.  Sensitivity  analyses  of  the  primary  and  secondary  efficacy  endpoints  will  also  be conducted using the PPS. The Randomized-Controlled Period Baseline is defined as the last available assessment value prior to first study drug infusion. In general, the baseline assessment will be the Day 1 assessment. For QMG and MGC, in the event that cholinesterase inhibitor was not withheld for at least 10 hours prior to administration of the QMG and MGC tests, the Screening Visit assessment will be used as Baseline. If cholinesterase inhibitor was not withheld for at least 10 hours for these visits, the Day 1 assessment will be used as Baseline.

Efficacy analyses of MG-ADL and QMG total scores will be performed on the OLEES. The OLE Baseline is defined as the last available assessment prior to first study drug administered in the OLE Period. In general, the OLE Baseline assessment will be the Day 183 assessment. In the event that cholinesterase inhibitor was not withheld for at least 10 hours prior to administration of the QMG test, the prior visit assessment will be used as baseline.

## Primary Analysis

The primary endpoint is change from Baseline in MG-ADL total score at Week 26 of the RandomizedControlled Period.

Change from Baseline in MG-ADL total score at Week 26 was analyzed using a mixed-effect model for repeated measures (MMRM; [Mallinckrodt 2001, 2004]). The model will include the MG-ADL change from Baseline score at each prespecified time point (Weeks 1, 2, 4, 10, 12, 18, and 26) as the response variable, fixed categorical effects of treatment, study visit and treatment-by-study visit interaction, the randomization stratification variable region; as well as fixed covariate of baseline MG-ADL total score. An unstructured covariance matrix will be used to model the correlations among repeated measurements within each patient. If this analysis fails to converge, the following structures will be tested and the final covariance structure will be determined by Akaike's information criterion: first order autoregressive, compound symmetry, and Toeplitz method. A difference in treatment effect between the ravulizumab and placebo treatment groups along with a 2-sided 95% confidence interval (CI) and p-value will be calculated. The Kenward-Rogers method will be used to estimate the denominator degrees of freedom. Missing data will not be imputed for the primary analysis. Similar summaries will be presented for the other Randomized-Controlled Period study visits. Absolute levels and the change in MG-ADL total score will be summarized by treatment group and visit.

## Subgroup Analyses

The following subgroups by treatment group were considered: Region, gender, race, age at first study drug infusion (18 to 65 years and &gt; 65 years), IST use at baseline (corticosteroid, corticosteroid + IST, none), years from diagnosis to informed consent (≤ median, &gt;median), MGFA (II, III, and IV), and baseline body weight categories (≥ 40 to &lt; 60 kg, ≥ 60 to &lt; 100 kg, and ≥ 100 kg). If the number of

<div style=\"page-break-after: always\"></div>

patients for a given subgroup category was less than 10, then the category maybe collapsed with another category.

Amendments of the analysis plan Prior to Unblinding or Database Lock

Additional analyses were implemented through Addendum 1.0 (dated 03 Dec 2020) and Addendum 2.0 Version 1.0 (dated 10 Jun 2021) to the final SAP.

The SAP Addendum 1.0 included changes required to address the impact of COVID-19 on the planned analyses as described in the Final SAP Version 1.0. The study objectives for this study did not change. Additionally,  the  originally  planned  statistical  methodology  as  specified  in  SAP  Version  1.0  has  not changed.

The SAP Addendum 2.0 included additional summaries of MG therapies for the Safety Set, additional MG therapy categories for subgroups for primary and secondary endpoint analyses of the Full Analysis Set, additional  covariance  structures  in  the  mixed-effect  model  for  repeated  measures  (MMRM)  for  the secondary endpoints of at least 3-point improvement in MG-ADL and at least 5-point improvement in QMG from baseline to Week 26, and a summary of treatment-emergent AEs during the RandomizedControlled  Period  utilizing  standardised  Medical  Dictionary  for  Regulatory  Activities  (MedDRA)  query (narrow)  (SMQ[N])  of  hypersensitivity  for  the  Safety  Set  (to  replace  the  infusion-related  reaction summary).

## Results

## Participant flow

Of the 242 screened patients, 67 patients were screen failures. The most common (≥ 5%) reasons for screen failure were not having a positive serologic test for anti-AChR antibodies at screening (n = 25) and not having an MGADL profile ≥ 6 (n = 16). Twenty -two patients failed initial screening but met all entry criteria upon second screening and were subsequently enrolled in the study.

In total, 175 patients were randomized and treated (placebo: N = 89; ravulizumab: N = 86) (Figure 9). Thirteen patients withdrew from the study prior to completing the Randomized-Controlled Period: 3 due to patient decision; 3 due to physician decision, 2 due to AEs ; 2 deaths (cerebral hemorrhage and COVID-19 pneumonia; 1 due to noncompliance with study drug; 1 due to protocol violation, and 1 due to other/Sponsor decision.

As of the clinical data cutoff date, 75 of the 79 patients in the Open-Label Extension Set (ie, patients who had received at least 1 dose of ravulizumab starting from Week 26 and who had reached Week 52 or would have completed the Week 52 Visit by the data cutoff dates but had withdrawn from the study prior to Week 52) had completed the Week 52 Visit (Table 20). Four of the 79 patients in the Open-Label Extension Set had withdrawn from the study during the Open-Label Extension Period (2 due to patient decision and 2 deaths due to COVID-19).

<div style=\"page-break-after: always\"></div>

<!-- image -->

a Two additional patients were randomized in error: 1 patient was randomized but could not be dosed due to a water leak in the laminar hood while preparing study drug; patient was ultimately screen failed. Additionally, 1 patient was randomized and screen failed due to pyridostigmine not being withheld 10 hours prior to Screening assessments; this patient was subsequently re-screened and re-randomized (patient was counted in the 'Randomized and treated' row).

b Other reason = Sponsor's request, measuring complement-related protein that could have led to potential unblinding (ie, the assessment would be biased)

c  Three patients in the ravulizumab group withdrew from the study for reasons related to COVID-19 during the RandomizedControlled Period (1 death, 1 due to noncompliance, 1 due to physician decision).

Abbreviations: AE = adverse event; COVID-19 = coronavirus disease 2019; FAS = Full Analysis Set

Table 20: Patient Disposition During the Open-label Extension Period (Open-label Extension Set)

|                                                              | Placebo to Ravulizumab (N=41) Overall   | Ravulizunab to Ravulizumab (N=38) Overall   | Total (N=79) Overall   |
|--------------------------------------------------------------|-----------------------------------------|---------------------------------------------|------------------------|
| Entered into Open-label Extension Period, n (%)              | 41 (100)                                | 38 (100)                                    | 79 (100)               |
| Treated, n (%)                                               | 41 (100)                                | 38 (100)                                    | 79 (100)               |
| Ongoing in Open-label Extension Period at data cutoff, n (%) | 40 (97.6)                               | 35 (92.1)                                   | 75 (94.9)              |
| Discontinued Open-label Extension Period, n (%)              | 1 (2.4)                                 | 3 (7.9)                                     | 4 (5.1)                |
| Death                                                        | 1 (2.4)                                 | 1 (2.6)                                     | 2 (2.5)                |
| Withdrawalby patient                                         | 0                                       | 2 (5.3)                                     | 2 (2.5)                |

Note:  The  Open-Label Extension Set consisted of all  patients  who  received  at  least 1  dose  of  ravulizumab  in  the  Open-Label Extension Period. Only patients reaching Week 52 or expected to reach Week 52 by the time of data cutoff were included.

<div style=\"page-break-after: always\"></div>

## Recruitment

Patients  were  enrolled  in  85  sites  across  13  countries  (Canada,  Czech  Republic,  Denmark,  France, Germany, Israel, Italy, Japan, The Netherlands, South Korea, Spain, Switzerland, and the US).

Date first patient enrolled: 26 Mar 2019

Data cutoff date: 11 May 2021

## Conduct of the study

Since the original  protocol  (dated  16  Nov  2018),  2  global  protocol  amendments  and  other  countryspecific amendments have been made as of the data cut-off date of 11 May 2021.

Table 21: Summary of Protocol Changes

| Amendment Number (C ountry) Date                  | Summary of Key Changes in the Amendment                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Amendment 1 (Global) 11 Dec 2018                  | The purpose of this amendment was to change duration of safety follow-up after last dose; add additional details on assessments, align pregnancy and clinical laboratory testing frequency with infusions; change supplemental dosing recommendations and sample collection when rescue therapy is provided; and update adverse event and pregnancy/contraception language. |
| Amendment 1.1 (Germany) 27 Jun 2019               | The purpose of this amendment was to exclude enrollment of patients with active systemic infections, as requested by Germany's competent national agency Paul-Ehrlich-Institut.                                                                                                                                                                                             |
| Amendment 1.2 (France) 14 Oct 2019                | The purpose of this amendment was to exclude enrollment of patients with active systemic infections, in answer to request by the French competent national agency, Agence Nationale de Sécurité du Médicament et des Produits de Santé.                                                                                                                                     |
| Amendment 1.3 (United Kingdom) 11 Nov 2019        | The purpose of this amendment was to comply with Good Clinical Practice Inspectors Working Group and Clinical Trial Facilitation Group guidelines which specify that the responsibility to break the treatment code in emergency situations resides solely with the Investigator.                                                                                           |
| Amendment 2 (Global) 25 Oct 2019                  | The purpose of this amendment was to revise secondary and exploratory endpoints, to decrease burden to patients by reduction in assessment and visit frequency, to provide additional guidance for supplemental dosing, and to clarify minor operational aspects of the protocol.                                                                                           |
| Amendment 2.1 (United Kingdom) 13 Dec 2019        | The purpose of this amendment was to revise secondary and exploratory endpoints, to decrease burden to patients by reduction in assessment and visit frequency, to provide additional guidance for supplemental dosing, and to clarify minor operational aspects of the protocol.                                                                                           |
| Amendment 2.2 (France) 02 Jun 2020                | The purpose of this amendment was to provide the instruction of visits at home or alternative healthcare facilities during the COVID-19 pandemic.                                                                                                                                                                                                                           |
| Amendment 2.3 (Spain, Germany, Japan) 02 Feb 2021 | The purpose of this amendment was to transition all patients in specified countries from the 10 mg/mL formulation to the 100 mg/mL formulation of ravulizumab during the Open-Label Extension Period.                                                                                                                                                                       |

Abbreviation: COVID-19 = coronavirus disease 2019

<div style=\"page-break-after: always\"></div>

Important deviations were reported for 41 (23.4%) patients during the Randomized-Controlled Period (Table 22). Additional details on each type of deviation are provided below.

Following  the  assessment  of  all  important  protocol  deviations,  Alexion  concluded  that  none  were considered to have impacted the safety of the patients or the reliability of the study data.

Table 22: Patients with Important Protocol Deviations During the Randomized-Controlled Period (Full Analysis Set)

|                                | Placebo (N = 89)   | Placebo (N = 89)       | Ravulizumab (N = 86)   | Ravulizumab (N = 86)   | Total (N = 175)   | Total (N = 175)        |
|--------------------------------|--------------------|------------------------|------------------------|------------------------|-------------------|------------------------|
|                                | Overall n (%)      | COVID-19 related n (%) | Overall (%) u          | COVID-19 related n (%) | Overall (%) uI    | COVID-19 related n (%) |
| At least 1 deviation           | 21 (23.6)          | 7 (7.9)                | 20 (23.3)              | 3 (3.5)                | 41 (23.4)         | 10 (5.7)               |
| Eligibility and entry criteria | 0                  | 0                      | 2 (2.3)                | 0                      | 2 (1.1)           | 0                      |
| Investigational product        | 8 (9.0)            | 5 (5.6)                | 4 (4.7)                | 3 (3.5)                | 12 (6.9)          | 8 (4.6)                |
| Concomitant medication         | 1 (1.1)            | 0                      | 2 (2.3)                | 0                      | 3 (1.7)           | 0                      |
| Informed consent               | 0                  | 0                      | 3 (3.5)                | 0                      | 3 (1.7)           | 0                      |
| Laboratoryassessment           | 0                  | 0                      | 0                      | 0                      | 0                 | 0                      |
| Visit schedule                 | 0                  | 0                      | 0                      | 0                      | 0                 | 0                      |
| Study procedures/tests         | 8 (9.0)            | 3 (3.4)                | 7 (8.1)                | 1 (1.2)                | 15 (8.6)          | 4 (2.3)                |
| Randomization                  | 1 (1.1)            | 0                      | 0                      | 0                      | 1 (0.6)           | 0                      |
| Safety reporting               | 6 (6.7)            | 0                      | 5 (5.8)                | 0                      | 11 (6.3)          | 0                      |
| Source document                | 1 (1.1)            | 1 (1.1)                | 0                      | 0                      | 1 (0.6)           | 1 (0.6)                |
| Other                          | 0                  | 0                      | 0                      | 0                      | 0                 | 0                      |

Note: Percentages were based on the number of patients in the respective treatment group and may add to more than 100% since a patient may have more than 1 important protocol deviation. Protocol deviations due to COVID-19 are also presented in the overall column.

Abbreviation: COVID-19 = coronavirus disease 2019

Since this study was conducted during the COVID 19 pandemic, it was anticipated that some patients would not be able to travel to the study site on the protocol-specified visit days and would potentially receive study drug outside of the dosing window. Therefore, the calculation for treatment compliance was modified from being based on the 'number of scheduled doses given/number of expected scheduled doses' to reflect the percentage of time during the Randomized-Controlled Period that patients were considered  to  have  complete  terminal  complement  inhibition  (ie,  100%  -  sum  [percentage  of  time patients were noncompliant with scheduled doses]).

## Baseline data

The main purpose of this amendment is to transition all patients in specified countries from the 10 mg/mL formulation to the 100 mg/mL formulation of ravulizumab during the Open-Label Extension Period.

<div style=\"page-break-after: always\"></div>

Table 23: Demographics and Baseline Characteristics (Full Analysis Set)

| Variable                                      | Placebo (N = 89)   | Ravulizumab (N = 86)   | Total (N = 175)   |
|-----------------------------------------------|--------------------|------------------------|-------------------|
| Sex, n (%)                                    |                    |                        |                   |
| Male                                          | 44 (49.4)          | 42 (48.8)              | 86 (49.1)         |
| Female                                        | 45 (50.6)          | 44 (51.2)              | 89 (50.9)         |
| Ethnicity, n (%)                              |                    |                        |                   |
| Not Hispanic or Latino                        | 78 (87.6)          | 79 (91.9)              | 157 (89.7)        |
| Not reported                                  | 5 (5.6)            | 3 (3.5)                | 8 (4.6)           |
| Hispanic or Latino                            | 5 (5.6)            | 2 (2.3)                | 7 (4.0)           |
| Unknown                                       | 1 (1.1)            | 2 (2.3)                | 3 (1.7)           |
| Race, n (%)                                   |                    |                        |                   |
| White                                         | 61 (68.5)          | 67 (77.9)              | 128 (73.1)        |
| Asian                                         | 16 (18.0)          | 15 (17.4)              | 31 (17.7)         |
| Not reported                                  | 5 (5.6)            | 2 (2.3)                | 7 (4.0)           |
| Black or African American                     | 4 (4.5)            | 2 (2.3)                | 6 (3.4)           |
| American Indian or Alaska Native              | 1 (1.1)            | 0                      | 1 (0.6)           |
| Other                                         | 1 (1.1)            | 0                      | 1 (0.6)           |
| Unknown                                       | 1 (1.1)            | 0                      | 1 (0.6)           |
| Native Hawaiian or other Pacific Islander     | 0                  | 0                      | 0                 |
| Age at first infusion (years)                 |                    |                        |                   |
| Mean (SD)                                     | 53.3 (16.05)       | 58.0 (13.82)           | 55.6 (15.14)      |
| Median                                        | 55.0               | 61.5                   | 58.0              |
| Min, max                                      | 20,82              | 19,79                  | 19,82             |
| Age at first infusion (years) category, n (%) |                    |                        |                   |
| 18 to 65 years                                | 65 (73.0)          | 56 (65.1)              | 121 (69.1)        |
| > 65 years                                    | 24 (27.0)          | 30 (34.9)              | 54 (30.9)         |
| Baseline weight (kg)                          |                    |                        |                   |
| Mean (SD) Median                              | 90.9 (29.45) 89.0  | 91.6 (23.37) 91.7      | 91.2 (26.57) 90.0 |
| Min, max                                      | 44.1, 185.0        | 40.0, 165.8            | 40.0, 185.0       |
| Baseline weight (kg) category, n (%)          |                    |                        |                   |
| ≥ 40 to < 60 kg                               | 11 (12.4)          | 7 (8.1)                | 18 (10.3)         |
| ≥ 60 to < 100 kg                              | 47 (52.8)          | 47 (54.7)              | 94 (53.7)         |
| ≥ 100 kg                                      | 31 (34.8)          | 32 (37.2)              | 63 (36.0)         |
| Region randomization stratification, n (%)    |                    |                        |                   |
| North America                                 | 40 (44.9)          | 40 (46.5)              | 80 (45.7)         |
| Europe                                        | 33 (37.1)          | 31 (36.0)              | 64 (36.6)         |
| Asia-Pacific                                  | 9 (10.1)           | 9 (10.5)               | 18 (10.3)         |
| Japan                                         | 7 (7.9)            | 6 (7.0)                | 13 (7.4)          |

Note: Percentages were based on the total number of patients in each group. Baseline was defined as the last available assessment value prior to first study drug infusion.

Abbreviations: max = maximum; min = minimum

<div style=\"page-break-after: always\"></div>

Disease characteristics at baseline are summarized in Table 24.

Table 24: Baseline Disease Characteristics (Full Analysis Set)

| Variable Category                                              | Placebo (N = 89)   | Ravulizumab (N = 86)   | Total (N = 175)   |
|----------------------------------------------------------------|--------------------|------------------------|-------------------|
| Age (years) at MG diagnosis                                    |                    |                        |                   |
| Mean (SD)                                                      | 43.7 (19.04)       | 48.6 (18.54)           | 46.1 (18.91)      |
| Median                                                         | 44.8               | 50.4                   | 47.9              |
| Min, max                                                       | 12,81              | 12,77                  | 12,81             |
| Years from MG diagnosis to informed consent                    |                    |                        |                   |
| Mean (SD)                                                      | 10.0 (8.90)        | 9.8 (9.68)             | 9.9 (9.27)        |
| Median                                                         | 7.6                | 5.7                    | 6.5               |
| Min, max                                                       | 0.5, 36.1          | 0.5,39.5               | 0.5,39.5          |
| Type of first MG clinical presentation, n (%)                  |                    |                        |                   |
| Ocular MG                                                      | 29 (32.6)          | 21 (24.4)              | 50 (28.6)         |
| Generalized MG (gMG)                                           | 60 (67.4)          | 65 (75.6)              | 125 (71.4)        |
| Time to gMG, if first presentation was ocular MG (months) 1n1  | 28                 | 20                     | 48 20.4 (45.71)   |
| Mean (SD) Median                                               | 24.1 (54.01) 6.0   | 15.2 (31.20) 3.0       | 4.0               |
| Min, max                                                       | 1.0, 288.0         | 1.0,120.0              | 1.0,288.0         |
| Maximum MGFA clinical classification prior to Screening. n (%) |                    |                        |                   |
| Class IIa                                                      | 10 (11.2)          | 12 (14.0)              | 22 (12.6)         |
| Class IIb                                                      | 8 (9.0)            | 12 (14.0)              | 20 (11.4)         |
| Class IIIa                                                     | 23 (25.8)          | 12 (14.0)              | 35 (20.0)         |
| Class IIIb                                                     | 18 (20.2)          | 24 (27.9)              | 42 (24.0)         |
| Class IVa                                                      | 9 (10.1)           | 5 (5.8)                | 14 (8.0)          |
| Class IVb                                                      | 12 (13.5)          | 12 (14.0)              | 24 (13.7)         |
| Class V                                                        | 9 (10.1)           | 8 (9.3)                | 17 (9.7)          |
| Baseline MGFA clinical classification, n (%)                   |                    |                        |                   |
| Class HIa                                                      | 24 (27.0)          | 22 (25.6)              | 46 (26.3)         |
| Class Ib                                                       | 15 (16.9)          | 17 (19.8)              | 32 (18.3)         |
| Class IIIa                                                     | 34 (38.2)          | 22 (25.6)              | 56 (32.0)         |
| Class IIIb                                                     | 11 (12.4)          | 19 (22.1)              | 30 (17.1)         |
| Class IVa                                                      | 4 (4.5)            | 2 (2.3)                | 6 (3.4)           |
| Class IVb                                                      | 1 (1.1)            | 4 (4.7)                | 5 (2.9)           |
| Baseline MG-ADL total score Mean (SD)                          | 8.9 (2.30)         | 9.1 (2.62)             | 9.0 (2.46)        |

<div style=\"page-break-after: always\"></div>

Table 24: Baseline Disease Characteristics (Full Analysis Set) (cont.)

| Variable Category                                                                  | Placebo (N = 89)   | Ravulizumab (N = 86)   | Total (N = 175)   |
|------------------------------------------------------------------------------------|--------------------|------------------------|-------------------|
| Median                                                                             | 9.0                | 9.0                    | 9.0               |
| Min, max                                                                           | 6.0, 15.0          | 6.0, 24.0              | 6.0, 24.0         |
| Baseline QMG total score                                                           |                    |                        |                   |
| Mean (SD)                                                                          | 14.5 (5.26)        | 14.8 (5.21)            | 14.7 (5.22)       |
| Median                                                                             | 14.0               | 15.0                   | 15.0              |
| Min, max                                                                           | 2.0,27.0           | 6.0, 39.0              | 2.0, 39.0         |
| Ventilator support any time prior to Screening, n (%) Yes                          | 13 (14.6)          | 17 (19.8)              | 30 (17.1)         |
| No                                                                                 | 76 (85.4)          | 69 (80.2)              | 145 (82.9)        |
| MG exacerbation including crisis events prior to Screening. n (%)                  |                    |                        |                   |
| Yes                                                                                | 57 (64.0)          | 58 (67.4)              | 115 (65.7)        |
| No                                                                                 | 32 (36.0)          | 28 (32.6)              | 60 (34.3)         |
| Total number of patients with MG exacerbations prior to Screening, n (%)           | 53 (59.6)          | 52 (60.5)              | 105 (60.0)        |
| Total number of patients taking MG medications at time of MG exacerbations, n (%)  | 51 (57.3)          | 47 (54.7)              | 98 (56.0)         |
| Total number of MG exacerbations prior to Screening, n                             | 169                | 100                    | 269               |
| Total patient-years prior to Screeninga                                            | 887.0              | 846.8                  | 1733.8            |
| RateofMGexacerbations/1ooPY                                                        | 19.1               | 11.8                   | 15.5              |
| Total number of patients with MG crisisb events prior to Screening, n (%)          | 17 (19.1)          | 21 (24.4)              | 38 (21.7)         |
| Total number of patients taking MG medications at time of MG crisisb events, n (%) | 17 (19.1)          | 19 (22.1)              | 36 (20.6)         |
| Total number of MG crisisb events prior to Screening, n                            | 33                 | 35                     | 68                |
| Rate of MG crisisb events / 100 PY                                                 | 3.7                | 4.1                    | 3.9               |

## Prior Therapy

Overall, usage of non-MG medications prior to the start of the study was similar between the placebo and ravulizumab groups. The most commonly used (in ≥ 25% of total patients) non -MG medications were drugs for peptic ulcer and gastro-oesophageal reflux disease (49.7%); lipid-modifying agents, plain (34.9%); and vitamin A and D, including combinations of the two (32.0%).

All patients used MG therapy (including symptomatic therapies) prior to the start of the study and usage was similar between the placebo and ravulizumab groups. Overall, the most common (in ≥ 25% of total patients)  MG  medications  used  prior  to  study  treatment  were  pyridostigmine  bromide  (77.7%), prednisone (51.4%), mycophenolate mofetil (32.6%), azathioprine (31.4%), and immunoglobulins not otherwise specified (28.6%).  The majority (50.9%) of patients used only 2 ISTs with the most common (20%) combination being corticosteroids and mycophenolate mofetil. Within 2 years prior to Screening, 19.4% of patients used any PE/PP and 43.4% of patients used IVIg.

## Concomitant Therapy

Overall, 97.7% of patients (100% in the ravulizumab and 95.5% in placebo group) took at least 1 nonMG  concomitant  medication during  the  Randomized-Controlled  Period.  Of  note,  patients  in  the ravulizumab group used lipid modifying agents (ravulizumab: 44.2%; placebo: 27.0%), blood glucose lowering drugs, excluding insulin (ravulizumab: 29.1%; placebo: 19.1%), and selective calcium channel

<div style=\"page-break-after: always\"></div>

blockers with mainly vascular effects (ravulizumab: 22.1%; placebo: 12.4%) more than those patients in the placebo group.

The most commonly reported (in ≥ 25% of patients) groupings of concomitant non -MG medications other  than  meningococcal  vaccine  were  drugs  for  peptic  ulcer  and  gastro-esophageal  reflux  disease (52.6%); other analgesics and antipyretics (41.1%); lipid-modifying agents, plain (35.4%); vitamin A and D, including combinations of the two (35.4%); antithrombotic agents (26.9%); anti-inflammatory and antirheumatic products, non-steroids (25.7%); and calcium (25.1%).

Regarding MG medications , a majority of patients (69.1%) were taking corticosteroids at the time of their  first  dose  of  study  drug  in  the  Randomized-Controlled  Period  (placebo:  73.0%;  ravulizumab 65.1%). Almost half (47.4%) of patients were using only 2 ISTs (placebo: 52.8%; ravulizumab 41.9%); the  most  common  (18.3%)  combination  was  corticosteroids  and  mycophenolate  mofetil  (placebo: 22.5%; ravulizumab 14.0%).

A  majority  (70.3%)  of  patients  continued  to  take  corticosteroids  during  the  Randomized-Controlled Period (placebo: 74.2%; ravulizumab 66.3%). Change (introduction, discontinuation, or increased or decreased dosage) of ISTs occurred in 24% of patients overall (placebo: 21%; ravulizumab 27%) during the Randomized-Controlled Period. The most common change was use of new immunoglobulins due to MG symptoms worsening (10.0%). Most of the changes in ISTs were either allowable or not clinically significant.

Overall, MG medications (other than IVIg) used by ≥ 25% of patients during the Randomized -Controlled Period were pyridostigmine bromide (65.7%), prednisone (45.1%), and mycophenolate mofetil (26.9%).

During the Randomized-Controlled Period, 10.3% of patients used IVIg (placebo: 14.6%; ravulizumab: 5.8%) and 1.7% of patients used any PE/PP (placebo: 1.1%; ravulizumab: 2.3%).

All  patients  used  concomitant  MG  medications  during  the  Open-Label  Extension  Period.  Overall, concomitant  MG  medications  (other  than  IVIg)  used  in  ≥  25%  of  patients  during  the  Open -Label Extension  Period  were  pyridostigmine  bromide  (64.6%),  prednisone  (54.4%),  and  mycophenolate mofetil (34.2%).

The most commonly used IST during the Open-Label Extension Period was corticosteroids (72.2%). A total  of  39.2% of patients used only 2 ISTs during the Open-Label Extension Period, with the most common (21.5%) combination being corticosteroids and mycophenolate mofetil.

During the Open-Label Extension Period, 6.3% of patients used IVIg and 3.8% of patients used any PE/PP.

In the Open-Label Extension Period of the study, physicians had the option to adjust IST therapies. Approximately half (50.6%) of patients had a change in concomitant MG medication during the OpenLabel Extension Period. The most common change was a decrease in corticosteroids for systemic use, plain due to MG symptoms improved (26.6%)

## Compliance

During the Randomized-Controlled Period, treatment compliance was 94.4% in the placebo group and 96.5% in the ravulizumab group. Including the Open-Label Extension Period for the subset of patients who reached (or would have reached) 52 weeks of exposure as of the data cutoff date, the mean (SD) ravulizumab  exposure  presented  in  this  safety  summary  is  234.3  (86.65)  days  in  127 patients: 258.2 (96.48) days  in  86  patients  randomized  to  ravulizumab  and  184  (6.78)  days  in  41  patients randomized  to  placebo  who  switched  to  ravulizumab  during  the  Open-Label  Extension  Period.  The majority (92.9%) of patients had 100% treatment compliance during the Ravulizumab Treatment Period (ie, since the first dose of ravulizumab).

<div style=\"page-break-after: always\"></div>

## Numbers analysed

## Table 25: Analysis Sets (All Randomized Patients)

|                                                                                                                             | Placebo n (%)   | Ravulizumab n (%)   | Total n (%)   |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------|---------------------|---------------|
| Randomizeda                                                                                                                 | 89              | 86                  | 175           |
| Safety Analysis Set                                                                                                         | 89 (100)        | 86 (100)            | 175 (100)     |
| Full Analysis Set                                                                                                           | 89 (100)        | 86 (100)            | 175 (100)     |
| Per Protocol Set                                                                                                            | 79 (88.8)       | 76 (88.4)           | 155 (88.6)    |
| Excluded                                                                                                                    | 10 (11.2)       | 10 (11.6)           | 20 (11.4)     |
| Eligibility criteria not met                                                                                                | 0               | 2 (2.3)             | 2 (1.1)       |
| Wrong study drug taken                                                                                                      | 0 3 (3.4)       | 0 3 (3.5)           | 0 6 (3.4)     |
| Cholinesterase inhibitor taken within 10 hours prior to QMG and MGC at Baseline or Week 26 Missed at least 1 scheduled dose | 5 (5.6)         | 3 (3.5)             | 8 (4.6)       |
| Did not receive at least 1 supplemental dose at the conclusion of rescue therapy                                            | 0               | 0                   | 0             |
| Changes in background MG medications                                                                                        | 1 (1.1)         | 1 (1.2) 0           | 2 (1.1) 0     |
| Emergency unblinding Received rescue medications on Day 1                                                                   | 0 0             | 0                   | 0             |
| Other major protocol deviationsb                                                                                            | 1 (1.1)         | 1 (1.2)             | 2 (1.1)       |
| Modified Full Analysis Set                                                                                                  | 85 (95.5)       | 80 (93.0)           | 165 (94.3)    |
| Excludedc                                                                                                                   | 4 (4.5)         | 6 (7.0)             | 10 (5.7)      |
| Had a COVID-19 related AE during Randomized- Controlled Period                                                              | 4 (4.5)         | 5 (5.8)             | 9 (5.1)       |
| Missed 2 consecutive scheduled doses during Randomized-Controlled Period due to COVID-19                                    | 0               | 1 (1.2)             | 1 (0.6)       |
| Terminated early during Randomized-Controlled Period due to COVID-19                                                        | 0               | 3 (3.5)             | 3 (1.7)       |
| Treated for COVID-19 during Randomized-Controlled Period with MG medications                                                | 0               | 3 (3.5)             | 3 (1.7)       |
| PK Analysis Set                                                                                                             | 89 (100)        | 86 (100)            | 175 (100)     |
| Open-Label Extension Setd                                                                                                   | 41 (46.1)       | 38 (44.2)           | 79 (45.1)     |
| Excluded                                                                                                                    | 0               | 5 (5.8)             | 5 (2.9)       |
| No open-label treatment received                                                                                            | 0               | 5 (5.8)             | 5 (2.9)       |
| Ravulizumab Treated Sete                                                                                                    | 41 (46.1)       | 86 (100)            | 127 (72.6)    |

a Two additional patients were randomized in error: 1 patient was randomized but could not be dosed due to a water leak in the laminar hood while preparing study drug; patient was ultimately screen failed. Additionally, 1 patient was randomized and screen failed due to pyridostigmine not being withheld 10 hours prior to Screening assessments; this patient was subsequently re-screened and re-randomized (patient was counted in the randomized and treated row)

b One patient (ravulizumab group) did not complete the spirometry assessments during the Randomized-Controlled Period and 1 patient  (placebo  group) had  C3, C4,  and  CH50  tests  performed during  the  study  which  could have  led  to unblinding  (Listing 16.2.2.3.1.2).

c Patients may have been counted in more than 1 category for the reason for exclusion.

d The Open-Label Extension Set consisted of all patients who received at least 1 dose of ravulizumab in the Open-Label Extension Period. Per scope, only patients reaching Week 52 or expected to reach Week 52 by the time of data cutoff were included.

e The Ravulizumab Treated Set consisted of all patients who received at least 1 dose of ravulizumab either in the RandomizedControlled Period or the Open-Label Extension Period. Per scope, only data during Randomized-Controlled Period were included for patients not expected to have reached Week 52 at data cutoff. This applied to both ravulizumab and placebo patients.

Abbreviations:  AE  =  adverse  event;  COVID-19  =  coronavirus  disease  2019;  MGC  =  Myasthenia  Gravis  Composite;  MG  = myasthenia gravis; PK = pharmacokinetic; QMG = Quantitative Myasthenia Gravis

## Outcomes and estimation

## Primary Efficacy Endpoint

MG-ADL Total Score

<div style=\"page-break-after: always\"></div>

The least-squares (LS) mean (SEM) reduction from Baseline to Week 26 in MG-ADL total score was significantly greater in the ravulizumab group (-3.1 [0.38]) compared to the placebo group (-1.4 [0.37]) during  the  Randomized-Controlled  Period  (mean  treatment  difference:  -1.6  [0.49];  95%  confidence interval [CI]: -2.6, -0.7; p = 0.0009).

In the ravulizumab group, improvement in MG-ADL total score was observed as early as Week 1 with improvement sustained through Week 26 (Figure 10).

Figure 10: Change from Baseline in MG-ADL Total Score During the Randomized-Controlled Period (Full Analysis Set)

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. Estimates were based on MMRM that included treatment group, stratification factor region, and MG-ADL total score at baseline, study visit, and study visit by treatment group interaction. P-values were for the comparison of treatment groups in change from baseline. An unstructured covariance structure was used.

* = p &lt; 0.05, ** = p &lt; 0.01, and *** = p &lt; 0.001 represent 2-sided nominal p-values.

The change from Baseline in MG-ADL total score to Week 26 was consistent with the Full Analysis Set for the Per Protocol Set and Modified Full Analysis Set.

## Sensitivity Analyses

The actual change from Baseline in the MG-ADL total score to Week 26 using pre-specified sensitivity analysis is summarized for the Full Analysis Set. The results of the sensitivity analysis supported the results of the primary analysis (Table 26).

Table 26: Sensitivity Analyses for MG-ADL from Baseline to Week 26

| AnalysisPopulation                                                                                 | LS Mean Treatment Difference (SEM)   | 95% CI     |   P-values |
|----------------------------------------------------------------------------------------------------|--------------------------------------|------------|------------|
| Full Analysis Set                                                                                  | -1.6 (0.49)                          | -2.6, -0.7 |     0.0009 |
| MMRM placebo-based                                                                                 | -1.6 (0.49)                          | -2.6, -0.7 |     0.001  |
| MMRM tipping point (occurs at shift of 6.5 points p-value = 0.0571)                                | -1.07 (0.56)                         | -2.18,0.03 |     0.0571 |
| MMRM excluding the randomization stratification region from the model                              | -1.7 (0.49)                          | -2.6, -0.7 |     0.0008 |
| MMRM including rescue therapy received (Yes/No) during theRandomized-Controlled Period in themodel | -1.6 (0.47)                          | -2.5, -0.6 |     0.0011 |
| Per Protocol Set                                                                                   | -1.7 (0.49)                          | -2.7,-0.7  |     0.0006 |
| Modified Full Analysis Set                                                                         | -1.8 (0.49)                          | -2.8, -0.9 |     0.0002 |

<div style=\"page-break-after: always\"></div>

Abbreviations: CI = confidence interval; LS = least square; MG-ADL = Myasthenia Gravis-Activities of Daily Living; MMRM = mixed-effect model for repeated measures; SEM = standard error of the mean

## Secondary Efficacy Endpoints

A statistically significant improvement was observed in the ravulizumab group compared to the placebo group  for  the  first  2  of  the  5  secondary  endpoints  (ie,  QMG  and  QMG  responder)  according  to  a prespecified hierarchical testing order (Table 27). Since the treatment difference did not reach statistical significance for the change from baseline in MG QoL15r total score assessment (p = 0.0636), nominal p values are presented for change from Baseline in Neuro QoL Fatigue score and improvement of at least 3 points in MG ADL total score at Week 26. Results for all secondary endpoints consistently favoured ravulizumab compared to placebo.

Table 27: ALXN1210-MG-306 Efficacy Results

|                                         | Ravulizumab (n =86) LS Mean (SEM)*      | Placebo (n = 89) LS Mean (SEM)*         | Statistic for Comparison                | Treatment Effect (95% CI)               | p-value                                 | (MMRM)                                  |
|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
| Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 | Secondary Efficacy Endpoints at Week 26 |
| QMGTotal Score                          | -2.8 (0.46)                             | -0.8 (0.45)                             | Difference Change Baseline              | in from                                 | -2.0 (-3.2 , -0.8)                      | 0.0009                                  |
| QMG ≥5 -point improvement*              | 30.0%                                   | 11.3%                                   | Odds ratio                              |                                         | 3.350 (1.443 , 7.777)                   | 0.0052                                  |
| MG-QOL15r                               | -3.3 (0.71)                             | -1.6 (0.70)                             | Difference Change                       | in from                                 | -1.7 (-3.4 , 0.1)                       | 0.0636                                  |
| Neuro-QOL-fatigue                       | -7.0 (1.92)                             | -4.8 (1.87)                             | Difference Change                       | in from                                 | -2.2 (-6.9 , 2.6)                       | 0.3734**                                |
| 5. MG- ADL ≥3 -point improvement*       | 56.7%                                   | 34.1%                                   | Odds ratio                              |                                         | 2.526 (1.330 , 4.799)                   | 0.0049**                                |

*Adjusted percentages within each treatment are displayed.

** Nominal p-values

Note: Secondary efficacy endpoints were tested in a hierarchical approach (numbers included for testing order). Hierarchical testing proceeded  from  1 to  5,  and  if  statistical  significance  was  not  achieved  (p-value  &gt;  0.05),  then  subsequent  endpoints  were  not considered statistically significant and all displayed p-values from analyses of lower hierarchy were to be considered nominal.

Abbreviations: CI= Confidence Interval, LS = Least Squares; MG-ADL=MG Activities of Daily Living total score,

MG-QoL15r= Revised 15-Component Myasthenia Gravis Quality of Life, MMRM = mixed-effect model for repeated measures; Neuro-QOL-fatigue = Neurological Quality of Life Fatigue, QMG = Quantitative MG total score,

SEM = Standard Error of Mean.

<div style=\"page-break-after: always\"></div>

## Change from Baseline in QMG Total Score

Figure  11:  Change  from  Baseline  in  QMG  Total  Score  During  the  Randomized-Controlled  Period  (Full Analysis Set)

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. In the event that cholinesterase inhibitor was not withheld for at least 10 hours prior to administration of the QMG assessment, the Screening visit assessment was used as Baseline. Estimates were based on MMRM that included treatment group, stratification factor region and QMG total score at baseline, study visit, and study visit by treatment group interaction. P-values were for the comparison of treatment groups in change from baseline. An unstructured covariance structure was used.

* = p&lt;0.05, ** = p&lt;0.01, and *** = p&lt;0.001 represent 2 -sided nominal p-values.

Abbreviations: BL = Baseline; MMRM = mixed-effect model for repeated measures; QMG = Quantitative Myasthenia Gravis

The change from Baseline in the QMG total score to Week 26 was consistent with the Full Analysis Set for the Per Protocol Set and Modified Full Analysis.

## QMG 5-point Response

There was a significantly larger proportion of clinical responders in the ravulizumab group than in the placebo group based on a ≥ 5 -point reduction in the QMG total score from Baseline to Week 26 (odds ratio [OR]: 3.350; 95% CI: 1.443, 7.777; p = 0.0052) during the Randomized-Controlled Period.

Figure 12: Proportion of Patients with Various Point Reductions in QMG Total Score at Week 26 (Full Analysis Set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. In the event that cholinesterase inhibitor was not withheld for at least 10 hours prior to administration of the QMG assessment, the Screening visit assessment was used as Baseline. Estimates are based on a GLMM that includes treatment group, stratification factor region and QMG total score at baseline, study visit and study visit by treatment group interaction. An unstructured covariance structure was used. Abbreviations: GLMM = generalized linear mixed model; QMG = Quantitative Myasthenia Gravis score for disease severity

Although not statistically significant (p = 0.0636), the LS mean (SEM) reductions from Baseline to Week 26 in MG-QoL15r total score and Neuro-QoL Fatigue score were numerically greater in the ravulizumab group than in the placebo group during the Randomized-Controlled Period. The improvements from Baseline at each study visit were greater in the ravulizumab group than the placebo group through 26 weeks.

## MG-QoL15r Total Score

Figure 13: Change from Baseline in the MG-QoL15r Score During the Randomized-Controlled Period (Full Analysis Set)

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. Estimates were based on MMRM that includes treatment group, stratification factor region and MG-QoL15r score at baseline, study visit, and study visit by treatment group interaction. P-values were for the comparison of treatment groups in change from baseline. An unstructured covariance structure was used.

* = p&lt;0.05 represents a 2 -sided nominal p-value.

Abbreviations: BL = Baseline; MG-QoL15r = Revised 15-Component Myasthenia Gravis Quality of Life; MMRM = mixed-effect model for repeated measure

## Neuro-QoL Fatigue Score

<div style=\"page-break-after: always\"></div>

Figure 14: Change from Baseline in Neuro-QoL Fatigue Total Score During the Randomized-Controlled Period (Full Analysis Set)

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. Estimates were based on MMRM that included treatment group, stratification factor region and Neuro-QoL Fatigue score at baseline, study visit and study visit by treatment group interaction. An unstructured covariance structure was used.

Abbreviations: BL = Baseline; MMRM = mixed-effect model for repeated measures; Neuro-QoL = Neurological Quality of Life

## MG-ADL 3-point Response

There was a larger proportion of clinical responders in the ravulizumab group than in the placebo group based on a ≥ 3 -point reduction in MG-ADL total score from Baseline to Week 26 (OR: 2.526; 95% CI: 1.330, 4.799; nominal p = 0.0049) during the Randomized-Controlled Period.

Figure 15: Proportion of Patients with Various Point Reductions in MG-ADL Total Score at Week 26 (Full Analysis Set)

<!-- image -->

Note: Baseline was defined as the last available assessment value prior to first study drug infusion. Estimates are based on a GLMM that includes treatment group, stratification factor region and MG-ADL total score at baseline, study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.

Abbreviations: GLMM = generalized linear mixed model; MG-ADL = Myasthenia Gravis Activities of Daily Living

## Exploratory Endpoints (Randomized-Controlled Period)

Myasthenia Gravis Composite (MGC) score

The LS mean (SEM) reduction from Baseline to Week 26 in Myasthenia Gravis Composite (MGC) score was significantly greater in the ravulizumab group (-6.1 [0.73]) compared to the placebo group (-3.2 [0.71]) during the Randomized-Controlled Period (mean treatment difference: -2.9 [0.93]; 95% CI: 4.8, -1.1; p = 0.0019).

<div style=\"page-break-after: always\"></div>

## EQ-5D-5L VAS and Health State Index

The  LS  mean  (SEM)  change  from  Baseline  to  Week  26  in  European  Quality  of  Life  Health  5-item questionnaire  dimensions  5-level  (EQ-5D-5L)  Visual  Analog  Scale  (VAS)  was  4.0  (2.12)  in  the ravulizumab group and 2.7 (2.07) in the placebo group during the Randomized-Controlled Period (mean treatment difference: 1.3 [2.69]; 95% CI: -4.0, 6.6; p = 0.6374)

## MG-ADL Subcomponent

The LS mean (SEM) reduction from Baseline to Week 26 in MG-ADL subcomponents was significantly greater in the ravulizumab group compared to the placebo group for respiratory score (p = 0.0484) and ocular score (p = 0.0028). Although not statistically significant at Week 26, the LS mean (SEM) reduction from Baseline to Week 26 for bulbar score and limbs score were numerically greater in the ravulizumab group compared to the placebo group at Week 26.

## QMG Subcomponent

The LS mean (SEM) change from Baseline to Week 26 in QMG subcomponents were significantly greater in the ravulizumab group compared to the placebo group for limbs score (p = 0.0134) and ocular score (p = 0.0020). Although not statistically significant at Week 26, the LS mean (SEM) change from Baseline to Week 26 in QMG subcomponents of bulbar score was numerically greater in the ravulizumab group compared to the placebo group at Week 26. The LS mean (SEM) change from Baseline to Week 26 in QMG subcomponents of respiratory score was not greater in the ravulizumab group compared to the placebo group at Week 26.

## Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS)

Patients  in  the  ravulizumab  group  were  more  likely  to  achieve  a  status  of  improved  and  minimal manifestations than patients in the placebo group at Week 26 (OR = 2.2; 95% CI = 1.2, 4.1; p = 0.0102).

Figure 16: Proportion of Patients in Each Category of the Myasthenia Gravis Foundation of America PostIntervention Status (MGFA-PIS) at Week 26 (Full Analysis Set)

<!-- image -->

Note: Myasthenia Gravis Foundation of America Post-Intervention Status (MGFA-PIS) is in comparison to pre-treatment assessment

## Hospitalizations

During the Randomized-Controlled Period, the number of patients with all-cause hospitalization was similar between ravulizumab and placebo groups. Most patients were hospitalized due to non-MG related causes.

<div style=\"page-break-after: always\"></div>

Table 28: Hospitalizations During the Randomized-Controlled Period (Full Analysis Set)

| Variable                                                                                                                               | Placebo (N = 89)   | Ravulizunab (N = 86)   |
|----------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------|
| Number of patients hospitalized during the Randomized-Controlled Period, n (%)                                                         | 19 (21)            | 16 (19)                |
| MG related hospitalizations Hospitalizations for study drug administration Non-MG related hospitalizations MG-related hospitalizations | 7 (8) 4 (4)        | 3 (3) 1 (1)            |
|                                                                                                                                        | 21                 |                        |
|                                                                                                                                        | 12 (13)            | 15 (17)                |
| Total number of all-cause hospitalizations                                                                                             |                    | 23                     |
|                                                                                                                                        | 9                  | 4                      |
| Total number of hospitalizations for study drug administration                                                                         | 5                  | 2                      |
| Non-MG related hospitalizations                                                                                                        | 12                 | 19                     |
| Number of patients with pre-planned hospitalization during the Randomized-Controlled Period, n (%)                                     | 6 (6.7)            | 2 (2.3)                |
| Total number of pre-planned hospitalizations                                                                                           | 7                  | 3                      |

## Clinical Deteriorations and Rescue Therapies

More patients in the placebo group compared to patients in the ravulizumab group reported clinical deterioration  that  met  protocol  criteria  (placebo:  16.9%;  ravulizumab:  9.3%)  and  required  rescue therapy for events of clinical deterioration (placebo: 15.7%; ravulizumab: 9.3%).

Table 29: Clinical Deteriorations During the Randomized-Controlled Period (Full Analysis Set)

| Variable                                                                                                                      | Placebo (N = 89)   | Ravulizumab (N = 86)   |
|-------------------------------------------------------------------------------------------------------------------------------|--------------------|------------------------|
| Total number of patients reporting clinical deterioration during Randomized-Controlled Period, n (%)                          | 18 (20.2)          | 10 (11.6)              |
| Total number of clinical deteriorations during Randomized-Controlled Period, n                                                | 30                 | 15                     |
| Total number of patients reporting clinical deterioration as per protocol criteria during Randomized-Controlled Period, n (%) | 15 (16.9)          | 8 (9.3)                |
| MG crisis                                                                                                                     | 1 (1.1)            | 0                      |
| Significant symptomatic worsening                                                                                             | 5 (5.6)            | 1 (1.2)a               |
| Rescue therapy, for health in jeopardy                                                                                        | 12 (13.5)          | 7 (8.1)                |
| Total number of clinical deterioration as per protocol criteria during                                                        | 26                 | 10                     |
| Randomized-Controlled Period, n                                                                                               |                    |                        |
| MG crisis                                                                                                                     | 1                  | 0                      |
| Significant symptomatic worsening                                                                                             | 6                  | 1                      |
| Rescue therapy, for health in jeopardy                                                                                        | 19                 | 9                      |
| Total number of patients requiring rescue therapy, n (%)                                                                      | 14 (15.7)          | 8 (9.3)                |
| High dosecorticosteroids                                                                                                      | 1 (1.1)            | 1 (1.2)                |
| Plasmapheresis/plasma exchange                                                                                                | 1 (1.1)            | 2 (2.3)                |
| IVIg                                                                                                                          | 12 (13.5)          | 5 (5.8)                |
| Total number of clinical deterioration events requiring rescue therapy, n                                                     | 24                 | 10                     |
| High dose corticosteroids                                                                                                     | 1                  | 1                      |
| Plasmapheresis/plasma exchange                                                                                                | 4                  | 2                      |
| IVIg                                                                                                                          | 19                 | 7                      |

## Other Efficacy Endpoints (Open-Label Extension)

During  the  Open-Label  Extension  Period,  a  rapid  and  sustained  improvement  was  observed  in  the PBO/RAV group while a sustained response was observed from Week 26 though Week 52 in the RAV/RAV group in MG-ADL total score, QMG total score, MG-QOL 15r total score and Neuro-QoL Fatigue score.

## MG-ADL Total Score

<div style=\"page-break-after: always\"></div>

Figure 17: Change from Randomized-Controlled Period Baseline in MG-ADL Total Score Through Week 52 (Open-Label Extension Set)

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion. Week 26 represented the start of the Open-Label Extension Period. Patients in the placebo group received placebo before Week 26 and received  ravulizumab  since  Week  26.  The  Open-Label  Extension  Set  consisted  of  all  patients  who  received  at  least  1  dose ravulizumab in the Open-Label Extension Period. Per scope, only patients reaching Week 52 or withdrew prior to Week 52 by the time of data cutoff were included.

Abbreviations: BL = Baseline; MG-ADL = Myasthenia Gravis-Activities of Daily Living; PBO = placebo; Ravu = ravulizumab

## QMG Total Score

Figure 18: Change from Randomized-Controlled Period Baseline in QMG Total Score Through Week 52 (Open-Label Extension Set)

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion. In the event that cholinesterase inhibitor was not withheld for at least 10 hours prior to administration of the QMG assessment, the Screening visit assessment was used as Baseline. Week 26 represented the start of the Open-Label Extension Period. Patients in the placebo group received placebo before Week 26 and received ravulizumab since Week 26.

Abbreviations: BL = Baseline; QMG = Quantitative Myasthenia Gravis; PBO = placebo; Ravu = ravulizumab

<div style=\"page-break-after: always\"></div>

## MG-QoL15r Total Score

Figure 19: Change from Randomized-Controlled Period Baseline in MG-QoL15r Score Through Week 52 (Open-Label Extension Set)

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion.  Week 26 represented the start of the Open-Label Extension Period. Patients in the placebo group received placebo before Week 26 and received ravulizumab since Week 26. The Open-Label Extension Set consists of all patients who received at least 1 dose ravulizumab in the Open-Label Extension Period. Per scope, only patients reaching Week 52 or withdrew prior to Week 52 by the time of data cutoff were included.

Abbreviations: BL = Baseline; MG-QoL15r = Revised 15-Component Myasthenia Gravis Quality of Life; PBO = placebo; Ravu = ravulizumab

Neuro-QoL Fatigue Score

Figure 20: Change from Randomized-Controlled Period Baseline in Neuro-QoL Fatigue Score Through Week 52 (Open-Label Extension Set)

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion. Week 26 represented the start of the Open-Label Extension Period. Patients in the placebo group received placebo before Week 26 and received  ravulizumab  since  Week  26.  The  Open-Label  Extension  Set  consisted  of  all  patients  who  received  at  least  1  dose ravulizumab in the Open-Label Extension Period. Per scope, only patients reaching Week 52 or withdrew prior to Week 52 by the time of data cutoff were included.

Abbreviations: BL = Baseline; Neuro-QoL = Neurological Quality of Life; PBO = placebo; Ravu = ravulizumab

<div style=\"page-break-after: always\"></div>

## Updated Study ALXN1210-MG-306 results

A CSR addendum was produced to provide further information for the 161 patients who received 1 or more doses of ravulizumab in the Open-Label Extension Period. Data available through 09 Nov 2021 for those  161  patients  demonstrate  that  clinically  meaningful  impacts  in  patients  with  generalized myasthenia gravis (gMG) are maintained through at least 60 weeks of ravulizumab treatment. This updated analysis represents 141.6 patient-years of ravulizumab exposure.

While all patients who entered the Open-Label Extension Period received ravulizumab, patients randomized to the ravulizumab group also received 26 weeks of ravulizumab treatment during the Randomized-Controlled Period (RAV/RAV group). Patients randomized to receive placebo during the Randomized-Controlled Period had their first dose of ravulizumab at the start of the Open-Label Extension Period (Day 183 Visit) (PBO/RAV group).

## Myasthenia Gravis-Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG)

Improvement in the MG-ADL total score observed during the Randomized-Controlled Period in the RAV/RAV group was sustained from Week 26 through Week 60 during the Open-Label Extension Period (least squares [LS] mean change at Week 60; -4.0 [95% confidence interval [CI]-4.8, -3.1]). During the Open-Label Extension Period, a rapid and sustained improvement of a similar magnitude to that in the RAV/RAV group during the Randomized-Controlled Period for MG-ADL total score through Week 60 was observed in the PBO/RAV group (LS mean change at Week 28: -3.2 [95% CI -4.0, -2.4]; LS mean change at Week 60 (-3.3 [95% CI -4.3, -2.2]).

Figure 21: Change from Randomized-Controlled Period Baseline in MG-ADL Total Score (LS Mean and 95% CI) Through Week 60

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion in the Randomized-Controlled Period. Week 26 represented the start of the Open-Label Extension Period. The Randomized-Controlled Period estimates are based on MMRM that includes treatment group, stratification factor region, baseline score, study visit, and study visit by treatment group interaction. Visits up to Week 26 were included in the model. The Open-Label Extension Period estimates are based on MMRM that includes stratification factor region, baseline score, and study visit. A model was fit for the ravulizumab and placebo of the Open-label Extension Set separately. Data up to Week 60 at data cut-off are included.

*, **, and *** represent two-sided nominal p-value is less than 0.05, 0.01 and 0.001 for the comparison of treatment groups in change from baseline during the Randomized-Controlled Period.

Abbreviations: CI = confidence interval; LS = least squares; MG-ADL = Myasthenia Gravis-Activities of Daily Living; MMRM = mixed-effect model for repeated measures; PBO/RAV = placebo/ravulizumab; RAV/RAV = ravulizumab/ravulizumab

Improvement in the QMG total score observed during the Randomized-Controlled Period in the RAV/RAV group was sustained from Week 26 through Week 60 during the Open-Label Extension Period

<div style=\"page-break-after: always\"></div>

(LS mean change at Week 60: -4.1 [95% CI -5.4, -2.9]). During the Open-Label Extension Period, a rapid and sustained improvement of a similar magnitude to that in the RAV/RAV group during the Randomized-Controlled Period for QMG total score through Week 60 was observed in the PBO/RAV group (LS mean change at Week 28: -2.7 [95% CI -4.0, -1.5]; LS mean change at Week 60 (-3.8 [95% CI -5.1, -2.4])

Figure 22: Change from Randomized-Controlled Period Baseline in QMG Total Score (LS Mean and 95% CI) Through Week 60

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion in the Randomized-Controlled Period Baseline. Week 26 represented the start of the Open-Label Extension Period. The Randomized-Controlled Period estimates are based on MMRM that includes treatment group, stratification factor region, baseline score, study visit, and study visit by treatment group interaction. Visits up to Week 26 were included in the model. The Open-Label Extension Period estimates are based on MMRM that includes stratification factor region, baseline score, and study visit. A model was fit for the ravulizumab and placebo of the Open-label Extension Set separately. Data up to Week 60 at data cut-off are included.

*, **, and *** represent two-sided nominal p-value is less than 0.05, 0.01 and 0.001 for the comparison of treatment groups in change from baseline during the Randomized-Controlled Period.

Abbreviations: CI = confidence interval; LS = least squares; MMRM = mixed-effect model for repeated measures; PBO/RAV = placebo/ravulizumab; QMG = Quantitative Myasthenia Gravis; RAV/RAV = ravulizumab/ravulizumab

## Other Myasthenia Gravis (MG)-Related Outcomes

Although the change from baseline compared to placebo was not statistically significant at Week 26 of the Randomized-Controlled Period, similar trends favouring ravulizumab were observed for the secondary endpoints of Revised Myasthenia Gravis Quality of Life 15-item scale total score (Figure 23) and the Neurological Quality of Life fatigue score (Figure 24) improvement which was continued up to Week 60.

Figure 23: Change from Randomized-Controlled Period Baseline in MG-QoL15r Score (LS Mean and 95% CI) Through Week 60

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion in the Randomized-Controlled Period Baseline. Week 26 represented the start of the Open-Label Extension Period. The Randomized-Controlled Period estimates are based on MMRM that includes treatment group, stratification factor region, baseline score, study visit, and study visit by treatment group interaction. Visits up to Week 26 were included in the model. The Open-Label Extension Period estimates are based on MMRM that includes stratification factor region, baseline score, and study visit. A model was fit for the ravulizumab and placebo of the Open-label Extension Set separately. Data up to Week 60 at data cut-off are included.

* represents two-sided nominal p-value is less than 0.05 for the comparison of treatment groups in change from baseline during the Randomized-Controlled Period.

Abbreviations: CI = confidence interval; LS = least squares; MG-QoL15r = revised Myasthenia Gravis Quality of Life 15-item scale; MMRM = mixed-effect model for repeated measures; PBO/RAV = placebo/ravulizumab; RAV/RAV = ravulizumab/ravulizumab

Source: ALXN1210-MG-306 Week 60 CSR Addendum Figure 14.2.2.3.2.3.5

Figure 24: Change from Randomized-Controlled Period Baseline in Neuro-QoL Fatigue Score (LS Mean and 95% CI) Through Week 60

<!-- image -->

Note: Randomized-Controlled Period Baseline was defined as the last available assessment value prior to first study drug infusion in the Randomized-Controlled Period Baseline. Week 26 represented the start of the Open-Label Extension Period. The Randomized-Controlled Period estimates are based on MMRM that includes treatment group, stratification factor region, baseline score, study visit, and study visit by treatment group interaction. Visits up to Week 26 were included in the model. The Open-Label Extension Period estimates are based on MMRM that includes stratification factor region, baseline score, and study visit. A model was fit for the ravulizumab and placebo of the Open-label Extension Set separately. Data up to Week 60 at data cut-off are included.

Abbreviations: CI = confidence interval; LS = least squares; MMRM = mixed-effect model for repeated measures; Neuro-QoL = Neurological Quality of Life; PBO/RAV = placebo/ravulizumab; RAV/RAV = ravulizumab/ravulizumab

During the Open-Label Extension Period of the study when immunosuppressant therapy (IST) dose adjustments were permitted per protocol, 47.8% of patients reported a change in their IST usage. The most common change was a decrease in corticosteroids (28.0%), with the most common reason for

<div style=\"page-break-after: always\"></div>

decrease being improvement in MG symptoms (21.7%), which further supports the efficacy of ravulizumab in patients with gMG.

## Estimated Completion Date

The estimated completion date when the last patient will exit Study ALXN1210-MG-306 is planned to occur by 31 Dec 2023.

## Ancillary analyses

## Subgroup Analysis

Subgroup analyses were based on the following categories (Table 30):

Table 30: Defined Subgroups

| Subgroup                                 | Categories                                      |
|------------------------------------------|-------------------------------------------------|
| Geographic regiona                       | Asia-Pacific; Europe; Japan; North America      |
| Sex                                      | Male; female                                    |
| Race                                     | Asian; Other; White                             |
| Age at first study drug infusion         | 18 to 65 years; > 65 years                      |
| IST use at baseline                      | Corticosteroid; corticosteroid + IST; IST; none |
| Years from diagnosis to informed consent | ≤ median; > median                              |
| Baseline MGFA Clinical Classification    | II; III; IV                                     |
| Baseline body weight                     | ≥ 40 to < 60 kg; ≥ 60 to < 100 kg; ≥ 100 kg     |

Abbreviations: IST = immunosuppressive therapy; MGFA = Myasthenia Gravis Foundation of America

## MG-ADL Total Score

No  sensitive  subgroups  were  identified  for  MG-ADL  total  score.  The  point  estimates  for  all  groups favoured ravulizumab (Figure 25).

Figure  25:  Forest  Plot  of  Change  from  Baseline  to  Week  26  in  MG-ADL  Total  Score,  Overall  and  by Subgroup (Full Analysis Set)

<!-- image -->

Note: Treatment difference was estimated for ravulizumab-placebo. Median years from diagnosis to informed consent was 6.5. Abbreviations:  CI  =  confidence  interval;  DIFF  =  difference;  IST  =  immunosuppressant  therapy;  LS  =  least  square;  MG-ADL  = Myasthenia Gravis-Activities of Daily Living; MGFA = Myasthenia Gravis Foundation of America

<div style=\"page-break-after: always\"></div>

## QMG Total Score

No sensitive subgroups were identified for QMG total score. The point estimates for most groups favored ravulizumab (Figure 26).

Figure 26: Forest Plot of Change from Baseline to Week 26 in QMG, Overall and by Subgroup (Full Analysis Set)

<!-- image -->

|                                                         |                    |                                           | LS Me an   | LS Me an           |                                    |               |
|---------------------------------------------------------|--------------------|-------------------------------------------|------------|--------------------|------------------------------------|---------------|
|                                                         | Number of Patients |                                           |            | PlaceboRavulizumab | DIFF (95% CI)                      | p-value       |
|                                                         |                    |                                           |            | (98=N)(68=N)       |                                    |               |
| Overall                                                 | 154                |                                           | -0.8       | -2.8               | -2.0 (-3.2, -0.8)                  | 0.0009        |
| Randomization Strata NorthAmerica                       | 70                 |                                           | -1.2       | -3.0               | -1.8 (-3.5,-0.2)                   | 0.0308        |
| Europe                                                  | 57                 |                                           | -1.0       | -3.4               | -2.4(-4.2,-0.6)                    | 0.0089        |
| Asia-Paafic                                             | 17                 |                                           | 0.3        | -3.2               | -3.5(-6.6,-0.4)                    | 0.0282        |
| Japan                                                   |                    |                                           | -0.6       | -0.4               | 0.2(-3.4, 3.9)                     | 0.9013        |
| Sex                                                     | 10                 |                                           | -1.2       | -2.2               | -1.0 (-2.8, 0.7)                   | 0.2492        |
| Male Female                                             | 77 77              |                                           | -0.5       | -3.2               | -2.7 (-4.3) -1.2)                  | 0.0008        |
| Race Asian                                              |                    |                                           | 0.0        | -2.2               | -2.2 (-5.5, 1.1)                   | 0.1782        |
|                                                         | 27 111             |                                           | -1.5       | -3.1               | -1.5 (-2.9,-0.2)                   | 0.0265        |
| White Other                                             | 16                 |                                           | 0.8        | -5.6               | -6.4 (-10.9, -1.9)                 | 0.0087        |
| Age_at Firstlnfusion 18to65Years                        | 107                |                                           | -0.6       | -2.8               | -2.2(-3.7,-0.8)                    | 0.0019        |
| >65Years                                                | 47                 |                                           | -1. 1      | -2.7               | -1.6(-3.9,0.6)                     | 0.1515        |
| ISTTherapy Use OnlyCoricosteroid Only OtherIST          | 32 35              |                                           | 0.3 -0.2   | -3.6               | -3.9 (-6.6, -1.2) -3.0(-5.3,-0.7)  | 0.0050 0.3166 |
| Corticosteroid+OtherIST None MedianYears from Diagnosis | 74 13              |                                           | -1. 1      | -3.2 -1.9          | -0.7(-2.2,0.7)                     | 0.0127        |
|                                                         | 73 81              |                                           | -1.5 -1. 7 | -1.8 -3.4          | -0.2 (-5.7, 5.2)                   | 0.9334        |
| <=Median >Median                                        | 76                 |                                           | -1.0 0.5   | -3.1               | -2.1(-3.7,-0.5)                    | 0.0640        |
| MGFA                                                    |                    |                                           | -0.2       | -2.6               | -1.7 (-3.4, -0.0) -2.4 (-4.1,-0.8) | 0.0475 0.0048 |
|                                                         | 69                 |                                           | -0.5       | -1.9               | -1.4 (-2.9, 0.1)                   |               |
| IV                                                      | 9                  |                                           |            | -3.8               | -4.4 (-9.4,0.7)                    | 0.0093 98800  |
| BaselineBodyWeight >=40to<60kg >=60to<100 kg            | 15                 |                                           | -2.8       | -3.0               | -0.2 (-2.7,2.3) -3.0 (-4.5, -1.6)  | 0.8701        |
|                                                         | 84                 |                                           | 0.0        |                    |                                    | <0.0001       |
| >=100kg                                                 | 55                 |                                           |            |                    | -1.4(-3.3, 0.5)                    | 0.1497        |
|                                                         |                    |                                           |            | -3.0               |                                    |               |
|                                                         |                    | -10 -5 0 5                                | -1.5       |                    |                                    |               |
|                                                         |                    | -20 10 Favors R avulizumab Favors Placebo | 20         | -2.9               |                                    |               |

Note: Treatment difference was estimated for ravulizumab-placebo. Median years from diagnosis to informed consent was 6.5.

Abbreviations: CI = confidence interval; DIFF = difference; IST = immunosuppressant therapy; LS = least square; MGFA = Myasthenia Gravis Foundation of America; QMG = Quantitative Myasthenia Gravis

## Summary of main study

The following table summarises the efficacy results from the main study supporting the present application. This summary should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 31 - Summary of Efficacy for trial ALXN1210-MG-306

| Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis   | Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Ravulizumab in Complement-Inhibitor-Naïve Adult Patients With Generalized Myasthenia Gravis   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                       | ALXN1210-MG-306, EudraCT number 2018-003243-39, NCT03920293                                                                                                                                                            | ALXN1210-MG-306, EudraCT number 2018-003243-39, NCT03920293                                                                                                                                                            |
| Design                                                                                                                                                                                                                 | Randomized, double-blind, placebo-controlled multicenter study                                                                                                                                                         | Randomized, double-blind, placebo-controlled multicenter study                                                                                                                                                         |
| Design                                                                                                                                                                                                                 | Duration of main phase: Duration of screening                                                                                                                                                                          | 26 weeks Up to 4 weeks Up to 2 years                                                                                                                                                                                   |
| Design                                                                                                                                                                                                                 | phase:                                                                                                                                                                                                                 |                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                 | Duration of extension phase:                                                                                                                                                                                           |                                                                                                                                                                                                                        |
| Hypothesis                                                                                                                                                                                                             | Superiority                                                                                                                                                                                                            | Superiority                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

Treatments groups

Endpoints and definitions

Database lock

Ravulizumab

Placebo

Primary endpoint

Secondary endpoint

Secondary endpoint

Secondary endpoint

Secondary endpoint

Secondary endpoint

30 Jun 2021

| Analysis description                            | Primary Analysis: Change from Baseline in MG-ADL total score at Week 26 was analyzed using MMRM      | Primary Analysis: Change from Baseline in MG-ADL total score at Week 26 was analyzed using MMRM      | Primary Analysis: Change from Baseline in MG-ADL total score at Week 26 was analyzed using MMRM      |
|-------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Analysis population and time point description  | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26 Week 26 | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26 Week 26 | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26 Week 26 |
| Descriptive statistics and estimate variability | Treatment group                                                                                      | Ravulizumab                                                                                          | Placebo                                                                                              |
| Descriptive statistics and estimate variability | Number of subject                                                                                    | 86                                                                                                   | 89                                                                                                   |
| Descriptive statistics and estimate variability | Mean change from Baseline in MG-ADL total score at Week 26                                           | -3.1                                                                                                 | -1.4                                                                                                 |
| Descriptive statistics and estimate variability | 95% confidence interval                                                                              | -3.8, -2.3                                                                                           | -2.1, -0.7                                                                                           |
| Effect estimate per comparison                  | Primary endpoint: Change from Baseline in MG-ADL total score at Week 26                              | Comparison groups                                                                                    | Ravulizumab and placebo                                                                              |
| Effect estimate per comparison                  |                                                                                                      | Difference between groups                                                                            | -1.6                                                                                                 |
| Effect estimate per comparison                  |                                                                                                      | Confidence interval                                                                                  | -2.6, -0.7                                                                                           |
| Effect estimate per comparison                  |                                                                                                      | P-value using REML based MMRM                                                                        | 0.0009                                                                                               |
| Analysis description                            | Secondary analysis: Change from Baseline in QMG total score at Week 26 was analyzed using MMRM.      | Secondary analysis: Change from Baseline in QMG total score at Week 26 was analyzed using MMRM.      | Secondary analysis: Change from Baseline in QMG total score at Week 26 was analyzed using MMRM.      |
| Analysis population and time point description  | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26         | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26         | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26         |
| Analysis population and time point description  | Treatment group                                                                                      | Ravulizumab                                                                                          | Placebo                                                                                              |

MG-ADL  total score

QMG

score

QMG

responder rate

MG-QoL15r score

Neuro-QoL

Fatigue score

MG-ADL

responder rate

total

Ravulizumab IV body weight-based loading dose on Day

1, followed by maintenance doses on Day 15 and every

8 weeks therafter

N = 86 patients

Matching treatment

N = 89 patients

Change from Baseline in MG-ADL total score at Week

26 was analyzed using MMRM

Change from Baseline in QMG total score at Week 26

was analyzed using MMRM.

Improvement  of  at  least  5  points  in  the  QMG  total score from Baseline at Week 26.

Change from Baseline in MG-QoL15r score at Week 26

was analyzed using MMRM.

Change from Baseline in Neuro-QoL Fatigue score at

Week 26 was analyzed using MMRM.

Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26.

<div style=\"page-break-after: always\"></div>

| Descriptive statistics and estimate variability   | Number of subject                                                                                     |                                                                                                       | 86                                                                                                    | 89                                                                                                    |
|---------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability   | Change from Baseline in QMG total score at Week 26                                                    | -2.8                                                                                                  |                                                                                                       | -0.8                                                                                                  |
| Descriptive statistics and estimate variability   | Confidence interval                                                                                   | -3.7, -1.9                                                                                            | -1.7,                                                                                                 | 0.1                                                                                                   |
| Effect estimate comparison                        | per Change from Baseline in QMG total score at Week 26                                                |                                                                                                       | Comparison groups                                                                                     | Ravulizumab and placebo                                                                               |
| Effect estimate comparison                        | per Change from Baseline in QMG total score at Week 26                                                | Difference between groups                                                                             |                                                                                                       | -2.0                                                                                                  |
| Effect estimate comparison                        | per Change from Baseline in QMG total score at Week 26                                                | 95% confidence interval                                                                               |                                                                                                       | -3.2, -0.8                                                                                            |
| Effect estimate comparison                        | per Change from Baseline in QMG total score at Week 26                                                | P-value using REML MMRM                                                                               | based                                                                                                 | 0.0009                                                                                                |
| Analysis description                              | Secondary analysis: Improvement of at least 5 points in the QMG total score from Baseline at Week 26. | Secondary analysis: Improvement of at least 5 points in the QMG total score from Baseline at Week 26. | Secondary analysis: Improvement of at least 5 points in the QMG total score from Baseline at Week 26. | Secondary analysis: Improvement of at least 5 points in the QMG total score from Baseline at Week 26. |
| Analysis population and time point description    | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          |
| Descriptive statistics and estimate variability   | Treatment group                                                                                       | Ravulizumab                                                                                           | Placebo                                                                                               | Placebo                                                                                               |
| Descriptive statistics and estimate variability   | Number of subject                                                                                     | 86                                                                                                    | 89                                                                                                    | 89                                                                                                    |
| Descriptive statistics and estimate variability   | QMG ≥5 -point improvement                                                                             | 30.0%                                                                                                 | 11.3%                                                                                                 | 11.3%                                                                                                 |
| Descriptive statistics and estimate variability   | Confidence interval                                                                                   | 19.2, 43.5                                                                                            | 5.6, 21.5                                                                                             | 5.6, 21.5                                                                                             |
| Effect estimate per comparison                    | Change from Baseline in QMG total score at Week 26                                                    | Comparison groups                                                                                     | Ravulizumab and placebo                                                                               | Ravulizumab and placebo                                                                               |
| Effect estimate per comparison                    | Change from Baseline in QMG total score at Week 26                                                    | Odds ratio                                                                                            | 3.350                                                                                                 | 3.350                                                                                                 |
| Effect estimate per comparison                    | Change from Baseline in QMG total score at Week 26                                                    | 95% confidence interval                                                                               | 1.443, 7.777                                                                                          | 1.443, 7.777                                                                                          |
| Effect estimate per comparison                    | Change from Baseline in QMG total score at Week 26                                                    | P-value using REML based MMRM                                                                         | 0.0052                                                                                                | 0.0052                                                                                                |
| Analysis description                              | Secondary analysis: Change from Baseline in MG-QoL15r score at Week 26 was analyzed using MMRM.       | Secondary analysis: Change from Baseline in MG-QoL15r score at Week 26 was analyzed using MMRM.       | Secondary analysis: Change from Baseline in MG-QoL15r score at Week 26 was analyzed using MMRM.       | Secondary analysis: Change from Baseline in MG-QoL15r score at Week 26 was analyzed using MMRM.       |
| Analysis population and time point description    | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26          |
| Descriptive statistics and estimate variability   | Treatment group                                                                                       | Ravulizumab                                                                                           | Placebo                                                                                               | Placebo                                                                                               |
| Descriptive statistics and estimate variability   | Number of subject                                                                                     | 86                                                                                                    | 89                                                                                                    | 89                                                                                                    |
| Descriptive statistics and estimate variability   | Change from Baseline in QMG total score at Week 26                                                    | -3.3                                                                                                  | -1.6                                                                                                  | -1.6                                                                                                  |
| Descriptive statistics and estimate variability   | Confidence interval                                                                                   | -4.7, -1.9                                                                                            | -3.0, -0.3                                                                                            | -3.0, -0.3                                                                                            |
| Effect estimate per comparison                    | MG-QOL15r                                                                                             | Comparison groups                                                                                     | Ravulizumab and placebo                                                                               | Ravulizumab and placebo                                                                               |
| Effect estimate per comparison                    | MG-QOL15r                                                                                             | Difference between                                                                                    | groups -1.7                                                                                           | groups -1.7                                                                                           |
| Effect estimate per comparison                    | MG-QOL15r                                                                                             | 95% confidence interval                                                                               | -3.4, 0.1                                                                                             | -3.4, 0.1                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                                          | P-value using REML based MMRM                                                                            | 0.0636                                                                                                   |
|-------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Analysis description                            | Secondary analysis: Change from Baseline in Neuro-QoL Fatigue score at Week 26 was analyzed using MMRM.  | Secondary analysis: Change from Baseline in Neuro-QoL Fatigue score at Week 26 was analyzed using MMRM.  | Secondary analysis: Change from Baseline in Neuro-QoL Fatigue score at Week 26 was analyzed using MMRM.  |
| Analysis population and time point description  | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             |
| Descriptive statistics and estimate variability | Treatment group                                                                                          | Ravulizumab                                                                                              | Placebo                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject                                                                                        | 86                                                                                                       | 89                                                                                                       |
| Descriptive statistics and estimate variability | Neuro-QOL-fatigue                                                                                        | -7.0                                                                                                     | -4.8                                                                                                     |
| Descriptive statistics and estimate variability | Confidence interval                                                                                      | -10.7, -3.2                                                                                              | -8.5, -1.1                                                                                               |
| Effect estimate per comparison                  | Change from Baseline in QMG total score at Week 26                                                       | Comparison groups                                                                                        | Ravulizumab and placebo                                                                                  |
| Effect estimate per comparison                  | Change from Baseline in QMG total score at Week 26                                                       | Difference between groups                                                                                | -2.2                                                                                                     |
| Effect estimate per comparison                  | Change from Baseline in QMG total score at Week 26                                                       | 95% confidence interval                                                                                  | -6.9, 2.6                                                                                                |
| Effect estimate per comparison                  | Change from Baseline in QMG total score at Week 26                                                       | P-value using REML based MMRM                                                                            | 0.3734*                                                                                                  |
| Notes                                           | * Nominal p-values                                                                                       | * Nominal p-values                                                                                       | * Nominal p-values                                                                                       |
| Analysis description                            | Secondary analysis: Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26. | Secondary analysis: Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26. | Secondary analysis: Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26. |
| Analysis population and time point description  | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             | Intent to treat (all randomized patients who received at least 1 dose of study drug) Week 26             |
| Descriptive statistics and estimate variability | Treatment group                                                                                          | Ravulizumab                                                                                              | Placebo                                                                                                  |
| Descriptive statistics and estimate variability | Number of subject                                                                                        | 86                                                                                                       | 89                                                                                                       |
| Descriptive statistics and estimate variability | MG- ADL ≥3 -point improvement*                                                                           | 56.7%                                                                                                    | 34.1%                                                                                                    |
| Descriptive statistics and estimate variability | Confidence interval                                                                                      | 44.3, 68.3                                                                                               | 23.8, 46.1                                                                                               |
| Effect estimate per comparison                  | Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26                      | Comparison groups                                                                                        | Ravulizumab and placebo                                                                                  |
| Effect estimate per comparison                  | Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26                      | Odds ratio                                                                                               | 2.526                                                                                                    |
| Effect estimate per comparison                  | Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26                      | 95% confidence interval                                                                                  | 1.330 , 4.799                                                                                            |
| Effect estimate per comparison                  | Improvement of at least 3 points in the MG-ADL total score from Baseline at Week 26                      | P-value using REML based MMRM                                                                            | 0.0049*                                                                                                  |
| Notes                                           | * Nominal p-values                                                                                       | * Nominal p-values                                                                                       | * Nominal p-values                                                                                       |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

## Design and conduct of clinical studies

The main efficacy data in support of this extension of indication application was obtained from one Phase III clinical trial (Study ALXN1210-MG-306; Study MG-306).

This submission was initially based on data from the 26-week double-blind phase (completed) and the available results from the extension phase (still ongoing) as of the first data cut-off date (11 May 2021). Additional data, was provided during the procedure, for the 161 patients who received 1 or more doses of ravulizumab in the extension period collected up to the Week 60 visit in the Open-Label Extension Period as of the data cut-off date (09 Nov 2021).

The selection criteria defined subjects with confirmed diagnosis of gMG (determined by the presence of AchR antibodies and electrophysiological/pharmacological confirmation) who were symptomatic (MGADL ≥ 6) in spite of being treated with current standard of care.

Prior or concomitant MG treatment was not a requisite at baseline which could have led to inclusion of recently diagnosed patients. However, in the study only one randomized patient was not previously treated.  Patients having received recent treatment with rituximab or IVIg/PE were excluded as well as those who had been previously treated with eculizumab.

A  total  of  242  patients  were  screened,  of  which  175  patients  were  randomized  (86  patients  to  the ravulizumab group and 89 patients to the placebo group). A total of 158 patients (90.3%) entered the Open-Label extension: 77 (89.5%) in ravulizumab arm and 81 (91.0%) in placebo arm. Only the data from 79 patients (38 patients from the ravulizumab group and 41 patients from the placebo group) who reached Week 52 by the time of the data cut-off are available for analysis. This is an important limitation for the assessment of the maintenance of the effect.

In Study MG-306 most of demographics and disease characteristics at baseline were well balanced over treatment  arms  and  the  population  is  considered  to  have  been  adequately  selected  and  is  as representative of the EU.

Most of the patients had moderate to severe weakness affecting muscles other than the ocular muscles (66% MGFA Class III/IV), all had received prior treatment for their condition and most of them were treated at entry with more than one MG medication. Patients presented with a mean MG-ADL total score of  9.0,  and  the  mean  QMG total score of 15.0.  As  such, CHMP considered that in spite of previous treatments, the patient population included in the trial showed a relevant disease burden in order to assess the effect of ravulizumab in the approved indication.

The proposed dosing regimen is based on body weight and is identical to that approved for the treatment of PHN and aHUS (for further discussion on the approved dosing regimen please refer to the discussion on clinical pharmacology above section 2.3.5). This is considered adequate by CHMP.

Patients on placebo, who entered the OLE period, received a loading dose of ravulizumab and those treated with ravulizumab in the randomized controlled period received a blinded dose of 900 mg of ravulizumab to ensure maintenance of complete complement component 5 (C5) inhibition until the next scheduled maintenance dose.

During the double-blind period ravulizumab was administered in a 10 mg/mL formulation. During the OLE period a total of 35 patients were switched to a 100 mg/mL formulation following the same dosing regimen than that received during the controlled period. The 74 patients from the US did not receive this formulation, apparently due to the lack of availability for supplying the product during the study

<div style=\"page-break-after: always\"></div>

duration. Apart from the differences between both formulations, those regarding qualitative composition, preparation, or administration conditions were not considered clinically relevant.

With respect to the impact of COVID 19 pandemic on the conduct of the study a total of five patients (3 patients on placebo and 2 patients on ravulizumab) missed a total of 6 infusions due to COVID-19 (3 placebo patients missed 1 infusion each and 2 ravulizumab-treated patients missed 1 and 2 infusions each). Patients on ravulizumab treatment and 2 patients on placebo did not receive further doses after COVID-19  and  discontinued  the  study.  One  placebo  patient  received  a  scheduled  dosing.  CHMP considered that since only a low number of patients missed infusions due to COVID-19 and this affected both arms in a similar way, no impact on the efficacy or safety results is expected.

Plasma exchange (PE), plasmapheresis (PP), and intravenous immunoglobulin (IVIg) have been shown to reduce ravulizumab serum levels As such, regarding the need for a supplemental dose in case of plasma exchange (PE), plasmapheresis (PP), or intravenous immunoglobulin (IVIg additional clarifications  were  requested  by  the  CHMP  on  whether  the  proposed  supplemental  dose  resulted  in comparable exposure over time. Simulations in four scenarios were performed where the rescue therapy with  plasma  exchange  (PE),  plasmapheresis  (PP)  or  intravenous  immunoglobulin  (IVIg)  could  be potentially administered: a) immediately after the loading dose (Day 1); b) at 2 weeks after the loading dose (immediately before the first maintenance dose on Day 15); c) immediately after any maintenance dose; and d) at 8 weeks after any maintenance dose (immediately before the next maintenance dose). The  body  weight  strata  were  also  taken  into  account.  The  simulations  performed  show  that  the recommended  supplemental  doses  of  ravulizumab  did  not  lead  to  apparent  drug  accumulation. Therefore, a supplemental dose of ravulizumab IV is recommended immediately after each PP or PE session or complete IVIg course. This information is appropriately reflected in section 4.2 of the Product Information (PI).

## Efficacy data and additional analyses

The evaluation of efficacy of ravulizumab focused on the assessment of the gMG signs and symptoms by the patient (MG-ADL; primary endpoint) and the physician (QMG; main secondary endpoint).

The primary endpoint was the change in MG-ADL score reported by the patient. At Week 26 ravulizumab arm showed a statistically significant reduction in MG-ADL score from baseline irrespective of rescue therapy in comparison with placebo.   Patients in the ravulizumab treatment group showed a 3.1-point reduction  whereas  patients  receiving  placebo  showed  a  1.4-point  reduction  (mean  difference:  -1.6 [0.49]; 95% confidence interval [CI]: -2.6, -0.7; p = 0.0009).

The MG-ADL responder criterion was met in 48 (56.7%) patients in the ravulizumab group compared to 30  (34.1%)  patients  in  the  placebo  group.  Of  note,  this  analysis  was  not  considered  (formally) statistically significant according to the prespecified hierarchical testing for secondary endpoints.

Main secondary endpoints assessed the effect of ravulizumab by the physician (QMG total score; QMG responder rate). A statistically significant difference was observed between ravulizumab and placebo (2.0  [-3.2,  -0.8];  p=0.009).  More  patients  on  ravulizumab  showed  significantly  better  control  of  the disease. 30% of patients on ravulizumab had ≥ 5 point reduction in the QMG total score compared with 11.3% placebo (OR 3.350 [95% CI 1.443, 7.777]; p=0.0052).

Of note, the efficacy analyses were conducted irrespective of the rescue therapy received by the patients in case of clinical deterioration. Additional analyses were conducted based on rescue therapy: one of them includes the change from baseline in MG-ADL total score up to the time of rescue therapy and the second  excludes  the  22  patients  requiring  rescue  therapy  (14  placebo-  and  8  ravulizumab-treated

<div style=\"page-break-after: always\"></div>

patients). The results do not suggest that the use of rescue therapy has had a significant impact on the response to ravulizumab.

According to the testing hierarchy, the remaining three secondary endpoints (change in MG-QOL15r score, change in Neuro-QoL fatigue scale, MG-ADL responder rate) were not considered statistically significant even if results numerically favoured ravulizumab compared to placebo.

MG Composite Scale results were in line with those observed for MG-ADL score and QMG scales. Patients treated with both ravulizumab and with placebo experienced a reduction in the scores (ravulizumab -6.1 [0.73], placebo -3.2 [0.71]). The difference was statistically significant (-2.9 [0.93]; 95% CI: -4.8, 1.1; p = 0.0019) although the clinical relevance is perceived as borderline considering the three-point reduction threshold established as clinically meaningful in the literature.

Achieving improvement with minimal manifestations of the disease was reported in 25.6% of patients in the ravulizumab group compared to 9.9% of patients in the placebo group at Week 26. More patients treated with placebo than those receiving ravulizumab suffered clinical deterioration (18 [20.2%] vs. 10 [11.6%]) or required  rescue  therapy  (14  [15.7%] vs.  8  [9.3%])  during  the  study.  Similarly,  fewer patients  on  ravulizumab  needed  hospitalization  due  to  MG  during  the  26  week  period  of  treatment compared to placebo (7 [8%] vs. 3 [3%]).

No  important  differences  were  observed  between  ravulizumab  and  placebo  in  subgroups  studied according region, sex, race, age, disease characteristics or body weight.

Overall, ravulizumab showed an effect over placebo on the control of symptoms assessed by the patient (MG-ADL score, primary endpoint) and by the physician (QMG score; secondary endpoint) in a population with an established condition of moderate severity in spite of concomitant MG therapy. This is consistent with the MGC score results, a scale derived from the other two scales mentioned above.

However,  the  clinical  meaningfulness  of  the  observed  changes  versus  the  respective  established thresholds  was  questioned  by  the  CHMP.  CHMP  considered  that    the  fact  that  the  analyses  were performed irrespective of whether rescue therapy was used could introduce a confounding factor in the assessment of the efficacy of ravulizumab. The small (absolute) differences between groups in relevant clinical  aspects such as required rescue therapy (difference 6.4%), clinical deterioration experienced (difference 8.6%) or need of hospitalization due to MG (difference 5%) additionally put into question the benefit of the product in the management of MG.

The statistically significant reduction experienced in symptoms of 1.6 points in the mean change in MGADL score (primary endpoint) with respect to baseline during the randomized controlled period was considered as a modest effect. This also applied to the observed findings in the main secondary endpoints when they were expressed in terms of absolute changes of the respective scales.

CHMP  acknowledged  that  Study  MG-306  included  a  population  on  IST  treatment  with  remaining symptomatology in whom an effect may be difficult to evidence due to the limited room for improvement and the fluctuating nature of the condition.

As stated, the clinical relevance of the treatment effect could be questioned based on the fact that it did not achieve the accepted thresholds for clinical meaningfulness for the utilized scales established in literature (i.e. MCID of 2 point 22 , 23 ). However, it should be considered that this difference has been defined  by  absolute  change  from  baseline  in  individual  patients,  and  not  as  differences  in  average changes between groups 24 . In this regard these thresholds should be used for individual responder

22  Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487-9.

23  Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31. 24  Chung AS, Copay AG, Olmscheid N, Campbell D, Walker JB, Chutkan N. Minimum clinically important difference: current trends in the spine literature. Spine. 2017;42(14):1096-1105.

<div style=\"page-break-after: always\"></div>

analyses  and  not  as  a  reference  point  for  a  population-average  drug-placebo  treatment  effect. Admittedly, this criterion could be considered as a cut-off value in responder analysis, as this is based on an 'individual level' approach. In this respect 63.9% of patients treated with ravulizumab and 53.0% of patients treated with placebo showed a 2-point reduction in MG-ADL score, with the reported 10.9% difference being of difficult interpretation. Moreover, the measured difference between ravulizumab and placebo did not achieve the treatment effect of 1.9 points on the MG-ADL score used at the planning stage.

An estimation of the effect size for the primary and secondary endpoints (MG-ADL and QMG scales) was provided in order to inform about the magnitude of treatment effects, showing an Hedge's g effect size of -0.49 and -0.50, respectively, which is defined as a moderate effect.

While there are some uncertainties on the clinical relevance of the treatment effect size, the totality of the demonstrated effects has to be considered. In this respect, the CHMP considered that the observed treatment effects are consistent across the responder rates reported both from the patient's (MG-ADL) and physician's perspective (QMG). It should also be highlighted that more stringent criteria led to clearer differences between the ravulizumab and the placebo groups.

From the patient perspective (QoL measures), the changes in the MG-QOL15r score and in the NeuroQoL  fatigue  scale  were  not  statistically  significant  even  if  results  numerically  favoured  ravulizumab compared to placebo.

Supportive evidence derives also from the clinical impact of ravulizumab in the course of the disease. Ravulizumab treated patients experienced less clinical deterioration, less MG-related hospitalization and required less rescue therapy than placebo treated patients (Table 3 above). The interpretation of these outcomes is limited by the reduced numbers of events by group and the exploratory nature of the endpoints. However, a consistent response has been shown in the scales measured, which reinforces the observed effect.   During the extension period, where changes in background therapy were allowed, 50.3% of patients had a change in concomitant MG medication.  The most common change was a decrease in corticosteroids for systemic use due to MG symptoms improved (20.7%) with 11 (6.5%) patients discontinuing corticosteroids for systemic use.

Whereas some uncertainties still remain (e.g., what treatment effect size with respect to placebo is to be considered clinically relevant) the totality of the data submitted supports the conclusion that efficacy has been sufficiently demonstrated in order to support the use of ravulizumab in the approved indication.

## Maintenance of the effect

Maintenance of the effect of ravulizumab beyond 6 month treatment is based on the still ongoing open label period, where all patients involved in Study MG-306 are treated with ravulizumab and followed up to 2 years.  An update of the Study MG-306 with a clinical database cut-off date of 09 Nov 2021 was provided during the assessment of this applicaton. Additional data from the 161 patients who received 1 or more doses of ravulizumab in the extension period collected up to the Week 60 visit in the OpenLabel Extension Period was provided. All patients received treatment with ravulizumab during the Open-Label Extension Period, including patients randomized to ravulizumab and patients randomized to placebo during the Randomized-Controlled Period (RAV/RAV and PBO/RAV group, respectively). When patients who received placebo in the randomized controlled period were treated with ravulizumab in the open-label extension period an improvement similar to that achieved by patients on active treatment in the first part of the study was observed. In patients previously treated with ravulizumab, the response was maintained.

<div style=\"page-break-after: always\"></div>

During this phase of the clinical trial background therapy could be adjusted. In this period 50.3% of patients had a change in concomitant MG medication.  The most common change was a decrease in corticosteroids for systemic use due to MG symptoms improved (20.7%) with 11 (6.5%) patients discontinuing corticosteroids for systemic use.

With the limitations given by the open label design and the fact that the study is still ongoing, the maintenance of the effect was considered sufficiently established. The final results of the study will have to be submitted once available.

Ravulizumab  is  structurally  related  to  eculizumab,  both  products  providing  sustained  inhibition  of complement component 5. It is therefore conceivable that gMG patients in treatment with eculizumab could be switched to ravulizumab seeking for more convenient administration if response is achieved. This is not the case in non-responder to eculizumab patients in whom non response to ravulizumab is likely. This information has been reflected in the SmPC.

## Wording of the indication

The initial proposed indication was:

' The treatment of adult patients with anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia  gravis  (gMG)  with  remaining  symptomatology  despite  at  least  one  immunomodulatory therapy (see section 5.1). '

CHMP considered that this proposal did not reflect the studied population. CHMP noted that the majority (50.9%) of patients used only 2 ISTs. In order to substantiate whether the use of immunomodulatory therapy (including the number of therapies received) has an impact on the efficacy of ravulizumab and defines the target population who should receive ravulizumab in clinical practice additional analyses were provided. With respect to prior use of IST, this does not appear to have a relevant impact on the effect of ravulizumab. And when it is observed it seems to be likely driven by the low number of subjects.

With respect to the available evidence in other subsets of the population that are covered by the broad indication proposed, e.g. MFGA class IV and V subjects further clarifications have been presented.

- a. there  were  only  9  patients  with  a  MGFA  Class  IV,  included  in  the  study.  The  mean  treatment difference in MG-ADL total score was -7.2 [3.26] (95% CI: -14.9, 0.4; p = 0.0593). The mean treatment difference in QMG total score was -4.4 [2.35]; (95% CI: -9.4, 0.7; p =0.0836). The results do not suggest that ravulizumab does not have an effect in these patients.
- b. patients with a MGFA Class V were excluded from the study. Available postmarketing data on the use of eculizumab nin Japan showing a similar response in these patients to that achieved by less severe  patients.  Give  the  similarities  with  ravulizumab  in  principle  there  are  not  reasons  for restricting the use of ravulizumab in this subset. However, the lack of Class V gMG patients treated with ravulizumab has been reflected in the SmPC.

Further justifications were provided to address the concerns raised regarding the wording of the indication and the appropriateness of adopting an indication similar to that approved for eculizumab. It was highlighted that there are several differences between both clinical developments.  The provided justification aims at addressing various aspects:

- a) There are differences in the selection criteria of pivotal study conducted with eculizumab (Study ECU-MG-301) and that conducted with ravulizumab (Study ALXN1210-MG-306). Whereas the patients enrolled in the eculizumab study were required to have failed to a previous treatment with

<div style=\"page-break-after: always\"></div>

≥2 IST or ≥1 IST + PE/IVIg, patients included in the ravulizumab study had no requirement for treatment failure. In this case the study allowed patients with/without concomitant treatment.

- b) The comparison of the populations enrolled in eculizumab and ravulizumab studies shows that in general the eculizumab population had more severe disease at entry than the ravulizumab population.
- c) Patients in the eculizumab study had received more lines of treatment than patients included in the ravulizumab study.
- In the eculizumab study 46.4% of patients had received ≥2 ISTs; 31.2% ≥3 ISTs and 20.8% ≥4 ISTs; 79.2% had received IVIg and 48.0% PP/PE.
- In the ravulizumab study 19.4% of patients had received only 1 IST; 50.9% only 2 ISTs, 43.4% had received IVIg and 19.4% PP/PE. A total of 6 patients had no received prior therapy at entry.
- d) The concomitant treatment at entry in patients receiving ravulizumab was as follows: 10.3% of patients were receiving no concomitant treatment with ISTs, 42.3% were using only 1 IST, and 47.4% were using 2 or more ISTs. These numbers have not been provided for eculizumab patients.

In general, patients included in the eculizumab study seems to correspond to a more severe, more heavily treated patients, in accordance with the approved indication in a refractory population, while the patient population included in the ravulizumab study would justify granting a broader indication.

As such, the wording of the approved indication for ravulizumab was amended as follows:

'Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive.'

## 2.4.4. Conclusions on the clinical efficacy

The effect of ravulizumab over placebo on the control of symptoms assessed by the patient (MG-ADL score, primary endpoint) and by the physician (QMG score; secondary endpoint) has been demonstrated. A consistent treatment effect has been shown based on available efficacy data that, even if of modest magnitude in the short-term, it can be considered a sufficiently robust demonstration of the clinical benefit of ravulizumab when added to standard therapy in patients with gMG. The findings from the (updated) Extension open label period further support the maintenance of the effect in this population. The final results of the study will have to be submitted once available.

## 2.5. Clinical safety

## Introduction

The overall safety evaluation is based on the following data from Study ALXN1210 MG 306:

- Randomized Controlled Period - data for the randomized, double-blind, placebo- controlled 26week treatment period.
- Ravulizumab Treatment Period - data through the 52 week data cut-off date (11 May 2021) were included for patients who had reached Week 52 or were expected to reach Week 52 by the time of

<div style=\"page-break-after: always\"></div>

the data cutoff date (ie, including patients who had withdrawn from the study prior to Week 52). Results for the Ravulizumab Treatment Period include data from:

- Patients treated with ravulizumab during the Randomized-Controlled Period regardless of whether the patients continued to receive treatment with ravulizumab during the Open-Label Extension Period (referred to as the RAV/RAV group)
- Patients treated with placebo during the Randomized-Controlled Period and who switched to ravulizumab in the Open-Label Extension Period (referred to as the PBO/RAV group)

All  safety  analyses  for  the  Randomized-Controlled  Period  are  presented  for  the Safety  Set which consisted of all patients who received at least 1 dose of study drug (ravulizumab or placebo).

All safety analyses for the Ravulizumab Treated Period are presented for the Ravulizumab Treated Set which consisted of all patients who received at least 1 dose of ravulizumab either in the RandomizedControlled Period or the Open-Label Extension Period.

Subgroup  analyses  were  based  on  geographic  region,  sex,  race,  age  at  first  study  drug  infusion, immunosuppressive therapy (IST) use at baseline, years from diagnosis to informed consent, baseline MGFA clinical classification, and baseline body weight categories.

## Patient exposure

In total, 175 patients were randomized and treated (placebo: n = 89; ravulizumab: n = 86). Thirteen patients  withdrew  from  the  study  prior  to  completing  the  Randomized-Controlled  Period,  including 2 patients who discontinued study drug due to AEs and 2 patients who died (cerebral hemorrhage and COVID-19 pneumonia).

As of the clinical database cutoff date, 75 of the 79 patients in the Open-Label Extension Set (ie, all patients who received at least 1 dose of ravulizumab starting from Week 26 and who have completed Week 52 study visit or who would have completed Week 52 by the data cutoff date but withdrew from the study) had completed the Week 52 Visit. Four of the 79 patients in the Open-Label Extension Set had withdrawn from the study during the Open-Label Extension Period (2 due to patient decision and 2 deaths due to COVID-19). A total of 75 patients were ongoing in the Open-Label Extension Period as of the  52-week  data  cutoff  date:  35  patients  who  received  ravulizumab  during  both  the  RandomizedControlled Period and the Open-Label Extension Period, and 40 patients who received placebo during the Randomized-Controlled Period and switched to ravulizumab in the Open-Label Extension Period.

Table 31: Patient Disposition During the Randomized-Controlled Period (All Randomized Patients)

|                                                                 | Placebo (N=89)   | Placebo (N=89)    | Ravulizumab (N=86)   | Ravulizumab (N=86)   | Total (N=175)   | Total (N=175)     |
|-----------------------------------------------------------------|------------------|-------------------|----------------------|----------------------|-----------------|-------------------|
|                                                                 | Overall          | COVID- 19 Related | Overall              | COVID- 19 Related    | Overall         | COVID- 19 Related |
| Randomized a , n (%)                                            | 89 (100)         |                   | 86 (100)             |                      | 175 (100)       |                   |
| Treated, n (%)                                                  | 89 (100)         |                   | 86 (100)             |                      | 175 (100)       |                   |
| Completed Randomized-Controlled Period (Week 26), n (%)         | 83 (93.3)        |                   | 79 (91.9)            |                      | 162 (92.6)      |                   |
| Did not Complete Randomized- Controlled Period (Week 26), n (%) | 6 (6.7)          | 0                 | 7 (8.1)              | 3 (3.5)              | 13 (7.4)        | 3 (1.7)           |
| Death                                                           | 0                | 0                 | 2 (2.3)              | 1 (1.2)              | 2 (1.1)         | 1 (0.6)           |
| Withdrawal by patient                                           | 1 (1.1)          | 0                 | 2 (2.3)              | 0                    | 3 (1.7)         | 0                 |
| Noncompliance with study drug                                   | 0                | 0                 | 1 (1.2)              | 1 (1.2)              | 1 (0.6)         | 1 (0.6)           |
| Physician decision                                              | 2 (2.2)          | 0                 | 1 (1.2)              | 1 (1.2)              | 3 (1.7)         | 1 (0.6)           |
| Protocol violation                                              | 0                | 0                 | 1 (1.2)              | 0                    | 1 (0.6)         | 0                 |
| Adverse event                                                   | 2 (2.2)          | 0                 | 0                    | 0                    | 2 (1.1)         | 0                 |

<div style=\"page-break-after: always\"></div>

|         | Placebo (N=89)   | Placebo (N=89)    | Ravulizumab (N=86)   | Ravulizumab (N=86)   | Total (N=175)   | Total (N=175)     |
|---------|------------------|-------------------|----------------------|----------------------|-----------------|-------------------|
|         | Overall          | COVID- 19 Related | Overall              | COVID- 19 Related    | Overall         | COVID- 19 Related |
| Other b | 1 (1.1)          | 0                 | 0                    | 0                    | 1 (0.6)         | 0                 |

Note: Reasons for study withdrawal due to COVID-19 are also presented in the overall column.

a   Two additional patients were randomized in error: 1 patient was randomized but could not be dosed due to a water leak in the laminar hood while preparing study drug; patient was ultimately screen failed. Additionally, 1 patient was randomized and screen failed due to pyridostigmine not being withheld 10 hours prior to Screening assessments; this patient was subsequently re-screened and re-randomized (patient was counted in the 'Randomized' row).

b Other reason = Sponsor's request, measuring complement-related protein that could have led to potential unblinding (ie, the assessment would be biased)

Abbreviations: COVID-19 = coronavirus disease 19

Overall, 50.9% of patients in the Safety Analysis Set were female; 73.1% were White, and the mean age was 55.6 years at the time of first infusion. The majority of patients (69.1%) were 18 to 65 years of age at the time of first infusion, and approximately half of the patients (53.7%) were in the weight category ≥ 60 kg to &lt; 100 kg at baseline.

Overall, 82 (47%) patients (placebo: 39 [44%]; ravulizumab: 43 [50%]) had hospitalizations within 2 years prior to Screening; mean number of hospitalizations was 2.3 for both treatment groups. A majority of  these  patients  had  hospitalizations  related  to  MG  (placebo: 32/39 patients;  ravulizumab:  32/43 patients); mean number of MG-related hospitalizations was 2.0 for both treatment groups.

## Adverse events

The safety profile for ravulizumab was similar to that of placebo in adult patients with gMG during the 26-week Randomized-Controlled Period (Table32).

Table 32: Overview of All Treatment-Emergent Adverse Events During the Randomized-Controlled Period (ALXN1210-MG-306 Safety Set)

|                                                        | Placebo (N = 89)                        | Ravulizumab (N = 86)                            |
|--------------------------------------------------------|-----------------------------------------|-------------------------------------------------|
|                                                        | n (%)                                   | n (%)                                           |
| Any AE                                                 | 77 (86.5)                               | 78 (90.7)                                       |
| Any SAE                                                | 14 (15.7)                               | 20 (23.3)                                       |
| Death                                                  | 0                                       | 2 (2.3)                                         |
| AE leading to discontinuation of study drug            | 3 (3.4)                                 | 2 (2.3)                                         |
| SAE leading to discontinuation of study drug           | 1 (1.1)                                 | 2 (2.3)                                         |
| AE by relationship to study drug Related               | 30 (33.7)                               | 29 (33.7)                                       |
| Not related by a                                       | 72 (80.9)                               | 76 (88.4)                                       |
| AE severity Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 by | 66 (74.2) 30 (33.7) 14 (15.7) 1 (1.1) 0 | 65 (75.6) 39 (45.3) 19 (22.1) 4 b (4.7) 2 (2.3) |
| SAE relationship to study drug Related                 | 4 (4.5)                                 | 2 (2.3)                                         |
| Not related                                            | 11 (12.4)                               | 18 (20.9)                                       |

Note: Patients were counted once in each severity or relationship category in case of multiple events. Treatment-emergent AEs were AEs with a start date on or after first dose date in the study. AEs were coded using MedDRA Version 24.0.

a Severity of AEs was graded using CTCAE Version 5.0. Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

b Two of the 4 patients had Grade 4 SAEs that subsequently resulted in death (Grade 5) (ie, events were counted in both severity categories).

<div style=\"page-break-after: always\"></div>

Abbreviations: AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; E = number of events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = serious adverse event

During the Ravulizumab Treatment Period, 86.6% of patients experienced at least 1 AE (Table 33).

As of the data cut-off date, 4 patients died during the study and no meningococcal infections were observed.

Table 33: Overview of All Treatment-emergent Adverse Events Since First Dose of Ravulizumab as of Data Cutoff Date (ALXN1210-MG-306 Ravulizumab Treated Set)

|                                              | Total                     | Total                       | Total                       |
|----------------------------------------------|---------------------------|-----------------------------|-----------------------------|
|                                              | 0 to 6 mo (N = 127) n (%) | > 6 to 12 mo (N = 97) n (%) | 0 to cutoff (N = 127) n (%) |
| Any AE                                       | 109 (85.8)                | 34 (35.1)                   | 110 (86.6)                  |
| Any SAE                                      | 25 (19.7)                 | 5 (5.2)                     | 27 (21.3)                   |
| Death                                        | 2 (1.6)                   | 2 (2.1)                     | 4 (3.1)                     |
| AE leading to discontinuation of study drug  | 2 (1.6)                   | 0                           | 2 (1.6)                     |
| SAE leading to discontinuation of study drug | 2 (1.6)                   | 0                           | 2 (1.6)                     |
| AE by relationship to study drug             |                           |                             |                             |
| Related                                      | 40 (31.5)                 | 10 (10.3)                   | 43 (33.9)                   |
| Not related                                  | 104 (81.9)                | 31 (32.0)                   | 107 (84.3)                  |
| AE by severity a                             |                           |                             |                             |
| Grade 1                                      | 89 (70.1)                 | 30 (30.9)                   | 90 (70.9)                   |
| Grade 2                                      | 47 (37.0)                 | 12 (12.4)                   | 54 (42.5)                   |
| Grade 3                                      | 24 (18.9)                 | 3 (3.1)                     | 27 (21.3)                   |
| Grade 4                                      | 5 (3.9)                   | 0                           | 5 b (3.9)                   |
| Grade 5                                      | 2 (1.6)                   | 2 (2.1)                     | 4 (3.1)                     |
| SAE by relationship to study drug            |                           |                             |                             |
| Related                                      | 3 (2.4)                   | 0                           | 3 (2.4)                     |
| Not related                                  | 22 (17.3)                 | 5 (5.2)                     | 24 (18.9)                   |

Note: The Ravulizumab Treated Set consisted of all patients who received at least 1 dose of ravulizumab either in the RandomizedControlled Period or the Open-Label Extension Period. Per scope, only data during Randomized-Controlled Period were included for patients not expected to have Week 52 at data cutoff. This would apply to both ravulizumab and placebo patients. Patients were counted once in each severity or relationship category in case of multiple events. At the time of the data cutoff date, data for only 13 patients receiving ravulizumab treatment &gt; 12 months was available; 2 of the 13 patients reported AEs during this period. AEs were coded using MedDRA Version 24.0.

a Severity of AEs was graded using CTCAE Version 5.0. Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = lifethreatening; Grade 5 = fatal.

- b   Two of the 5 patients had Grade 4 SAEs that subsequently resulted in death (Grade 5) (ie, events were counted in both severity categories).

Abbreviations:  AE = adverse  event;  CTCAE = Common  Terminology  Criteria  for  Adverse  Events;  E = number  of  events; MedDRA = Medical Dictionary for Regulatory Activities; mo = months; SAE = serious adverse event

As of the 60-week CSR cut-off date , the mean duration of ravulizumab treatment is 306.1 days, and the maximum is 442.0 days (Table 34). Total exposure to ravulizumab was 141.6 patient-years, compared to 81.5 patient-years in the initial CSR.

Table 34: Treatment Administration During the Ravulizumab Treatment Period Through the Data Cut-off Date (Ravulizumab Treated Set)

<div style=\"page-break-after: always\"></div>

| Variable                                                      | PBO/RAV (N = 83)                | RAV/RAV (N =86)             | Total (N = 169)               |
|---------------------------------------------------------------|---------------------------------|-----------------------------|-------------------------------|
| Study duration from informed consenta (days)                  |                                 |                             |                               |
| Mean (SD) Median                                              | 430.7 (31.59) 442.0             | 406.7 (85.13) 441.0         | 418.4 (65.56) 442.0           |
| Min, max Ravulizumab treatment durationb (days)               |                                 |                             |                               |
| Mean (SD) Median Min, max                                     | 225.6 (31.43) 239.0 63.0, 258.0 | 383.8 (85.20) 421.0         | 306.1 (102.18) 246.0          |
| Ravulizumab treatment duration category,n (%) > 0 to 6 months |                                 |                             |                               |
| >6to 12months > 12 to 18 months                               | 3 (3.6) 80 (96.4) 0 (0.0)       | 14.0, 442.0 6 (7.0) 5 (5.8) | 14.0, 442.0 9 (5.3) 85 (50.3) |
| >18 to 24 months                                              | 0 (0.0)                         | 75 (87.2) 0 (0.0)           | 75 (44.4) 0 (0.0)             |
| >24months                                                     |                                 |                             |                               |
|                                                               | 0 (0.0)                         |                             |                               |
|                                                               |                                 | 0 (0.0)                     |                               |
| Patient-years of exposure to ravulizumab                      | 51.3                            |                             | 141.6                         |
|                                                               |                                 |                             | 0 (0.0)                       |
|                                                               |                                 | 90.4                        |                               |
| Number of ravulizumab infusions per patient Mean (SD)         | 5.7 (0.86)                      | 9.2 (2.34)                  | 7.4 (2.50)                    |
| Median                                                        | 6.0                             |                             | 6.0                           |
|                                                               |                                 | 10.0                        |                               |
| Min, max Total infusions                                      | 2.0, 8.0 469                    | 1.0, 15.0 788               | 1.0, 15.0 1257                |

Note: The Ravulizumab Treated Set consists of all patients who received at least 1 dose of ravulizumab either in the Randomized-Controlled Period or the Open-Label Extension Period. Data up to Week 60 at data cutoff date are included.

a Study duration = data cutoff date/discontinuation - date of informed consent + 1.

b Ravulizumab treatment duration = data cutoff date/discontinuation - first ravulizumab infusion date + 1.

Abbreviations: max = maximum; Min = minimum ; PBO = placebo; RAV = ravulizumab; SD = standard deviation

## Common Adverse Events

During the Randomized-Controlled Period , the most frequently reported AEs (≥ 10% of all patients) were headache (placebo: 25.8%; ravulizumab: 18.6%), diarrhoea (placebo: 12.4%; ravulizumab: 15.1%), and nausea (placebo: 10.1%; ravulizumab: 10.5%) (Table 35).

Table 35: Treatment-emergent Adverse Events Experienced by 5% or More of Patients in Any Treatment Group During the Randomized-Controlled Period (ALXN1210-MG-306 Safety Set)

| System Organ Class Preferred Term                                            | Placebo (N = 89) n (%)                | Ravulizumab (N = 86) n (%)                     | Total (N = 175) n (%)                          |
|------------------------------------------------------------------------------|---------------------------------------|------------------------------------------------|------------------------------------------------|
| Any AE                                                                       | 77 (86.5)                             | 78 (90.7)                                      | 155 (88.6)                                     |
| Infections and infestations COVID-19 Urinary tract infection Nasopharyngitis | 28 (31.5) 3 (3.4) 4 (4.5) 5 (5.6)     | 38 (44.2) 5 (5.8) 5 (5.8) 3 (3.5)              | 66 (37.7) 8 (4.6) 9 (5.1) 8 (4.6)              |
| Nervous system disorders Headache Dizziness Gastrointestinal disorders       | 32 (36.0) 23 (25.8) 3 (3.4) 29 (32.6) | 16 (18.6) 8 (9.3) 29 (33.7) 13 (15.1) 9 (10.5) | 11 (6.3) 58 (33.1) 24 (13.7) 18 (10.3) 5 (2.9) |
| Abdominal pain Musculoskeletal and connective tissue disorders Back pain     | 23 (25.8) 5 (5.6)                     | 5 (5.8) 23 (26.7)                              | 46 (26.3) 12 (6.9) 13 (7.4)                    |
| Arthralgia General disorders                                                 | 7 (7.9) 21                            |                                                |                                                |
| Injury, poisoning and procedural Infusion-related reaction                   | (23.6) 6 (6.7) 5 (5.6) 17 (19.1)      | 30 (34.9)                                      | 62 (35.4)                                      |
|                                                                              |                                       |                                                | 39 (22.3)                                      |
|                                                                              | 11 (12.4)                             |                                                |                                                |
| Diarrhoea                                                                    |                                       |                                                |                                                |
| Nausea                                                                       | 9 (10.1)                              |                                                |                                                |
|                                                                              | 0                                     |                                                |                                                |
|                                                                              |                                       | 7 (8.1)                                        |                                                |
|                                                                              |                                       | 6 (7.0)                                        |                                                |
|                                                                              | site conditions                       | 22 (25.6)                                      | 43 (24.6)                                      |
| Fatigue                                                                      |                                       |                                                | 6 (3.4)                                        |
|                                                                              |                                       | 1 (1.2)                                        |                                                |
|                                                                              | 5 (5.6)                               | 0                                              | 23                                             |
|                                                                              |                                       | 6                                              |                                                |
|                                                                              |                                       | (7.0)                                          |                                                |
| complications                                                                |                                       |                                                |                                                |
| Pyrexia                                                                      |                                       |                                                |                                                |
|                                                                              |                                       |                                                | (13.1)                                         |
|                                                                              |                                       |                                                | 5 (2.9)                                        |
|                                                                              |                                       | 6 (7.0)                                        |                                                |
|                                                                              |                                       |                                                | 12                                             |
|                                                                              |                                       |                                                | (6.9)                                          |
|                                                                              | and administration                    |                                                |                                                |

<div style=\"page-break-after: always\"></div>

Note: In summarizing n (%), if a patient had multiple events for a particular SOC or Preferred Term, he/she was counted only once for that SOC or Preferred Term. Results were sorted by Ravulizumab column in descending order of SOC percentage and then Preferred Term within SOC. AEs were coded using MedDRA 24.0.

Abbreviations: AE = adverse event; COVID-19 = coronavirus disease  2019;  MedDRA = Medical  Dictionary for Regulatory Activities; SOC = system organ class

As  of  the  data  cutoff  date,  the  most  frequently  reported  AEs  (≥  10%  of  total  patients)  in  the Ravulizumab Treated Set, were headache (18.1%), diarrhoea (12.6%), and nausea (10.2%) (Table 36). Of the patients who experienced headaches, most of the AEs of headache (24 of 30 events) occurred during the first 6 months of treatment.

Table 36: Treatment-emergent  Adverse  Events  in  by  5%  or  More  of  Patients  During  the Ravulizumab  Treatment  Period  Through  the  Data  Cutoff  Date  (ALXN1210-MG-306 Ravulizumab Treated Set)

| System Organ Class Preferred term                                                     | Total                             | Total                             | Total                             |
|---------------------------------------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                                                                       | 0 to 6 mo (N = 127) n (%)         | > 6 to 12 mo (N = 97) n (%)       | 0 to cutoff (N = 127) n (%)       |
| Any AE                                                                                | 109 (85.8)                        | 34 (35.1)                         | 110 (86.6)                        |
| Infections and infestations Urinary tract infection Upper respiratory tract infection | 51 (40.2) 7 (5.5) 7 (5.5) 6 (4.7) | 13 (13.4) 1 (1.0) 1 (1.0) 2 (2.1) | 57 (44.9) 9 (7.1) 8 (6.3) 7 (5.5) |
| Nervous system disorders Headache                                                     | 38 (29.9) 21 (16.5)               | 3 (3.1)                           | 42 (33.1) 23 (18.1)               |
| Dizziness Gastrointestinal disorders Diarrhoea                                        | 38 (29.9) 14 (11.0)               | 3 (3.1)                           | 11 (8.7)                          |
| COVID-19                                                                              |                                   |                                   |                                   |
|                                                                                       |                                   | 8 (8.2)                           |                                   |
|                                                                                       | 10 (7.9)                          |                                   |                                   |
|                                                                                       |                                   |                                   | 41 (32.3)                         |
|                                                                                       |                                   | 6 (6.2)                           | 16 (12.6)                         |
| Nausea                                                                                |                                   | 2 (2.1)                           |                                   |
| Abdominal pain                                                                        | 12 (9.4) 7 (5.5)                  | 3 (3.1)                           | 13 (10.2) 8 (6.3)                 |
| Musculoskeletal and connective tissue                                                 | 27 (21.3)                         | 1 (1.0) 8 (8.2)                   | 32 (25.2)                         |
| Arthralgia                                                                            | 8 (6.3)                           | 1 (1.0)                           | 9 (7.1)                           |
| Back pain                                                                             | 7 (5.5)                           | 1 (1.0)                           | 8 (6.3)                           |
| General disorders Fatigue                                                             | 26 (20.5) 6 (4.7)                 | 3 (3.1)                           | 8 (6.3)                           |
| and administration                                                                    |                                   | 10 (10.3)                         | 29 (22.8)                         |

Note: The Ravulizumab Treated Set consisted of all patients who received at least 1 dose of ravulizumab either in the Randomized-Controlled Period or the Open-Label Extension Period. Per scope, only data during the Randomized-Controlled Period were included for patients not expected to have Week 52 at data cutoff. This applied to both RAV/RAV and PBO/RAV patients. In summarizing n (%), if a patient had multiple events for a particular SOC or Preferred Term, the patient was counted only once for that SOC or Preferred Term. At the time of the data cutoff date, data for  only  13  patients  receiving  ravulizumab  treatment  &gt; 12 months  were  available;  2  of  the  13  patients  reported  AEs  during  this  period (ALXN1210-MG-306 CSR Table 14.3.3.1.1.4). AEs were coded using MedDRA Version 24.0.

Abbreviations: AE = adverse event; COVID-19 = coronavirus disease  2019;  MedDRA = Medical  Dictionary for Regulatory Activities; mo = months; SOC = system organ class

## Adverse Events Through Week 60

During the Ravulizumab Treatment Period, 88.8% of patients experienced at least 1 adverse event (AE; 881 events) (Table 37).

At least 1 treatment-emergent serious adverse event (SAE) was experienced by 41 (24.3%) patients (75 events). Seven (4.1%) patients (10 events) had SAEs related to coronavirus disease 2019 (COVID-19) or suspected COVID 19. Five (3%) patients experienced an SAE assessed as related to investigational product.

A total of 3 patients in the RAV/RAV group had SAEs which led to discontinuation of study drug. SAEs of infected skin ulcer and COVID-19 pneumonia with fatal outcome occurred in 1 patient each during the Randomized Controlled Period; and 1 SAE of myasthenia gravis occurred in 1 patient during the Open-Label Extension Period.

<div style=\"page-break-after: always\"></div>

Of the 881 AEs in the Ravulizumab Treatment Period, most AEs were Grade 1 or Grade 2 in severity.

A total of 30 (17.8%) patients in the Ravulizumab Treated Set experienced AEs that had a maximum severity of Grade 3. All the Grade 3 AEs occurred in 1 patient each with the exception of pyrexia, pneumonia, syncope, dyspnea, urticaria, and hypertension (2 patients each) and myasthenia gravis (4 patients).

Seven (4.1%) patients experienced AEs that had a maximum severity of Grade 4 which included: headache, hypotension, vein rupture, appendicitis, arthritis bacterial, COVID-19 pneumonia, and suspected COVID-19.

Table 37: Overview of Treatment-Emergent Adverse Events During the Ravulizumab Treatment Period Through Week 60 as of the Data Cutoff Date (Ravulizumab Treated Set)

|                                                      | TotalTreatmentDurationwithRavulizunab   | TotalTreatmentDurationwithRavulizunab   | TotalTreatmentDurationwithRavulizunab   | TotalTreatmentDurationwithRavulizunab   |
|------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                      | 0 to 6 months (N = 169) n (%)           | >6to12months (N =160) (%) uI            | >12 to18months (N = 75) n (%)           | O to Cutoff (N =169) n (%)              |
| Any AE                                               | 143 (84.6)                              | 90 (56.3)                               | 23 (30.7)                               | 150 (88.8)                              |
| Any SAE                                              | 30 (17.8)                               | 18 (11.3)                               | 2 (2.7)                                 | 41 (24.3)                               |
| Death                                                | 2 (1.2)                                 | 2 (1.3)                                 | 0                                       | 4 (2.4)                                 |
| AEleadingtodiscontinuationof study drug              | 2 (1.2)                                 | 1 (0.6)                                 | 0                                       | 3 (1.8)                                 |
| SAEleadingtodiscontinuation of study drug            | 2 (1.2)                                 | 1 (0.6)                                 | 0                                       | 3 (1.8)                                 |
| AE by relationship to study drug Related Not related | 50 (29.6) 138 (81.7)                    | 19 (11.9) 84 (52.5)                     | 7 (9.3) 20 (26.7)                       | 58 (34.3) 148 (87.6)                    |
| AE by severitya                                      |                                         |                                         |                                         |                                         |
| Grade 1                                              | 116 (68.6)                              | 72 (45.0)                               | 15 (20.0)                               | 127 (75.1)                              |
| Grade 2                                              | 63 (37.3)                               | 39 (24.4)                               | 10 (13.3)                               | 82 (48.5)                               |
| Grade 3                                              | 28 (16.6)                               | 13 (8.1)                                | 2 (2.7)                                 | 39 (23.1)                               |
| Grade 4                                              | 7 (4.1)                                 | 2 (1.3)                                 | 0                                       | 9 (5.3)                                 |
| Grade 5                                              | 2 (1.2)                                 | 2 (1.3)                                 | 0                                       | 4 (2.4)                                 |
| SAEbyrelationshiptostudy Snp                         |                                         |                                         |                                         |                                         |
| Related                                              | 4 (2.4)                                 | 1 (0.6)                                 | 0                                       | 5 (3.0)                                 |
| Not related                                          | 26 (15.4)                               | 18 (11.3)                               | 2 (2.7)                                 | 38 (22.5)                               |

Note: The Ravulizumab Treated Set consisted of all patients who received at least 1 dose of ravulizumab either in the Randomized-Controlled Period or the Open-Label Extension Period. Data up to Week 60 at data cut-off date are included. Patients were counted once in each severity or relationship category in case of multiple events. AEs were coded using MedDRA Version 24.1.

a Severity of AEs was graded using CTCAE Version 5.0. Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = fatal.

Abbreviations: AE = adverse event; CTCAE = Common Terminology Criteria for Adverse Events; MedDRA = Medical Dictionary for Regulatory Activities; SAE = serious adverse event

## Adverse Events of Special Interest

As of the 52-week data cut-off date, no meningococcal infections were reported during the study.

## Infusion Reactions

Local (infusion site or injection site reactions), systemic (infusion-associated/infusion-related reactions), and immune-mediated reactions were evaluated during the Randomized-Controlled Period.

Table 38: Definitions for Infusion Reactions Local Administration Reaction

Systemic Reaction

Immunemediated Reactions

<div style=\"page-break-after: always\"></div>

| Infusion site/ injection site reactions                | Infusion-associated/ Infusion-related reactions                                                                                            | Hypersensitivity                                                                                           |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|
| AEs localized to the site of study drug administration | Systemic AEs occurring during or within 24 hours of the start of infusion (eg, fever and/or shaking chills, flushing and/or itching, etc.) | AEs with Preferred Terms in the narrow SMQ of Anaphylactic reaction and the narrow SMQ of Hypersensitivity |

Abbreviations: AE = adverse event; SMQ = Standardised MedDRA (Medical Dictionary for Regulatory Activities) Query

The percentage of patients who reported infusion reactions during the Randomized-Controlled Period was similar between the treatment groups (Table 39). The most common infusion reaction was headache (placebo: 15.7%; ravulizumab: 11.6%). All events of infusion-related reactions occurred in the placebo group.

Table 39: Infusion Reactions During the Randomized -Controlled Period (Safety Set)

| System Organ Class Preferred Term                                                                                                                                                                                                                                                                                                                                       | Placebo (N=89)                | Ravulizumab (N=86)                    | Total (N=175)                  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------|---------------------------------------|--------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                         | n (%)                         | n (%)                                 | n (%)                          |
| Any infusion reaction                                                                                                                                                                                                                                                                                                                                                   | 28 (31.5)                     | 28 (32.6)                             | 56 (32.0)                      |
| Nervous system disorders Headache Dizziness                                                                                                                                                                                                                                                                                                                             | 15 (16.9) 14 (15.7) 3 (3.4)   | 13 (15.1) 10 (11.6) 4 (4.7) 11 (12.8) | 28 (16.0) 24 (13.7) 7 (4.0) 20 |
| Gastrointestinal disorders Nausea                                                                                                                                                                                                                                                                                                                                       | 9 (10.1) 5 (5.6)              | 7 (8.1) 5 (5.8)                       | 12 (6.9)                       |
| Chills Infusion site extravasation Infusion site haematoma Infusion site pain Injection site reaction Vaccination site irritation Vaccination site reaction Catheter site erythema Injection site bruising Pyrexia Skin and subcutaneous tissue disorders Rash Pruritus Eczema Urticaria Respiratory, thoracic and mediastinal Dyspnoea Rhinitis allergic Eye disorders | 3 (3.4)                       | 2 (2.3) 1 (1.2)                       | (11.4) 8 (4.6) 2 (1.1)         |
| disorders                                                                                                                                                                                                                                                                                                                                                               | 0 0 0 0 0 0 0 1 (1.1) 1 (1.1) |                                       |                                |
| Diarrhoea Abdominal pain                                                                                                                                                                                                                                                                                                                                                |                               |                                       |                                |
|                                                                                                                                                                                                                                                                                                                                                                         | 0                             |                                       |                                |
| Vomiting                                                                                                                                                                                                                                                                                                                                                                | 1                             |                                       | 2                              |
|                                                                                                                                                                                                                                                                                                                                                                         | (1.1)                         |                                       | (1.1)                          |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 0                                     | 1 (0.6)                        |
| Abdominal distension                                                                                                                                                                                                                                                                                                                                                    |                               |                                       |                                |
| General disorders and administration site conditions Fatigue                                                                                                                                                                                                                                                                                                            | 6 (6.7)                       | 10 (11.6)                             | 16 (9.1)                       |
|                                                                                                                                                                                                                                                                                                                                                                         | 3 (3.4)                       | 3 (3.5)                               | 6 (3.4)                        |
| Asthenia                                                                                                                                                                                                                                                                                                                                                                | 0                             | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2) 1 (1.2)                       | 1 (0.6) 1 (0.6)                |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               |                                       | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 0                                     | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         |                               | 0                                     |                                |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 0 3 (3.5)                             | 1 (0.6) 6 (3.4)                |
|                                                                                                                                                                                                                                                                                                                                                                         | 3 (3.4) 2 (2.2)               | 2 (2.3)                               | 4 (2.3)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 0                             | 1 (1.2)                               | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 0                                     | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 0                                     | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 2 (2.3) 2 (2.3)                       | 3 (1.7) 2                      |
|                                                                                                                                                                                                                                                                                                                                                                         | 0                             |                                       | (1.1)                          |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 0                                     | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       | 1 (1.2) 1 (1.2)                       | 2 (1.1)                        |
| Swelling of eyelid Eye swelling                                                                                                                                                                                                                                                                                                                                         | 0 1 (1.1)                     | 0                                     | 1 (0.6)                        |
|                                                                                                                                                                                                                                                                                                                                                                         | 0                             |                                       | 1 (0.6)                        |
| Immune system disorders Drug hypersensitivity                                                                                                                                                                                                                                                                                                                           | 0                             | 1 (1.2) 1 (1.2)                       | 1 (0.6) 1 (0.6)                |
| Musculoskeletal and connective                                                                                                                                                                                                                                                                                                                                          |                               |                                       |                                |
| tissue disorders Arthralgia                                                                                                                                                                                                                                                                                                                                             | 0                             | 1 (1.2) 1 (1.2)                       | 1 (0.6) 1 (0.6)                |
| Vascular                                                                                                                                                                                                                                                                                                                                                                | 0                             | 1 (1.2)                               |                                |
| disorders Hypertension                                                                                                                                                                                                                                                                                                                                                  | 2 (2.2)                       | 1 (1.2)                               | 3 (1.7) 3 (1.7)                |
| Injury, poisoning and procedural                                                                                                                                                                                                                                                                                                                                        | 2 (2.2) 6 (6.7)               |                                       |                                |
| complications                                                                                                                                                                                                                                                                                                                                                           |                               | 0 0                                   | 6 (3.4) 5 (2.9)                |
| Infusion related reaction Injection related reaction                                                                                                                                                                                                                                                                                                                    | 5 (5.6)                       | 0                                     |                                |
|                                                                                                                                                                                                                                                                                                                                                                         | 1 (1.1)                       |                                       | 1 (0.6)                        |

<div style=\"page-break-after: always\"></div>

Table 39: Infusion Reactions During the Randomized -Controlled Period (Safety Set)

| System Organ Class Preferred Term   | Placebo (N=89)   | Ravulizumab (N=86)   | Total (N=175)   |
|-------------------------------------|------------------|----------------------|-----------------|
|                                     | n (%)            | n (%)                | n (%)           |
| Psychiatric disorders               | 1 (1.1)          | 0                    | 1 (0.6)         |
| Anxiety                             | 1 (1.1)          | 0                    | 1 (0.6)         |

Notes: In summarizing n (%), if a patient had multiple events for a particular SOC or preferred term, he/she was counted only once for that SOC or preferred term. Treatment emergent AEs are AEs with a start date on or after first dose date in the study. Results were sorted by Ravulizumab column in descending order of SOC percentage and then PT within SOC. AEs were coded using MedDRA 24.0.

Abbreviations: MedDRA = Medical Dictionary for Regulatory Activities; SOC = system organ class

Only 1 patient (placebo group) had an infusion reaction that was a SAE (infusion-related reaction) during the Randomized-Controlled Period. Two patients in the placebo group had infusion interruptions and withdrew from the study due to infusion reactions. One patient in the ravulizumab group had an infusion interruption due to infusion site extravasation on Day 69.

Infusion Reactions Through Week 60

Local (infusion site or injection site reactions), systemic (infusion-associated/infusion-related reactions), and immune-mediated reactions as defined in Table 40 were evaluated during the Randomized-Controlled Period.

Table 40: Definitions for Infusion Reactions

| LocalAdministration Reaction                          | SystemicReaction                                                                                                                      | Immune-mediatedReactions                                                                           |
|-------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Infusionsite/ injectionsitereactions                  | Infusion-associated/ Infusion-relatedreactions                                                                                        | Hypersensitivity                                                                                   |
| AEs localized to the site of study drugadministration | Systemic AEs occurring during or within24hoursof thestartof infusion (eg, fever and/or shaking chills, flushing and/or itching. etc.) | AEswithPreferred Terms in the narrowSMQof Anaphylactic reaction andthenarrowSMQof Hypersensitivity |

Abbreviations: AE = adverse event; SMQ = Standardized MedDRA (Medical Dictionary for Regulatory Activities) Query

A total of 59 (34.9%) patients reported infusion reactions during the Ravulizumab Treatment Period. The most common infusion reactions were headache (11.2%) and nausea (6.5%). A total of 9 infusions in 8 patients had interruptions due to AEs. In 7 of the 8 patients, the infusion was subsequently re-started and completed.

## Serious adverse event/deaths/other significant events

Other Serious Adverse Events During the Randomized-Controlled Period

Overall,  34  (19.4%)  patients  in  the  Safety  Set  experienced  1 or  more  SAEs  (51  events)  during  the Randomized-Controlled Period; 14 (15.7%) patients in the placebo group and 20 (23.3%) patients in the ravulizumab group (Table ).

Four (4.5%) patients in the placebo group and 7 (8.1%) patients in the ravulizumab group had SAEs in the SOC of Infections and infestations: all SAEs of infections were observed in 1 patient each, with the exception  of  COVID-19  pneumonia  (ravulizumab:  n = 2)  and  cellulitis  (placebo:  n = 2).  A  higher percentage of patients in the ravulizumab group reported AEs in the SOCs of Infection and infestations and  Respiratory,  thoracic,  and  mediastinal  disorders.  The  AEs  reported  in  the  SOC  of  Respiratory,

<div style=\"page-break-after: always\"></div>

thoracic, and mediastinal disorders were consistent with symptoms of the underlying disease and/or comorbid diseases.

Two patients in the ravulizumab group had SAEs of transient ischemic attack; both events were assessed as not related to study drug by the Investigator: 1 patient had a history of supraventricular tachycardia, hypertension, and coronary artery disease and 1 patient had a history of hypertension and dyslipidaemia.

Three patients had SAEs that resulted in discontinuation of study drug.

Three patients had SAEs that resulted in interruption of study treatment: 2 patients in the placebo group (herpes zoster and cellulitis) and 1 patient in the ravulizumab group (bacterial arthritis).

Six patients had SAEs that were assessed to be related to study drug by the Investigator; 4 patients in the placebo group (cellulitis: n = 2; herpes zoster: n = 1; and infusion-related reaction: n = 1) and 2 patients in the ravulizumab group (dysphagia: n = 1; tendonitis: n = 1).

One patient in the ravulizumab group had an SAE of suicide attempt; the patient was hospitalized on Day 122 and discharged on Day 132. The patient had a prior history of depression and suicide attempt and this event was assessed as not related to study drug by the Investigator.

<div style=\"page-break-after: always\"></div>

Table 41: Treatment-emergent  Serious  Adverse  Events  During  the  Randomized-Controlled Period by System Organ Class and Preferred Term (ALXN1210-MG-306 Safety Set)

| System Organ Class Preferred Term                                              | Placebo (N = 89)   | Ravulizumab (N = 86)   | Total (N = 175)   |
|--------------------------------------------------------------------------------|--------------------|------------------------|-------------------|
|                                                                                | n (%)              | n (%)                  | n (%)             |
| Any SAE                                                                        | 14 (15.7)          | 20 (23.3)              | 34 (19.4)         |
| Infections and infestations                                                    | 4 (4.5)            | 7 (8.1)                | 11 (6.3)          |
| COVID-19 pneumonia                                                             | 0                  | 2 (2.3)                | 2 (1.1)           |
| Arthritis bacterial                                                            |                    | 1 (1.2)                | 1 (0.6)           |
| Diverticulitis                                                                 | 0 0                | 1 (1.2)                | 1 (0.6)           |
| Gangrene                                                                       | 0                  | 1 (1.2)                | 1 (0.6)           |
| Gastroenteritis viral                                                          | 0                  | 1 (1.2)                | 1 (0.6)           |
| Herpes zoster                                                                  | 1 (1.1)            | 1 (1.2)                | 2 (1.1)           |
| Infected skin ulcer                                                            | 0                  | 1 (1.2)                | 1 (0.6)           |
| Pneumonia respiratory syncytial viral                                          | 0                  | 1 (1.2)                | 1 (0.6)           |
| Staphylococcal sepsis                                                          | 0                  | 1 (1.2)                | 1 (0.6)           |
| COVID-19                                                                       | 1 (1.1)            | 0                      | 1 (0.6)           |
| Cellulitis                                                                     | 2 (2.2)            | 0                      | 2 (1.1)           |
| Nervous system disorders                                                       | 4 (4.5)            | 5 (5.8)                | 9 (5.1)           |
| Transient ischaemic attack                                                     | 0                  | 2 (2.3)                | 2 (1.1)           |
| Cerebral haemorrhage                                                           | 0                  | 1 (1.2)                | 1 (0.6)           |
| Myasthenia gravis crisis a                                                     | 0                  | 1 (1.2)                | 1 (0.6)           |
| Syncope                                                                        | 0                  | 1 (1.2)                | 1 (0.6)           |
| Facial paresis                                                                 | 1 (1.1)            | 0                      | 1 (0.6)           |
| Myasthenia gravis                                                              | 3 (3.4)            | 0                      | 3 (1.7)           |
| Trigeminal neuralgia                                                           | 1 (1.1)            | 0                      | 1 (0.6)           |
| Musculoskeletal and connective tissue disorders Intervertebral disc protrusion | 1 (1.1) 0          | 3 (3.5) 1 (1.2)        | 4 (2.3) 1 (0.6)   |
| Nodal osteoarthritis                                                           | 0                  | 1 (1.2)                | 1 (0.6)           |
| Tendonitis                                                                     | 0                  | 1 (1.2)                | 1 (0.6)           |
| Spinal stenosis                                                                | 1 (1.1)            | 0                      | 1 (0.6)           |
| Respiratory, thoracic, and mediastinal disorders                               | 0                  | 3 (3.5)                | 3 (1.7)           |
| Dyspnoea                                                                       | 0                  | 1 (1.2)                | 1 (0.6)           |
| Dyspnoea exertional                                                            | 0                  | 1 (1.2)                | 1 (0.6)           |
| Lung infiltration                                                              | 0                  | 1 (1.2)                | 1 (0.6)           |
| Gastrointestinal disorders                                                     | 1 (1.1)            | 2 (2.3)                | 3 (1.7)           |
| Dysphagia                                                                      | 0                  | 1 (1.2)                | 1 (0.6)           |
| Nausea                                                                         | 0                  | 1 (1.2)                | 1 (0.6)           |
| Enteritis                                                                      | 1 (1.1)            | 0                      | 1 (0.6)           |
| General disorders and administration site conditions Asthenia                  | 0 0                | 2 (2.3) 1 (1.2)        | 2 (1.1) 1 (0.6)   |
| General physical health deterioration                                          | 0                  | 1 (1.2)                | 1 (0.6)           |
| Non-cardiac chest pain                                                         | 0                  | 1 (1.2)                | 1 (0.6)           |
| unspecified (incl cysts and                                                    | 0                  | 2 (2.3)                | 2 (1.1)           |
| Neoplasms benign, malignant and Squamous cell carcinoma of skin                | 0                  | 1 (1.2)                | 1 (0.6)           |
| Ureteral neoplasm                                                              | 0                  | 1 (1.2)                | 1 (0.6)           |
| Cardiac disorders                                                              | 0                  | 1 (1.2)                | 1 (0.6)           |
| Congestive cardiomyopathy                                                      | 0                  | 1 (1.2)                | 1 (0.6)           |
| Eye disorders                                                                  | 0                  | 1 (1.2)                | 1 (0.6)           |
| Visual impairment                                                              | 0                  | 1 (1.2)                | 1 (0.6)           |
| Injury, poisoning and procedural complications                                 | 1 (1.1)            | 1 (1.2)                | 2 (1.1)           |
| Multiple fractures                                                             | 0                  | 1 (1.2)                | 1 (0.6)           |
| Infusion-related reaction                                                      | 1 (1.1)            | 0                      | 1 (0.6)           |
| Metabolism and nutrition disorders                                             | 1 (1.1)            | 1 (1.2)                | 2 (1.1)           |
| Steroid diabetes                                                               | 0                  | 1 (1.2)                | 1 (0.6)           |
| Diabetic ketoacidosis                                                          | 1 (1.1)            | 0                      | 1 (0.6)           |
| Psychiatric disorders                                                          | 0                  | 1 (1.2) 1 (1.2)        | 1 (0.6) (0.6)     |
| Suicide attempt                                                                | 0                  | 0                      | 1 2               |
| Renal and urinary disorders                                                    | 2 (2.2)            |                        | (1.1) 1 (0.6)     |
| Nephrotic syndrome Renal failure                                               | 1 (1.1) 1 (1.1)    | 0 0                    | 1 (0.6)           |
| Skin and subcutaneous tissue disorders                                         | 1 (1.1)            | 0                      | 1 (0.6)           |
| Granuloma skin                                                                 | 1 (1.1)            |                        | 1                 |
|                                                                                |                    | 0                      | (0.6)             |

<div style=\"page-break-after: always\"></div>

Notes: In summarizing n (%), if a patient had multiple events for a particular SOC or Preferred Term, the patient was counted only once for that SOC or Preferred Term. Results were sorted by Ravulizumab column in descending order of SOC percentage and then Preferred Term within SOC. AEs were coded using MedDRA version 24.0.

a One patient in the ravulizumab group experienced a clinical deterioration under the per protocol criteria of 'Significant symptomatic worsening' which was also reported as an SAE of MG crisis.

Abbreviations:  AE  =  adverse  event(s);  COVID-19 = coronavirus  disease  19;  E = total  number  of  events;  MedDRA = Medical  Dictionary  for Regulatory Activities; SOC = system organ class

## Other Serious Adverse Events During Ravulizumab Treatment Period Through the Data Cutoff Date

As of the 52-week data cutoff date, 27 (21.3%) patients in the Ravulizumab Treated Set had experienced 1 or more SAEs during ravulizumab treatment (Table ). Overall, 12 (9.4%) patients reported SAEs in the SOC of Infections and infestations and 6 (4.7%) patients reported SAEs in the SOC of Nervous system disorders.

For  the  patients  in  the  RAV/RAV group  who  experienced  SAEs,  most  SAEs  occurred  during  the Randomized-Controlled Period; 4 patients who were treated with ravulizumab during the RandomizedControlled Period had SAEs between &gt; 6 to 12 months of ravulizumab treatment during the Open-Label Extension Period.

Five patients in the PBO/RAV group had SAEs after switching to ravulizumab during the Open-Label Extension Period. One patient had an SAE assessed as related to study drug during the Open-Label Extension Period which was due to 'worsening of MG symptoms.'

After the 52-week data cutoff date, 1 patient in the placebo group who switched to ravulizumab during the Open-Label Extension Period had a non-fatal SAE of meningitis (unknown aetiology). The patient had  received  meningococcal  vaccination  prior  to  study  entry.  The  event  was  considered  by  the Investigator to be related to ravulizumab (compatible with partially treated bacterial meningitis). No action  was  taken  with  ravulizumab  in  response  to  this  event  and  the  patient  continued  to  receive ravulizumab in the study.

Table 42: Treatment-emergent  Serious  Adverse  Events  During  the  Ravulizumab  Treatment Period Through the Data Cutoff Date (ALXN1210-MG-306 Ravulizumab Treated Set)

| System Organ Class Preferred term     | Total                     | Total                       | Total                       |
|---------------------------------------|---------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred term     | 0 to 6 mo (N = 127) n (%) | > 6 to 12 mo (N = 97) n (%) | 0 to cutoff (N = 127) n (%) |
| Any SAE                               | 25 (19.7)                 | 5 (5.2)                     | 27 (21.3)                   |
| Infections and infestations COVID-19  | 10 (7.9) 1 (0.8)          | 3 (3.1) 2 (2.1)             | 12 (9.4) 2 (1.6)            |
| COVID-19 pneumonia                    | 2 (1.6)                   | 0                           | 2 (1.6)                     |
| Arthritis bacterial                   | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Diverticulitis                        | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Gangrene                              | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Gastroenteritis viral                 | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Herpes zoster                         | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Infected skin ulcer                   | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Pneumonia respiratory syncytial viral | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Pneumonia viral                       | 0                         | 1 (1.0)                     | 1 (0.8)                     |
| Staphylococcal sepsis                 | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Suspected COVID-19                    | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Urinary tract infection               | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Nervous system disorders              | 6 (4.7)                   | 0                           | 6 (4.7)                     |
| Transient ischaemic attack            | 2 (1.6)                   | 0                           | 2 (1.6)                     |

<div style=\"page-break-after: always\"></div>

Table 42: Treatment-emergent  Serious  Adverse  Events  During  the  Ravulizumab  Treatment Period Through the Data Cutoff Date (ALXN1210-MG-306 Ravulizumab Treated Set)

| System Organ Class Preferred term                             | Total                     | Total                       | Total                       |
|---------------------------------------------------------------|---------------------------|-----------------------------|-----------------------------|
| System Organ Class Preferred term                             | 0 to 6 mo (N = 127) n (%) | > 6 to 12 mo (N = 97) n (%) | 0 to cutoff (N = 127) n (%) |
| Cerebral haemorrhage                                          | 1 (0.8) 1 (0.8)           | 0 0                         | 1 (0.8) 1 (0.8)             |
| Myasthenia gravis Myasthenia gravis crisis                    | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Syncope                                                       | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| General disorders and administration site conditions          | 3 (2.4)                   | 1 (1.0)                     | 4 (3.1)                     |
| Asthenia                                                      | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Chest pain                                                    | 0                         | 1 (1.0) 0                   | 1 (0.8)                     |
| General physical health deterioration                         | 1 (0.8)                   |                             | 1 (0.8)                     |
| Non-cardiac chest pain                                        | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Pyrexia                                                       | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Injury, poisoning and procedural complications                | 2 (1.6)                   | 1 (1.0)                     | 3 (2.4)                     |
| Lumbar vertebral fracture                                     | 0                         | 1 (1.0)                     | 1 (0.8)                     |
| Multiple fractures                                            | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Patella fracture                                              | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Musculoskeletal and connective tissue disorders               | 3 (2.4)                   | 0                           | 3 (2.4)                     |
| Intervertebral disc protrusion                                | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Nodal osteoarthritis                                          | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Tendonitis                                                    | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Respiratory, thoracic, and mediastinal disorders              | 3 (2.4)                   | 0                           | 3 (2.4)                     |
| Dyspnoea                                                      | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Dyspnoea exertional                                           | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Lung infiltration                                             | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Eye disorders Cataract                                        | 1 (0.8) 0                 | 1 (1.0) 1 (1.0)             | 2 (1.6) 1 (0.8)             |
| Visual impairment                                             | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Gastrointestinal disorders                                    | 2 (1.6)                   | 0                           | 2 (1.6)                     |
| Dysphagia                                                     | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Nausea                                                        | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Neoplasms benign, malignant and unspecified (incl and polyps) | 2 (1.6)                   | 0                           | 2 (1.6)                     |
| Squamous cell carcinoma of skin                               | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Ureteral neoplasm                                             | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Cardiac disorders                                             | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Congestive cardiomyopathy                                     | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Metabolism and nutrition disorders                            | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Steroid diabetes                                              | 1 (0.8)                   | 0                           | 1 (0.8)                     |
| Psychiatric disorders                                         | 1 (0.8)                   | 0                           | 1 (0.8)                     |
|                                                               |                           |                             | 1 (0.8)                     |
| Suicide attempt                                               | 1 (0.8)                   | 0                           |                             |

Note: The Ravulizumab Treated Set consisted of all patients who received at least 1 dose of ravulizumab either in the Randomized-Controlled Period or the Open-Label Extension Period. Per scope, only data during Randomized-Controlled Period were included for patients not expected to have Week 52 at data cutoff. This applied to both RAV/RAV and PBO/RAV patients. In summarizing n (%), if a patient had multiple events for a particular SOC or Preferred Term, the patient was counted only once for that SOC or Preferred Term. AEs were coded using MedDRA Version 24.0.

Abbreviations: AE = adverse event; COVID-19 = coronavirus disease 19; MedDRA = Medical Dictionary for Regulatory Activities; mo = months; SAE = serious adverse event; SOC = system organ class

## Deaths

A total of 7 deaths occurred in the study by the time of 60-week CSR addendum (2 in the randomized control period and 5 in the Open Label Extension Period). None of the deaths were related to study drug by the Investigator. These deaths are summarized in the Table 43 below.

<div style=\"page-break-after: always\"></div>

Table 43: Deaths reported in Initial Clinical Study Report and 60-week Addendum Report from ALXN1210MG-306 Study

| Report                                            | Preferred Term             | Period from Study             | Descriptive Summary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------------------|----------------------------|-------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Clinical Study Report (primary analysis)          | COVID-19 pneumonia         | Randomized- Controlled Period | Thepatient hadamedical historyofgMG,arrhythmia,anddiabetesmellitusreceivingprednisonepyridostigmine, Period. On Day 163, the patient was transferred to the ICU and intubated. The patient was diagnosed with atrial fibrillation and worsening of hyperglycemia. On Day 178,the patient experienced staphylococcal sepsis. On Day 179, the patient died from respiratory and circulatory arrest during hospitalization due to COVID-19.                                                                                                                                                                                |
| Clinical Study Report (primary analysis)          | Cerebral hemorrhage        | Randomized- Controlled Period | Thepatient hada medical historyof gMGatrialfibrillation,diabetesmellitushyperlipidemia,andhypertension and was receiving corticosteroid and immunosuppressant treatment for gMG and edoxaban for treatment of atrial fibrillation. The patient was admitted to the hospital with diagnosis of cerebral hemorrhage on Day 138. The patient underwentendoscopichematomaremovalwhichwas unsuccessful andsufferedcomplicationsof continuedbleeding and respiratory arfrest and was intubated. On Day 142, a second surgery was performed which was also unsuccessful and onDay145,thepatient died duetocerebral hemorrhage. |
| Clinical Study Report (primary analysis)          | COVID-19                   | Open-Label Extension          | The patient had a medical history of gMG, hypertension, hyperlipidemia, atrial septal defect, pre-diabetes, morbid admittedtothehospitalonDay204duetoaCOVID-19infection.Thepatienthadreceivedravulizumabduringthe Randomized-ControlledPeriod.OnDay216,thepatientdiedduetoCOVID-19                                                                                                                                                                                                                                                                                                                                      |
| Clinical Study Report (primary analysis)          | COVID-19                   | Open-Label Extension          | Thepatienthad amedicalhistoryofgMGatrialfibrillationhyperlipidemiahypertension,bloodcholesterol admittedtothehospitalduetoCOVID-19onDay174ofravulizumabtreatmentduringtheOpen-LabelExtension duetoCOVID-19complications.                                                                                                                                                                                                                                                                                                                                                                                                |
| 60-week CSR addendum (reported after data cutoff) | COVID-19                   | Open-Label Extension          | The patient had a medical history of gMG and thymectomy,was receiving mycophenolate mofetil for gMG, and was admittedtothehospitalbecauseofCOVID-19onDay355ofravulizumabtreatmentduringtheOpen-Label ExtensionPeriod.Thepatient dieddue toCOVID-19complicationsonDay391 andhadreceivedplaceboduringthe Randomized-ControlledPeriod.                                                                                                                                                                                                                                                                                     |
| 60-week CSR addendum (reported after data cutoff) | Toxicity to various agents | Open-Label Extension          | treatmentforgMG,gabapentinforgeneralizedpain,and alprazolamfordepression.The cause of death was listed as combined drug intoxication by drugs including fentanyl, gabapentin, and alprazolam taken at the same time and was indicatedtobeanaccident.ThepatienthadreceivedplaceboduringtheRandomized-ControlledPeriod.Thepatient died onDay 606of the Open-Label ExtensionPeriod.                                                                                                                                                                                                                                        |
| 60-week CSR addendum (reported after data cutoff) | Death                      | Open-Label Extension          | The patient died on 23 Sep 2021 due to an unknown cause (autopsy report and death certificate were not provided). The last dose ofravulizumabwasreceived on Day 251(29 Mar 2021).The patient's last contact with the site was 26 Jun2021 andwasdiscontinuedfrom thestudyduetophysician decision on08Sep2021.Thepatient alsohadSAEs of pneumonia,mitral valve stenosis,and vein rupture.                                                                                                                                                                                                                                 |

## Adverse Events Related to COVID-19

During the Randomized-Controlled Period, 4 (4.5%) patients in the placebo group and 5 (5.8%) patients in the ravulizumab group had COVID-19 related AEs per the MedDRA v24.0 SMQ search of 'COVID-19.' None of these events was considered to be related to study drug by the Investigator.

As of the data cutoff date, 9 total patients in the Ravulizumab Treated Set experienced COVID-19 related AEs (ie, includes the 5 patients in the ravulizumab group who had COVID-19 related AEs during the Randomized-Controlled Period). However, upon additional medical review 1 of the 9 patients had an event of viral pneumonia which was not confirmed to be related to COVID-19. None of these events was considered to be related to study drug by the Investigator.

<div style=\"page-break-after: always\"></div>

Six patients had COVID-19 related SAEs; however, upon additional medical review 1 of the 6 patients had an SAE of viral pneumonia which was not confirmed to be related to COVID-19. Three patients died during the study due to COVID-19; all 3 patients had multiple underlying risk factors for COVID-19 complications (such as metabolic, respiratory, and cardiovascular disease and obesity).

## Laboratory findings

There were no clinically significant changes in laboratory parameters in Study ALXN1210-MG-306 that were of safety concern.

- Vital signs, physical examination, and ECG: No safety signals were identified.
- Columbia-Suicidal Severity Rating Scale: None of the patients in the ravulizumab group had suicidal  ideation  or  suicidal  behavior  at  the  timepoint  of  the  C-SSRS  evaluations  during  the Randomized-Controlled Period. Although suicidal ideation and/or suicidal behavior was not noted during the C-SSRS evaluation timepoints, it was noted that 1 patient in the ravulizumab group was hospitalized during the Randomized-Controlled Period due to a suicide attempt. This patient had a prior history of depression and suicide attempt; the SAE was considered not related to study drug by the Investigator.
- Pregnancy: No patients or partners became pregnant during the study.

## Immunogenicity

No treatment-emergent ADA-positive findings were observed after ravulizumab administration in any patients during the Randomized-Controlled Period. All assay results for antidrug neutralizing antibodies were negative.

## Safety in special populations

## Intrinsic Factors

Analyses of the safety profile by intrinsic factors (ie, sex, race, age, geographic location) identified no sensitive  subgroups  that  were  considered  to  have  an  influence  on  the  overall  safety  profile  of ravulizumab..

## Extrinsic Factors

Analyses  of  the  safety  profile  by  extrinsic  factors  (ie,  immunosuppressant  therapy  use  at  baseline) identified no sensitive subgroups that were considered to have an influence on the overall safety profile of ravulizumab. Some extrinsic factors, including immunosuppressant therapy use, were included as categorical covariates in the population PK analysis.

## Safety related to drug-drug interactions and other interactions

No formal drug-drug interaction studies have been conducted with ravulizumab IV.

<div style=\"page-break-after: always\"></div>

## Discontinuation due to adverse events

During the Randomized-Controlled Period, 3 (3.4%) patients in the placebo group and 2 (2.3%) patients in the ravulizumab group discontinued study drug due to AEs:

- 2 patients (placebo) discontinued study drug and withdrew from the study due to infusion-related reactions (1 SAE and 1 non-serious AE; both events were considered related to study drug by the Investigator)
- 1 patient (placebo) discontinued study drug due to non-serious back pain (not related to study drug) and withdrew from the study due to physician decision on Day 101.
- 1 patient (ravulizumab) discontinued study drug due to an SAE of infected skin ulcer (not related to study drug) and subsequently withdrew from the study on Day 153 due to physician decision
- 1 patient (ravulizumab) died due to COVID-19 pneumonia

As of the data cutoff date, 4 patients who received ravulizumab during the Randomized-Controlled Period had SAEs which led to discontinuation of study drug (includes the 2 patients in the ravulizumab group who had SAEs which led to discontinuation of study drug during the Randomized-Controlled Period as well as 2 patients in the ravulizumab group who died during ravulizumab treatment in the Open-Label Extension Period.

None of the patients who received placebo during the Randomized-Controlled Period discontinued study drug after switching to ravulizumab during the Open-Label Extension Period.

## Post marketing experience

The  estimated  postmarketing  exposure  to  ravulizumab  IV  since  the  first  Marketing  Authorization (21 Dec 2018) through 30 Jun 2021 was 3996.7 PY for PNH and aHUS indications.

Meningococcal infection remains an important identified risk for ravulizumab IV based on the mechanism of  action,  findings  from  the  ravulizumab  clinical  studies,  and  long-term  experience  with  eculizumab (Soliris), another approved C5 complement inhibitor.

Three patients with PNH reported meningococcal infection in the postmarketing setting of ravulizumab (2 patients with serotype non-typeable and 1 patient with unknown serotype) with a reporting rate of approximately 0.08 per 100 PY [3 patients/3996.7 PY], between 197 to 322 days of the first dose of ravulizumab  IV.  Administration  of  a  meningococcal  vaccination  at  least  2 weeks  prior  to  the administration of ravulizumab IV was confirmed in all 3 patients.

Long-term postmarketing experience with eculizumab showed consistent reporting rate of meningococcal infections in eculizumab-treated patients over the past 10 years at approximately 0.3 to 0.5 per  100 PY with  the  reporting  rate  for  fatal  outcomes  at  0.03 per  100 PY representing  9.2%  of patients  who  experienced  meningococcal  infections, similar  to the  proportion  of  fatal  events  in  the general population among individuals with meningococcal infections (10% to 15%) (MacNeil, 2018 25 ; Van Deuren, 2000 26 ).

Additionally, hypersensitivity reactions were confirmed as an identified risk based on a cumulative data review of the Standardised MedDRA Query (SMQ) hypersensitivity

<div style=\"page-break-after: always\"></div>

## 2.5.1. Discussion on clinical safety

The safety of ravulizumab in gMG has been evaluated in one Phase 3 study (Study ALXN1210 MG-306) which includes a placebo-controlled 26-week treatment period (completed) and a 2-year open label extension still ongoing. The primary analysis for Study 306 was conducted with a clinical cut-off date of 11 May 2021.

Overall, a total of 86 patients were exposed to ravulizumab in the Randomized-Controlled Period. These patients were treated with the proposed dosing regimen for a median duration of 25.6 weeks. Treatment compliance was 94.4% in the placebo group and 96.5% in the ravulizumab group.

The demographic and baseline characteristics were balanced between the placebo and ravulizumab groups.

Regarding the long-term safety profile, only 35 patients have been treated, for a period of 52 weeks. A such, the CHMP considered that the safety database presents limitations especially regarding less frequent or delayed events.  However, given the low prevalence of Myasthenia Gravis, patient exposure is considered acceptable for the short-term safety assessment of ravulizumab.

The available safety information of ravulizumab in the already authorised indications (PNH, aHUS) can be  taken  as  supportive  taking  into  account  that  patients  have  been  treated  with  the  same  dosing regimen. Study ALXN1210-MG-306 is expected to be completed (last patient's last visit) by 30 May 2023. The final clinical study report (CSR) will be available within 12 months from study completion (Q2 2024) and will be submitted once available.

An updated analysis of Study ALXN1210-MG-306 was performed and submitted during this application (data cut-off date 09 Nov 2021) that includes data through Week 60 for 169 patients.

The safety profile for ravulizumab was similar to that of placebo in adult patients with gMG during the 26-week Randomized-Controlled Period.

Most patients included in the Randomized-Controlled period reported AEs: 90.7% in the ravulizumab group  vs.  86.5%  in  the  placebo  group.  Of  them,  33.7%  of  both  ravulizumab-  and  placebo-treated patients reported AEs considered as related to study drug.

A total of 5 patients withdrew from study treatment due to AEs (3 on placebo, 2 on ravulizumab) during the  double-blind  period  in  Study  MG-306.  Three  of  them  (1  on  placebo,  2  on  ravulizumab)  were considered  as  serious.  Two  additional  patients  discontinued  the  treatment  due  to  SAEs  during  the extension period.

During the Ravulizumab Treatment Period, 86.6% of patients experienced at least 1 AE. The percentage of patients reporting AEs was 35.1% during months 6 to 12 of ravulizumab treatment, compared to 85.8% during months 0 to 6 of ravulizumab treatment. The majority of AEs were considered to be not related to study drug,

During the Randomized-Controlled Period, headache, diarrhoea), and nausea were the most frequently reported AEs (≥ 10% of all patients).

Regarding adverse events through week 60, the most frequently reported AEs (≥ 10% of all patients) were headache and diarrhoea. A total of 58 (34.3%) patients reported AEs assessed as related to study drug by the Investigator. There was no trend towards increase in the incidence of AEs with longer-term

25  MacNeil JR, Blain AE, Wang X, Cohn AC. Current Epidemiology and Trends in Meningococcal Disease-United States, 19962015. Clin Infect Dis. 2018 Apr 3;66(8):1276-1281.

26  van Deuren M, Brandtzaeg P, van der Meer JW. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000 Jan;13(1):144-66, table of contents.

<div style=\"page-break-after: always\"></div>

exposure to ravulizumab and the safety profile has shown to remain consistent over time. The percentage of patients reporting AEs was 84.6%, 56.3%, and 30.7% during months 0 to 6, &gt; 6 to 12, and &gt; 12 to 18 of ravulizumab treatment, respectively. No new safety signals have emerged with longer exposure to ravulizumab

Injection-related reactions were reported in a similar rate by ravulizumab (32.6%) and placebo (31.5%). No relevant differences were observed between both groups.

No new adverse events have been reported in this new population. Overall, the AE profile is consistent with that known for ravulizumab in other indications.

The majority of the events were of mild or moderate severity. Severe events were reported by 16 of patients treated with ravulizumab (18.6%) vs. 14 (15.7%) of those on placebo.

More  ravulizumab  treated  patients  experienced  ≥1  SAE  (23.3%  ravulizumab  vs..  15.7%  placebo), although most of them were considered as not related to the study drug. The most frequently reported SAEs were those related with infections and Nervous System disorders.

Life-threatening events were reported by 2 patients treated with ravulizumab (2.3%): arthritis bacterial (n = 1); and COVID-19 pneumonia (n = 1) vs. 1 (1.1%) of those on placebo: diabetic ketoacidosis (n = 1).

The incidence and nature of SAEs during the open-label period is similar to those reported during the double-blind period. The most frequently reported AEs were headache (16.6%), diarrhoea (13.6%), nausea (9.5%), back pain (9.5%), fatigue (9.5%), nasopharyngitis (8.9%), urinary tract infection (8.9%), arthralgia (8.9%), dizziness (8.3%), abdominal pain (5.3%) COVID-19 (5.3%) and upper respiratory tract infection (5.3%). No clear safety signals were identified. All AEs mentioned above were already reflected in the PI with the exception of COVID-19 and urinary tract infections. Regarding the urinary infections reported it was explained that the differences between groups were driven by one patient, that all patients reporting urinary infections had other predisposing risk factors and that the incidence did not increase with longer exposure to ravulizumab.

Around 21% of patients reported at least a SAE. The most frequently reported were those related to infections (9.4%) and nervous system disorders (4.7%).

A total of 7 deaths occurred in the study but none were related to study drug by the investigator.

Only  meningococcal infections  were  included  as  Adverse  events  of  special  interest.  No  events  were reported during the analysed period. However, after the 52-week data cutoff date, 1 patient in the placebo group who switched to ravulizumab during the Open-Label Extension Period had a non-fatal SAE of meningitis of unknown aetiology. The patient had received meningococcal vaccination prior to study entry.  The  event  was  considered  by  the  Investigator  to  be  related  to  ravulizumab  (compatible  with partially treated bacterial meningitis). No action was taken with ravulizumab in response to this event and the patient continued to receive ravulizumab in the study.

Regarding the safety profile in special populations, subgroup analyses were performed by sex, race, age, geographic  location.  No  relevant  differences  were  detected  between  different  subgroups.  However, results for some of the subgroups should be interpreted with caution given the small number of patients. With respect to drug-drug interactions no specific studies were conducted, the subgroup analysis by immunosuppressant therapy used at baseline did not show any relevant safety signal.

No  clinically  significant  changes  in  the  laboratory  results,  vital  signs,  physical  examinations,  and electrocardiograms were observed.

<div style=\"page-break-after: always\"></div>

The postmarketing global data by the data cut-off date of 30 Jun 2021 do not seem to show any new safety concern.

## 2.5.2. Conclusions on clinical safety

The safety database of ravulizumab in the approved indication is considered limited both in terms of the number of exposed patients and the duration of the exposure. However, the small size of the safety database is not unexpected considering the rarity of the condition.

Given the low prevalence of Myasthenia Gravis, patient exposure is considered acceptable for the shortterm safety assessment of ravulizumab.

As for the long-term safety profile the extension study is ongoing.

Overall, the reported AE profile is consistent with that known for ravulizumab in other indications, with no unexpected findings.

CHMP considered that the available safety data supports the use of ravulizumab in the approved indication.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 4 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 4 with the following content:

## Safety concerns

| Summary of Safety Concerns   | Summary of Safety Concerns                                                                                                                                                                                                               |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Meningococcal infection                                                                                                                                                                                                                  |
| Important potential risks    | Serious haemolysis after dinug discontinuation in PNH patients Severe TMA complications in aHUS patients after ravulizumab discontinuation Immunogenicity Serious infections Malignancies and haematologic abnormalities in PNH patients |
| Missing information          | Use in pregnant and breast-feeding women                                                                                                                                                                                                 |

Abbreviations: aHUS = atypical haemolytic uraemic syndrome; PNH = paroxysmal nocturnal haemoglobinuria; TMA = thrombotic microangiopathy

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

| Study/Status                                                                                                                                                                                                      | Summary of Objectives                                                                                                                                                                                                                                                                                                                                                         | Safety Concerns Addressed                                                                                                                                                                                                    | Milestones                                                   | Due Dates                                                    |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
| Category 3 -required additional pharmacovigilance activities                                                                                                                                                      | Category 3 -required additional pharmacovigilance activities                                                                                                                                                                                                                                                                                                                  | Category 3 -required additional pharmacovigilance activities                                                                                                                                                                 | Category 3 -required additional pharmacovigilance activities | Category 3 -required additional pharmacovigilance activities |
| \"A Phase 3, Randomized, Open-Label. Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naive Adult Patients with Paroxysmal Noctumal Hemoglobinuria (PNH): (ALXN1210- PNH-301) Ongoing | To evaluate the safety and efficacy of ALXN1210 administered by intravenous infusion to adult patients with PNH who are naive to complement inhibitor treatment To collect and evaluate safety data specific to the use of ULTOMIRIS and to collect data to characterise the progression of PNH as well as clinical outcomes, mortality and morbidity in treated PNH patients | Meningococcal infection Serious haemolysis after drug discontinuation in PNH patients Immunogenicity Serious infections Malignancies and haematologic abnormalities in PNH patients Use in pregnant and breast-feeding women | Final CSR                                                    | Oct2023                                                      |
| \"A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Noctumal Hemoglobinuria (PNH) Currently Treated with Eculizumab\" (ALXN1210- PNH-302)  | To collect and evaluate efficacy and safety data specific to the use of ULTOMIRIS and to collect data to characterise the progression of PNH as well as clinical outcomes, mortality and morbidity in treated PNH patients                                                                                                                                                    | Meningococcal infection Serious haemolysis after drug discontinuation in PNH patients Immunogenicity Serious infections Malignancies and haematologic abnormalities in PNH patients Use in pregnant and breast-feeding women | Final CSR                                                    | Dec 2022                                                     |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| CHMP adopted a report   |
|-------------------------|

<div style=\"page-break-after: always\"></div>

## Risk minimisation measures

| Safety Concerm                                                              | RiskMfinimisationMfeasures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Pharmacovigilance Aetivities                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Meningococcal infection                                                     | Routine risk minimisation measwres SmPC sections 4.3, 4.4, and 4.8 PL sections 2 and4 Recommendations for vaccination/antibiotic prophylaxis in SmPC section 4.4 and PL section 2 Signs and symptoms of meningococcal infections listed in SmPC section 4.4 and PL. section 2 Restricted medical prescription Additional risk minimisation measuwres Educational materials PNH/aHUS/gMG Physician's Guide PNH/aHUS/gMG Patient's Information Brochure PNH/aHUS Parent's Information Brochure Patient card Conholled distribuhion Revaccination reminder | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questiommaire Additional pharmacovigilance activihies: Study ALXN1210-PNH-301 (final study report date: Oet 2023) StudyALXN1210-PNH-302 (final study report date: Dec 2022) PNH regishry (M07-001) aHUS regishy (Ml1-001) StudyALXN1210-aHUS-311 (final study report date: Dec 2023) |
| Serious haemolysis after drug discontinuation in PNH patients               | Rouhine nisk minimisation measures SmPC section 4.4 PL section 3 Monitoring of patients who discontimuedUL TOMIRIS recommended in SmPC section 4.4 and PL section 3 Additional niskminimisation measwres Educational materials PNH Physician's Guide PNH Patient's Information Brochure PNH Parent's Information Brochure                                                                                                                                                                                                                               | Additional pharmacovigilance activihies: StudyALXN1210-PNH-301 (final study report date: Oct 2023) Study ALXN1210-PNH-302 (final study report date: Dec 2022) PNH registhry (M07-001)                                                                                                                                                                                                                                  |
| Severe TMA complieations in aHUS patients after ravulizumab discontinuation | Rouhine nisk minimisation measwres SmPC section 4.4 Additional risk minimisation measuwres Educational materials aHUS Physician's Guide aHUS Patient's Information Brochure aHUS Parent'sInformation Brochure                                                                                                                                                                                                                                                                                                                                           | Additional pharmacovigilance activihies: aHUS regishy (M11-001) StudyALXN1210-aHUS-311 (final study report date: Dec 2023)                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                              | RiskMinimisation Measures                                                                                                                                                                                                                                                                                                                                                                                                   | Pharmacovigilance Activities                                                                                                                                                                                                                                            |
|-------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immunogenicity                                              | Routine risk minimisation measures SmPC sections 4.4 and 4.8 Additional risk minimisation measures Educational materials PNH/aHUS/gMG Physician's Guide PNH/aHUS/gMG Patient's Information Brochure PNH/aHUS Parent's Information Brochure                                                                                                                                                                                  | Additional pharmacovigilance activities: Study ALXN1210-PNH-301 (final study report date: Oct 2023) Study ALXN1210-PNH-302 (final study repoit date: Dec 2022) aHUS registry (M11-001) Study ALXN1210-aHUS-311 (final study report date: Dec 2023)                      |
| Serious infections                                          | Routine risk minimisation measures SmPC sections 4.3, 4.4 and 4.8 PL sections 2,3 and 4 Recommendations for vaccination ofpaediatric patients against Haemophilus influenzae and pneumococcal infections in SmPC section 4.4 and PL section 2. Additionalrisk minimisation measures Educational materials PNH/aHUS/gMG Physician's Guide PNH/aHUS/gMG Patient's Information Brochure PNH/aHUS Parent's Information Brochure | Additional pharmacovigilance activities: Study ALXN1210-PNH-301 (final study report date: Oct2023) StudyALXN1210-PNH-302 (final study report date: Dec 2022) PNH registry (M07-001) aHUS registry (M11-001) Study ALXN1210-aHUS-311 (final study report date: Dec 2023) |
| Malignancies and haematologic abnormalities in PNH patients | Routine risk minimisation measures None proposed Additional risk minimisation measures: PNH Physician's Guide PNH Patient's Information Brochure PNH Parent's Information Brochure                                                                                                                                                                                                                                          | Additional pharmacovigilance activities: Study ALXN1210-PNH-301 (final study report date: Oct 2023) Study ALXN1210-PNH-302 (final study report date: Dec 2022) PNH registry (M07-001)                                                                                   |

<div style=\"page-break-after: always\"></div>

| Safety Concern                           | Risk Minimisation Measures                                                                                                                                                                                                                                                             | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Use in pregnant and breast-feeding women | Routine risk minimisation measures SmPC sections 4.6 and 5.3 PL section 2 Recommendations on contraception in SmPC section 4.8 and PL section 2 Additional risk minimisation measures Educational materials PNH/aHUS/gMG Physician's Guide PNH/aHUS/gMG Patient's Information Brochure | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Specific adverse reaction follow-up questionnaire Additional pharmacovigilance activities: Study ALXN1210-PNH-301 (final study report date: Oct 2023) Study ALXN1210-PNH-302 (final study report date: Dec 2022) PNH registry (M07-001) aHUS registry (M11-001) Study ALXN1210-aHUS-311 (final study report date: Dec 2023) |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Ultomiris 300 mg/ 30 mL concentrate for solution for infusion (parent leaflet). The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The approved indication for Ultomiris is:

'Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive.'

<div style=\"page-break-after: always\"></div>

Myasthenia  gravis  (MG)  is  a  rare  complement-mediated  autoimmune  disease  characterised  by the production of autoantibodies targeting proteins located at the neuromuscular junction. The most common target of autoantibodies in gMG is the nicotinic acetylcholine receptor (AChR).

Patients with gMG present with muscle weakness that characteristically becomes more severe with repeated use and recovers with rest. Muscle weakness can be localised to specific muscles, but often progresses to more diffuse muscle weakness 27,28,29 . Generalised myasthenia gravis symptoms can become life-threatening when muscle weakness involves muscles that are responsible for breathing. The most dangerous complication of gMG, known as myasthenic crisis, requires hospitalisation, intubation, and mechanical ventilation. Approximately 15% to 20% of patients with gMG will experience a myasthenic crisis within 2 years of diagnosis 30 .

## 3.1.2. Available therapies and unmet medical need

Most therapies for gMG focus on either augmenting the AChR signal or non-specifically suppressing the autoimmune response. First-line therapy for symptomatic gMG is treatment with acetylcholinesterase (AChE) inhibitors  and  in patients  who  remain  symptomatic,  corticosteroids with or  without  systemic immunosuppressants  are  used  off-label.  Immunosuppressants  used  frequently  in  gMG  include azathioprine  and  mycophenolate mofetil. Cyclosporine, methotrexate, tacrolimus, cyclophosphamide, and rituximab are also used occasionally. Intravenous immunoglobulin (IVIG) and plasma exchange (PLEX)  are  typically  used  short-term  to  manage  worsening  MG  symptoms  and  in  patients  with myasthenic  crisis  or  life-threatening  signs  such  as  respiratory  insufficiency  or  dysphagia 31 , 32 . Eculizumab,  a  monoclonal  antibody,  has  been  approved  for  the  treatment  of  refractory  generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive.

## 3.1.3. Main clinical studies

Clinical evidence supporting the new indication is primarily based on the ongoing Study ALXN1210-MG306. Study ALXN1210 MG 306 is a Phase 3, randomized, double-blind, parallel-group, placebo controlled, 26-week multicenter study with an ongoing open-label extension to evaluate the safety and efficacy of ravulizumab (n=86) administered by IV infusion compared to placebo (n=89)  in adult patients with gMG.

The study consists of an up to 4-week Screening Period, a 26 week double-blind, Randomized Controlled Period, and an Open-Label Extension Period of up to 2 years. Patients were treated on a body weight-based posology receiving a loading dose of 2400-3000 mg followed by maintenance doses of 3000 -3600 mg on Day 15 and then every 8 weeks (q8w). This dosing regimen is identical to that approved for the treatment of PHN and aHUS.

## 3.2. Favourable effects

Study MG-306 met its primary endpoint (change from Baseline in MG-ADL total score at Week 26 of the Randomized-Controlled Period). Patients treated with ravulizumab showed significantly better control of MG symptoms than those who received placebo on the subjective assessment by the patient (MG-ADL).

27  Chamanza R, Marxfeld HA, Blanco AI, Naylor SW, Bradley AE. Toxicol Pathol.2010;38(4):642-57.

28  Gilhus NE, Verschuuren JJ. Lancet Neurol. 2015;14(10):1023-36.

29  Gilhus NE. N Engl J Med. 2016;375(26):2570-2581.

30  Ramizuddin, M. IOSR J Dent Med Sci. 2014;13(7):67-97

31  Riedemann NC, Guo RF, Laudes IJ, et al. FASEB J. 2002;16(8):887-8.

32  Sanders DB, Wolfe GI, Benatar M, et al. Neurology. 2016;87(4):419-25.

<div style=\"page-break-after: always\"></div>

At Week 26 the mean difference between the treatment arms was -1.6 (95% CI -2.6, -0.7; p = 0.0009).

This was supported by sensitivity analyses in the PP population as well as by supplemental analyses for the primary endpoint.

The secondary endpoints, also assessed changes from baseline to Week 26, included the change in the Quantitative Myasthenia Gravis (QMG) total score, the proportion of patients with improvements of at least 5 and 3 points in the QMG and MG-ADL total scores, respectively, as well as changes in quality-oflife assessments.

The quantitative evaluation of relevant muscle groups by the physician (QMG) measured as secondary endpoint also showed a statistically significant difference between ravulizumab and placebo. The LS mean (SEM) reduction from Baseline to Week 26 in QMG total score was -2.0 [0.59]; 95% CI: -3.2, 0.8; p = 0.0009).

A numerically greater effect was observed in the QoL MG scales (change in MG-QOL15r score, change in Neuro-QoL fatigue scale) favouring ravulizumab although according to testing hierarchy, they did not reach statistical significance. The LS mean (SEM) reduction from Baseline to Week 26 in MG-QoL15r total score was -1.7 [0.7]; 95% CI: -3.4, 0.1; p=0.0636.

The LS mean (SEM) reduction from Baseline to Week 26 in Neuro-QoL Fatigue score was -2.2; 95% CI: -6.9, 2.6; p=0.3734.

30% of patients on ravulizumab had ≥ 5 point reduction in the QMG total score compared with 11.3% placebo (OR 3.350 [95% CI 1.443, 7.777]; p=0.0052).

In  addition,  more  patients  in  the  ravulizumab  group  (56.7%)  compared  to  placebo  group  (34.1%) achieved  a ≥ 3-point  reduction,  although  this  analysis  was  not  considered  (formally)  statistically significant according to the prespecified hierarchical testing for secondary endpoints.  MG Composite Scale results are in line with those observed for MG-ADL score and QMG scales. Patients treated with both ravulizumab and with placebo experienced a reduction in the scores (ravulizumab -6.1 [0.73], placebo -3.2 [0.71]). The difference was statistically significant (-2.9 [0.93]; 95% CI: -4.8, -1.1; p = 0.0019).

Patients in the ravulizumab arm suffered fewer clinical deteriorations (10 [11.6%] vs. 18 [20.2%]) or rescue  therapy  (8  [9.3%]  vs.  14  [15.7%])  than  the  patients  in  the  placebo  arm  during  the  study. Similarly, fewer patients on ravulizumab needed hospitalization due to MG during the 26 week period of treatment compared to placebo (7 [8%] vs. 3 [3%]).

Maintenance of the effect of ravulizumab beyond 6-month treatment is based on the still ongoing open label period, where all patients involved in Study MG-306 are treated with ravulizumab and followed up to 2 years.  An update of the Study MG-306 with a clinical database cut-off date of 09 Nov 2021 was provided during this application. Additional data from the 161 patients who received 1 or more doses of ravulizumab in the extension period collected up to the Week 60 visit in the Open-Label Extension Period have been provided. All patients received treatment with ravulizumab during the Open-Label Extension Period, including patients randomized to ravulizumab and patients randomized to placebo during the Randomized-Controlled Period (RAV/RAV and PBO/RAV group, respectively). When patients who received placebo in the randomized controlled period were treated with ravulizumab in the openlabel extension period an improvement similar to that showed by patients on active treatment in the previous study was observed. In patients previously treated with ravulizumab, the response was maintained.

During this phase of the clinical trial background therapy could be adjusted. In this period 50.3% of patients had a change in concomitant MG medication.  The most common change was a decrease in

<div style=\"page-break-after: always\"></div>

corticosteroids for systemic use due to MG symptoms improved (20.7%) with 11 (6.5%) patients discontinuing corticosteroids for systemic use.

## 3.3. Uncertainties and limitations about favourable effects

The magnitude of the effect regarding the primary endpoint was questioned by CHMP. CHMP considered that the statistically significant reduction experienced in symptoms of 1.6 points in the mean change in MG-ADL score (primary endpoint) with respect to baseline during the randomized controlled period was modest. This also applied to the observed findings in the main secondary endpoints, when they were expressed in terms of absolute changes of the respective scales.

The clinical relevance of the treatment effect was questioned based on the fact that it did not achieve the accepted thresholds for clinical meaningfulness for the utilized scales established in literature (i.e. MCID of 2 point 33 , 34 ).

CHMP considered that these thresholds should be used for individual responder analyses and not as a reference point for a population-average drug-placebo treatment effect. Admittedly, this criterion could be considered as a cut-off value in responder analysis, as this is based on an 'individual level' approach. In this respect 63.9% of patients treated with ravulizumab and 53.0% of patients treated with placebo showed  a  2-point  reduction  in  MG-ADL  score,  being  the  reported  10.9%  difference  of  difficult interpretation. Moreover, the measured difference between ravulizumab and placebo did not achieve the treatment effect of 1.9 points on the MG-ADL score used at the planning stage.

An estimation of the effect size for the primary and secondary endpoints (MG-ADL and QMG scales) was provided in order to inform about the magnitude of treatment effects, showing an Hedge's g effect size of -0.49 and -0.50, respectively, which is defined as a moderate effect.

From the patient perspective (QoL measures), the changes MG-QOL15r score and in Neuro-QoL fatigue scale were not statistically significant even if results numerically favoured ravulizumab compared to placebo.

As it was reflected also by the inclusion criteria on prior/concomitant medications, in the ravulizumab study 306, gMG patients of lower disease severity were also included.

## 3.4. Unfavourable effects

In the Randomized-Controlled Period headache, diarrhoea and nausea were the most frequently reported AEs (≥ 10% of all patients). Overall, the AE profile is consistent with that known for ravulizumab in other indications.

More  ravulizumab  treated  patients  experienced  ≥1  SAE  (23.3%  ravulizumab  vs.  15.7%  placebo), although most of them were considered as not related to the study drug. The most frequently reported SAEs were those related with infections (8.1% of patients treated with ravulizumab, 4.5% of patients treated with placebo); and Nervous System disorders (5.8% of patients treated with ravulizumab, 4.5% of patients treated with placebo).

In the Ravulizumab Treated Set 88.8% of patients reported AEs (related AEs 34.3%). No additional safety issues were identified with prolonged and repeated administration of ravulizumab. As for the

33  Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487-9.

34  Muppidi S, Wolfe GI, Conaway M, Burns TM. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31.

<div style=\"page-break-after: always\"></div>

long-term safety profile the most frequently reported AEs were headache (16.6%), diarrhoea (13.6%), nausea (9.5%), back pain (9.5%), fatigue (9.5%), nasopharyngitis (8.9%), urinary tract infection (8.9%), arthralgia (8.9%), dizziness (8.3%), abdominal pain (5.3%) COVID-19 (5.3%) and upper respiratory tract infection (5.3%).

No meningococcal infections were reported during the analysed period. After the 52-week data cut-off date, 1 patient in the placebo group who switched to ravulizumab had a non-fatal SAE of meningitis of unknown aetiology during the Open-Label Extension Period.

Seven  deaths  have  been  reported  in  the  total  ravulizumab  group.  None  of  the  fatal  events  were considered by the investigator to be related to ravulizumab treatment.

## 3.5. Uncertainties and limitations about unfavourable effects

Overall, a total of 86 patients were exposed to ravulizumab in the Randomized-Controlled Period. These patients were treated with the proposed dosing regimen for a median duration of 25.6 weeks. Treatment compliance was 94.4% in the placebo group and 96.5% in the ravulizumab group. A such, the CHMP considered that the safety database presents limitations especially regarding less frequent or delayed events.

## 3.6. Effects Table

Effects  Table  for  Ultomiris  (ravulizumab)  for  the treatment  of  adult  patients  with  AChR antibody-positive gMG with remaining symptomatology despite at least one immunomodulatory therapy (data cut-off: 11 May 2021) - Study ALXN1210-MG-306

| Effect                                  | Short descripti on                               | Unit                 | Ravulizumab          | Placebo              | Uncertainties / Strength of evidence                                                   | References                 |
|-----------------------------------------|--------------------------------------------------|----------------------|----------------------|----------------------|----------------------------------------------------------------------------------------|----------------------------|
| Favourable Effects                      | Favourable Effects                               | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                                     | Favourable Effects         |
| Primary endpoint MG-ADL                 | Change from Baseline in MG-ADL Total Score       | LS mean (SEM)        | -3.1 (0.38)          | -1.4 (0.37)          | Treatment Effect -1.6 (95% CI: -2.6, -0.7) P-value 0.0009 Difference < 2 points (MCDI) | Study ALXN1210- MG-306     |
| Second endpoint 1 QMG Total Score       | Change from Baseline in QMG Total Score          | LS mean (SEM)        | -2.8 (0.46)          | -0.8 (0.45)          | Treatment Effect -2.0 (95% CI: -3.2, -0.8) P-value 0.0009 Difference < 3 points (MCDI) | Study MG-306               |
| Second endpoint 2 QMG responder rate    | QMG ≥5 - point improvement                       | %                    | 30.0%                | 11.3%                | OR 3.350 (95% CI: 1.443 , 7.777) P-value 0.0052                                        | Study MG-306               |
| Second endpoint 3 MG-QOL15r             | Change from Baseline in MG-QOL15r Score          | LS mean (SEM)        | -3.3 (0.71)          | -1.6 (0.70)          | Treatment Effect -1.7 (95% CI: -3.4 , 0.1) P-value 0.0636                              | Study MG-306               |
| Second endpoint 4 Neuro-QOL- fatigue    | Change from Baseline in Neuro-QOL- fatigue Score | LS mean (SEM)        | -7.0 (1.92)          | -4.8 (1.87)          | Treatment Effect -2.2 (95% CI: (-6.9 , 2.6) P-value 0.3734 (Nominal p-values)          | Study MG-306               |
| Second endpoint 5 MG-ADL responder rate | MG- ADL ≥3 - point improvement                   | %                    | 56.7%                | 34.1%                | OR 2.526 (95% CI: 1.330 , 4.799) P-value 0.0049 (Nominal p-values)                     | Study MG-306               |
| Unfavourable Effects                    | Unfavourable Effects                             | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                   | Unfavourable Effects       |
| AEs                                     | Incidence of AEs regardless of causality         | n (%)                | 78 (90.7)            | 77 (86.5)            |                                                                                        | Study ALXN1210- MG-306 RCP |
| Related AEs                             | Proportion                                       | n (%)                | 29 (33.7)            | 30 (33.7)            |                                                                                        | Study MG-306 RCP           |
| SAEs                                    | Incidence of serious                             | n (%)                | 20 (23.3)            | 14 (15.7)            |                                                                                        | Study MG-306 RCP           |

<div style=\"page-break-after: always\"></div>

| Effect         | Short descripti on                       | Unit   | Ravulizumab   | Placebo   | Uncertainties / Strength of evidence   | References       |
|----------------|------------------------------------------|--------|---------------|-----------|----------------------------------------|------------------|
|                | adverse events                           |        |               |           |                                        |                  |
| Death          | Proportion                               | n (%)  | 2 (2.3)       | 0         |                                        | Study MG-306 RCP |
| AEs            | Incidence of AEs regardless of causality | n (%)  | 110 (86.6)    |           |                                        | Study MG-306 RTS |
| Related AEs    | Proportion                               | n (%)  | 43 (33.9)     |           |                                        | Study MG-306 RTS |
| SAEs           | Incidence of serious adverse events      | n (%)  | 27 (21.3)     |           |                                        | Study MG-306 RTS |
| Death          | Proportion                               | n (%)  | 4 (3.1)       |           |                                        | Study MG-306 RTS |
| Headache       | Common TEAE                              | n (%)  | 16 (18.6)     | 23 (25.8) |                                        | Study MG-306 RCP |
| Diarrhoea      | Common TEAE                              | n (%)  | 13 (15.1)     | 11 (12.4) |                                        | Study MG-306 RCP |
| Nausea         | Common TEAE                              | n (%)  | 9 (10.5)      | 9 (10.1)  |                                        | Study MG-306 RCP |
| Dizziness      | Common TEAE                              | n (%)  | 8 (9.3)       | 3 (3.4)   |                                        | Study MG-306 RCP |
| Back pain      | Common TEAE                              | n (%)  | 7 (8.1)       | 5 (5.6)   |                                        | Study MG-306 RCP |
| Arthralgia     | Common TEAE                              | n (%)  | 6 (7.0)       | 7 (7.9)   |                                        | Study MG-306 RCP |
| Fatigue        | Common TEAE                              | n (%)  | 6 (7.0)       | 6 (6.7)   |                                        | Study MG-306 RCP |
| Abdominal pain | Common TEAE                              | n (%)  | 5 (5.8)       | 0         |                                        | Study MG-306 RCP |

Abbreviations: CI= Confidence Interval, LS = Least Squares; MG-ADL=MG Activities of Daily Living total score, MG-QoL15r= Revised 15-Component  Myasthenia  Gravis  Quality  of  Life,  MMRM  =  mixed-effect  model  for  repeated  measures;  Neuro-QOL-fatigue  = Neurological Quality of Life Fatigue, QMG = Quantitative MG total score, SEM = Standard Error of Mean, RCP= Randomized-Controlled Period, RTS= Ravulizumab Treated Set

Notes: Secondary efficacy endpoints were tested in a hierarchical approach (numbers included for testing order). Hierarchical testing proceeded  from  1 to  5,  and  if  statistical  significance  was  not  achieved  (p-value  &gt;  0.05),  then  subsequent  endpoints  were  not considered statistically significant and all displayed p-values from analyses of lower hierarchy were to be considered nominal.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

Generalized Myasthenia Gravis is associated with relevant disability due to muscle weakness and fatigue of fluctuating course especially in patients with at least moderate condition. Treatment is aimed to control the symptoms and the underlying immune dysregulation. With respect to the structurally related eculizumab (administered every 2 weeks) ravulizumab allows a reduction in the frequency of infusions. It represents a reduced treatment burden, which is of value for the patients usually requiring numerous other treatments in the context of a chronic disease.

Overall, ravulizumab has shown an effect over placebo on the control of symptoms assessed by the patient (MG-ADL score, primary endpoint) and by the physician (QMG score; secondary endpoint) in a population with an established, advanced condition of moderate severity in spite of concomitant MG therapy. This is consistent with MGC score results, a scale derived from the other two scales.

While the magnitude of a clinically relevant effect could be questioned, the totality of the evidence should be considered when concluding on the efficacy of ravulizumab. In this respect the observed treatment effects are consistent across the responder rates reporte d both from the patient's (≥ 3 -point reduction in MG-ADL total score) and physician's perspective ( ≥ 5 point reduction in the QMG total

<div style=\"page-break-after: always\"></div>

score). It should also be mentioned that more stringent criteria (i.e. greater point reduction thresholds) led to more clear differences between the ravulizumab and the placebo groups.

Supportive evidence derives also from the clinical impact of ravulizumab in the course of the disease. Ravulizumab treated patients experienced less clinical deterioration, less MG-related hospitalization and required less rescue therapy than placebo treated patients. However, the interpretation of these outcomes is limited by the reduced numbers of events by group and the exploratory nature of the endpoints. However, a consistent response has been shown in the scales measured, which reinforces the observed effect.   During the extension period, where changes in background therapy were allowed, 50.3% of patients had a change in concomitant MG medication.  The most common change was a decrease in corticosteroids for systemic use due to MG symptoms improved (20.7%) with 11 (6.5%) patients discontinuing corticosteroids for systemic use.

Maintenance of the effect of ravulizumab beyond 6-month treatment is based on the still ongoing open label period, where all patients involved in Study MG-306 are treated with ravulizumab and followed up to 2 years.  With the limitations given by the open label design and the fact that the study is still ongoing, the maintenance of the effect is considered sufficiently established. The final results of the study will be submitted once available.

The safety database of ravulizumab in the proposed indication is considered limited in terms of the number of exposed patients. The updated analysis of Study ALXN1210-MG-306 performed (data cutoff date 09 Nov 2021) includes data from 169 patients through Week 60.

The small size of the safety database is not unexpected considering the rarity of the condition. Overall, the reported AE profile is consistent with that known for ravulizumab in other indications. No additional safety issues were identified with prolonged and repeated administration of ravulizumab.

The extension study is ongoing. The MAH should submit the final results when available in order to complete the long-term efficacy and safety assessment.

## 3.7.2. Balance of benefits and risks

Ravulizumab has shown an effect over placebo on the control of symptoms assessed by the patient and by the physician. Whereas some uncertainties still remain (e.g. what treatment effect size with respect to placebo is to be considered clinically relevant) the totality of data submitted supports the conclusion that efficacy has been sufficiently demonstrated to support the use of ravuzilumab in the approved indication.

Long-term efficacy is based on the effect of ravulizumab during the open label extension period of the study, still ongoing.  With the limitations given by the open label design and the fact that the study is still ongoing, the maintenance of the effect is considered sufficiently supported.

The observed safety profile of ravulizumab per se does not raise any severe or unexpected concerns and it is consistent with that known for ravulizumab in other indications; it is noted, however, that the conclusions are based on a very limited safety database.

As for the wording of the indication CHMP considered that taking into account that eculizumab and ravulizumab are structurally similar, do share the same mechanism of action and that the design of study ECU-MG-301, which supported approval  of eculizumab for the treatment of refractory generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive, was similar to that of the ravulizumab MG-306 study, the same indication wording as the one for Soliris could be considered adequate also for ravulizumab. However further justification was provided that demonstrated that there are several differences between the population included in

<div style=\"page-break-after: always\"></div>

the eculizumab study (Study ECU-MG-301) and that included in the ravulizumab study (Study ALXN1210-MG-306). In general, patients included in eculizumab study seem to correspond to a more severe, more heavily treated population, in accordance to the requirement of having failed to at least 2 previous treatments and the approved indication in a refractory population.

Whereas the fact that ravulizumab and eculizumab share biochemical structure, mechanism of action and target population would favour granting a similar therapeutic indication, the differences in the population in whom the efficacy and safety data have been obtained would justify a different wording. This does not necessary mean that the effect of both medicinal products differs from each other but that the therapeutic indication is adjusted to the available evidence.

Considering the above, granting a broader indication to ravulizumab seems justified. As such, the final approved indication for ravulizumab is:

'Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody positive.'

Regarding the claim for an additional year of market protection submitted by the MAH, it is considered that Ultomiris in the claimed indication brings a significant clinical benefit over existing therapies based on an improved efficacy compared to acetylcholinesterase inhibitors, corticosteroids and azathioprine, and a major contribution to patient care compared to Soliris (based on a reduced treatment burden with approximately 7 infusions for ravulizumab versus 26 infusions for eculizumab annually).

## 3.7.3. Additional considerations on the benefit-risk balance

Not applicable.

## 3.8. Conclusions

The overall B/R of Ultomiris is positive.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of adult patients with generalized myasthenia gravis (gMG).  As a consequence, Sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 and 6.6 of the SmPC and corresponding sections in the Package Leaflet are updated accordingly. The RMP has been updated to version 4.0 to align with the indication extension. Lastly, the minor editorial corrections are made throughout the SmPc and package leaflet. The Applicant also requested 1 year of market protection for

<div style=\"page-break-after: always\"></div>

a new indication (Article 14(11) of Regulation (EC) 726/2004).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CHMP by consensus is of the opinion that Ultomiris is similar to Soliris and not similar to Vygart within the meaning of Article 3 of Commission Regulation (EC) No. 847/200.

## Derogation(s) from market exclusivity

The CHMP by consensus is of the opinion that pursuant to Article 8 of Regulation (EC) No. 141/2000 the following derogation laid down in Article 8.3 of the same Regulation apply:

the holder of the marketing authorisation for Soliris has given his consent to the MAH.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion: EMEA/H/C/004954/II/0026